{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2012/legemiddelstatistikk-20122-pdf.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Topic: Drug use Institute of Houston 911 Acknowledgement:Julie 2011: Legemiddelstatistikk 2011:2: til andre form\u00e5l som er Reseptregisteret. Mer use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies. This report is the fifth edition of the annual statistics from NorPD. This year's report is a theme issue focusing on drug use in the elderly population. Part 1 of the report presents some key figures on drug use in elderly 65 years and is focusing on selected drug groups and the use of these in the elderly population. General information about NorPD, drug statistics, classifica- tion of drug and measurement methods is included in part 2 of the report. Part 3 contains some key figures from NorPD and the main tables with information about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2007-2011). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2011, information about age, gender and costs are included in the tables. The ATC/DDD version of January 2012 has been used in the report, see also www.whocc.no NorPD also has a website where you can find complementary information. The website is: www. norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objec - tives of NorPD. More information about this can be found in part 3 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no). Department of Pharmacoepidemiology Norwegian Institute of Public Health April 8 eldre D\u00f8gndose (DDD) ..................................................................................................................... 46 2.6 WHO Collaborating Centre for Drug Statistics Methodology ........................................................ 47 3. Reseptregisteret 2007-2011 ...................................................................................................................... av hovedtabellene .......................................................................................................... 53 3.3 ATC main groups .................................................................................................................................... 57 3.4 ATC group A - Alimentary tract and metabolism ............................................................................ 58 3.5 ATC group B - Blood and bloodforming organs ................................................................................ 69 3.6 ATC group C - Cardiovascular system .............................................................................................. 72 3. 7 ATC group D - Dermatologicals ........................................................................................................... 79 3.8 ATC group G - Genito urinary system and sex hormones ............................................................. 85 3.9 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins .................. 90 3.10 ATC group J - Antiinfectives for systemic use .................................................................................. 93 3.11 ATC group L - Antineoplastic and immunomodulating agents ..................................................... 99 3.12 ATC group M - Musculo-skeletal system ........................................................................................ 102Legemiddelstatistikk 2012:2 Folkehelseinstituttet 9 3.13 ATC group N - Nervous system ........................................................................................................ 106 3.14 ATC group P - Antiparasitic products, insecticides and repellents ............................................ 115 3.15 ATC group R - Respiratory system .................................................................................................. 117 3.16 ATC group S - Sensory organs .......................................................................................................... 121 3.17 ATC group V - Various ......................................................................................................................... 125 forkortelser og definisjoner basert p\u00e5 10 Legemiddelstatistikk 2012:2 FolkehelseinstituttetContents Preface .................................................................................................................................................................... 7 1. Drug use in the elderly .................................................................................................................................... 13 1.1 Drug use in the elderly ( 65 years) - some key figures ................................................................. 13 1.2 Use of anti-dementia drugs in the elderly population (ATC group NO6D) ................................... 18 1.3 Use of cardiovascular drugs in the elderly (ATC group C) ............................................................... 22 1.4 Use of drugs for osteoporosis in the elderly population ................................................................ 27 1.5 The use of non- steroid anti - inflammatory drugs (NSAIDs) in the elderly ............................... 31 1.6 Use of hypnotics in the elderly population ........................................................................................ 34 1.7 Use of antibiotics in the elderly ........................................................................................................... 38 2. General information about the Norwegian Prescription Database and drug statistics .................... 41 2.1 About the NorPD .................................................................................................................................... 41 2.2 Prescription statistic in the other Nordic countries ........................................................................ 44 2.3 The Norwegian Drug Wholesales Statistics ..................................................................................... 45 2.4 The Anatomical Therapeutic Chemical (ATC) classification system ............................................ 45 2.5 The Defined Daily Dose (DDD) ............................................................................................................. 46 2.6 The WHO Collaborating Centre for Drug Statistics Methodology ................................................ 47 3. The Norwegian Prescription Database (NorPD) 2007-2011 .................................................................. 49 3.1 Selected key figures from NorPD ....................................................................................................... 49 3.2 Description of the main tables ............................................................................................................ 53 3.3 ATC main groups .................................................................................................................................... 57 3.4 ATC group A - Alimentary tract and metabolism ............................................................................ 58 3.5 ATC group B - Blood and bloodforming organs ................................................................................ 69 3.6 ATC group C - Cardiovascular system .............................................................................................. 72 3. 7 ATC group D - Dermatologicals ........................................................................................................... 79 3.8 ATC group G - Genito urinary system and sex hormones ............................................................. 85 3.9 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins .................. 90 3.10 ATC group J - Antiinfectives for systemic use .................................................................................. 93 3.11 ATC group L - Antineoplastic and immunomodulating agents ..................................................... 99 3.12 ATC group M - Musculo-skeletal system ........................................................................................ 102Legemiddelstatistikk 2012:2 Folkehelseinstituttet 11 3.13 ATC group N - Nervous system ........................................................................................................ 106 3.14 ATC group P - Antiparasitic products, insecticides and repellents ............................................ 115 3.15 ATC group R - Respiratory system .................................................................................................. 117 3.16 ATC group S - Sensory organs .......................................................................................................... 121 3.17 ATC group V - Various ......................................................................................................................... 125 Some abbreviations and definitions .......................................................................................................... 126 Population in Norway 2007-2011 (as of 1st July) ................................................................................... 127 Population by age in 2011 (as of 1st July) .................................................................................................. 127 List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2012 .................................................................................. 128Legemiddelstatistikk 2012:2 Folkehelseinstituttet 131. Drug use in the elderly 1.1 Drug use in the elderly ( 65 years) - some key figures This report is a theme issue focusing on the use of drugs in the elderly. In the theme section, we have chosen 65 years as a definition of elderly. Most developed world countries have accepted the chron- ological age of 65 years as a definition of 'elderly' or older person (1). In the tables in Part 3 of this book, however, we have chosen a definition of 70 years for the oldest age group. This definition has been used in similar tables in all previous editions of the report. To be able to compare with previous years and to follow the trends in drug use over time in all the reports, we have chosen to keep this definition in part 3. Extensive medicinal treatment is common in the elderly and the use of drugs in the population increases with age. Drug consumption by individuals 1. Legemidler og eldre 1.1 1 Table 1.1.a: Total population in Norway in 2011 65 years and percent living in institutionsSource: Statistics Norway AlderMen Women Total Number of individuals% living in institutionsNumber of individuals% living in institutionsNumber of individuals% living in institutions 65-69 112 862 0.6 115 283 0.5 228 145 0.6 70-74 78 248 1.4 87 060 1.4 165 308 1.4 75-79 59 022 3.0 73 721 3.5 132 743 3.3 80-84 45 690 6.3 66 514 8.0 112 204 7.3 85-89 26 983 11.4 51 304 16.2 78 287 14.5 90 10 986 21.1 31 673 30.4 42 659 28.0 65 333 791 3.5 425 555 6.5 759 346 5.2 14 Legemiddelstatistikk 2012:2 Folkehelseinstituttetin hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database (NorPD). This will often provide artificially low figures for the number of drug users, particularly in the oldest age groups. Table 1.1.a shows the proportion of the total population 65 years by women and men and five year age groups who lived in institutions (nursing homes) in 2010 based on figures from Statistics Norway. The figure is less than one percent in the age group 65-69 and increases to 28% among those over 90 years. Overall, 5% of all those who were 65 years or older lived in a nursing home in 2010. Based on these data, we have in this theme section estimated preva- lence of drug users for the population living outside institutions for a few drug groups (hypnotics and antibiotics), see chapter 1.6 and 1.7. For the other drug groups presented, such estimates are not calculated. Figures from NorPD show that in the age group 65 years, 90% of the population had at least one drug dispensed on prescription in 2011. If we adjust according to the elderly living at home, the prevalence increases to 96%. In the general population, the preva- lence of drug use was about 69% in 2011 (table 3.1.a). Figure 1.1.a shows that the proportion was lower among the elderly because prescriptions for patients in institu- tions are excluded. Calculations based on the elderly population living outside institutions give a prevalence between 95 and 100% in the oldest age groups. The proportion of drug users is high in the oldest age groups, with a use of multiple drugs and a higher sykehjem er ikke tilgjengelig p\u00e5 aldersgruppen 65-69 28 \u00e5r. Totalt sett er andelen i sykehjem vel den som ikke er i institusjon, se delkapittel 1.6 og en andel p\u00e5 Figure 1.1.a: One year prevalence (%) of dispensed prescriptions in 2011 for men and women aged 65 years and older100 80 604020 0Proportion (%) of the population Women Men Age65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 90+ Legemiddelstatistikk 2012:2 Folkehelseinstituttet 15quantity of each in terms of DDDs. In 2011, the 65 year age group constituted a share of 21% of all drug users and 47% of the total number of DDDs dispensed on prescription (table 1.1.b). The largest proportion of elderly is in ATC group B (anti-thrombotic medicines) and ATC group C (drugs for cardiovascular disease) where the proportion of drug users 65 years are 61% and 52%, respectively, and they use 63% and 61% of the total number of DDDs. Table 1.1.c shows the 25 most used prescription drugs in the elderly. Acetylsalicylic acid (Albyl-E\u00ae), used to prevent thrombosis, is top of the list and is used by every third person over 65 years of age. Number two and three on the list are simvastatin (Zocor\u00ae), a cholesterol-lowering drug used to prevent cardiovas- cular disease, and metoprolol (Seloken\u00ae, Selo-Zok\u00ae), a beta blocker for the treatment of high blood pressure, heart failure and other cardiovascular diseases. The most common hypnotic, zopiclone (Imovane\u00ae), was used by 19% of the elderly. On average, each user in this age group was prescribed 200 DDDs (1 DDD = 7.5 mg) of zopiclone during a year, while the average among users under 65 years was 150 DDD. Zopi- clone is approved for use in patients with short term sleeping problems, and as add-on therapy for shorter periods in patients with chronic sleeping problems. Among the 25 most commonly prescribed drugs, in addition to zopiclone we find three other addictive drugs (combination of codeine and paracetamol, diazepam and oxazepam). See also chapter 1.6 about the use of hypnotics.21 % av alle legemiddelbrukerne og 47 andelen eldre legemiddelbrukere er henholdsvis 61 % og 52 %, og de bruker 63 % og 61 % av totalt gruppen eldre brukte i gjennomsnitt (1 DDD = 7,5 mg) av zopiklon i l\u00f8pet av som ble Table 1.1.b: Number of individuals having a prescription dispensed in 2011 in the major ATC groups and the cor - responding sales in total number of DDDs. Proportion (%) in the age group 65 years and older is given in brackets ATC groupTotal number of individuals (% 65 years or older)Total million DDDs (% 65 years or older) A Alimentary tract and metabolism 742 144 (40) 234 (47) B Blood and blood forming organs 597 870 (61) 215 (63) C Cardiovascular system 998 419 (52) 717 (61) G Genito urinary system and sex hormones 745 296 (20) 170 (19) H Systemic hormonal preparations, excl. sex hormones and insulins 402 895 (36) 68 (40) J Antiinfectives for systemic use 1 326 119 (20) 32 (31) M Musculo-skeletal system 927 190 (25) 81 (44) N Nervous system 1 279 567 (31) 342 (34) R Respiratory system 1 223 304 (20) 247 (31) Total 3 430 812 (21) 2170 (47) 16 Legemiddelstatistikk 2012:2 FolkehelseinstituttetTable 1.1.c: The 25 most commonly prescribed drugs (defined as ATC 5th level) dispensed to individuals aged 65 years in Norway in 2011. Number of individuals (n) and proportion of the population (%) Total Women Men ATC code Active ingredient Use n (%) (%) n (%) 1B01AC06 acetylsalicylic acid Antithrombotic 253 967 (20.0) 83 376 (23.9) 4N05CF01 zopiclone Hypnotic 148 578 (18.9) 103 077 (23.6) 45 501 (13.1) 5N02BE01 paracetamol Analgesic 133 597 (17.0) 91 354 (20.9) 42 243 (12.1) 6N02AA59codeine and paracet - amolAnalgesic 105 465 (13.4) 64 422 (14.7) 41 043 (11.8) 7M01AB05 diclofenac NSAID/analgesic 79 728 45 (9.7) 8C08CA01 amlodipineAntihypertensive/cardiac diseases78 264 (10.0) 40 524 (9.3) 740 (10.8) 9H03AA01 levothyroxine sodium Thyroxine supplement 76 068 (9.7) 61 130 14 938 (4.3) 10 B01AA03 warfarin Antithrombotic 72 041 (9.2) 30 876 (7.1) 41 165 (11.8) 11 J01CE02 phenoxymethylpenicillin Antibacterial 71 323 (9.1) 38 489 (8.8) 32 834 (9.4) 12 C03CA01 furosemide Diuretic 70 396 (9.0) 43 320 (9.9) 27 076 (7.8) 13 C10AA05 atorvastatin Cholesterol-lowering 68 582 (8.7) 35 004 (8.0) 33 578 (9.6) 14 H02AB06 prednisolone Corticosteroid 67 561 (8.6) 39 861 (9.1) 27 700 (7.9) 15 J01CA08 pivmecillinam Antibacterial 65 351 (8.3) 51 400 (11.8) 13 951 (4.0) 16 R05DA01 ethylmorphine Cough suppressant 56 032 (7.1) 33 583 (7.7) 22 449 (6.4) 17 R05CB01 acetylcysteine Mucolytic 55 724 (7.1) 31 500 (7.2) 24 224 (7.0) 18 A12AX Calcium, combinations calcium/vitamin D supplement55 624 (7.1) 47 013 (10.8) 8 611 (2.5) 19 N05BA04 oxazepam Anxiolytic 52 972 (6.7) 38 525 (8.8) 14 447 (4.1) 20 A10BA02 metformin Diabetes 51 938 (6.6) 24 726 (5.7) 27 212 (7.8) 21 N05BA01 diazepam Anxiolytic 50 669 (6.4) 35 818 (8.2) 14 851 (4.3) 22 A02BC02 pantoprazole Reflux oesophagitis 49 691 (6.3) 28 222 (6.5) 21 469 (6.2) 23 N02AX02 tramadol Analgesic 48 240 (6.1) 31 481 (7.2) 16 759 (4.8) 24 A02BC05 esomeprazole Reflux oesophagitis 47 442 (6.0) 28 622 (6.5) 18 820 (5.4) 25 R06AE07 cetirizine Antihistamine 45 370 (5.8) (4.2)Legemiddelstatistikk 2012:2 Folkehelseinstituttet 17Figure 1.1.b shows the percentage distribution of the total number of individuals by the number of drugs (defined as different ATC 5th levels) that were dispensed during 2011 to users 65 years or older, compared to the rest of the population (0-64 years). 57% of the elderly drug users used more than five drugs compared to below 20 % for those under 65 years,. In 2011, 21% of drug users 65 years were prescribed more than 10 different drugs. This percentage has increased from 18% in 2005. For those under 65 years, the proportion was 4.2% in 2011. Evidence-based guidelines often recom-mend several medicines to treat or prevent disease. Individuals treated for several illnesses will often use multiple drugs. The figures from NorPD show that many elderly people will need to handle many drugs, increasing the risk of misuse. Some recently published studies have focused on this issue (2.3). It is important to investigate further to gain more knowledge on how drug therapy for the elderly can be optimized to avoid overuse, underuse or misuse.utlevert i l\u00f8pet av 2011 legemidler, mens for de under 65 \u00e5r var andelen under 20 %. I 2011 fikk 21 % av legemiddel-brukere 65 \u00e5r mer enn har \u00f8kt fra 18 % i 2005. For de under 65 \u00e5r var andelen som brukte over S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206 3. Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly - a modern epidemic? Eur J Clin Pharmacol. 2012 Feb 15. [Epub ahead of print] Figure 1.1.b. Proportion (%) of total drug users according to number of drugs dispensed (ATC codes) in 2011 in the age groups 0-64 and 65 years and older30 25 20 1510 5 0Proportion (%) of users 0-64 years 65 years and older Number of drugs (ATC codes)1 2 3 4 5 6 7 8 9 10 >10 18 Legemiddelstatistikk 2012:2 Folkehelseinstituttet1.2 Use of anti-dementia drugs in the elderly population (ATC group NO6D) Around 60% of patients with dementia have Alzheim- er's disease, the most common form of dementia. Vascular dementia due to cardiovascular disease is the second most common and accounts for 20% (1-3). The first drugs for the treatment of Alzheimer's disease were introduced in Norway around 2000. Four drugs are currently approved; donepezil (Aricept\u00ae), rivastigmine (Exelon\u00ae) and similar way, whereas memantine (Ebixa\u00ae) has a different mechanism of action. All drugs have limited efficacy and cannot halt disease progres- sion, only the worsening of symptoms. Results form randomized clinical trials with anti-dementia drugs have shown great variation in efficacy that implies that some patients have a positive effect, while others have little or no effect. However, it is not possible to know in advance of treatment which patients will gain the highest benefits. In July 2002, anti-dementia drugs were included in the reimbursement system. Memantine was marketed in Norway in 2002 and was included in the reimbursement system from December 2010. The requirement for reimburse - ment of anti-dementia drugs set by the Norwegian authorities is that \"the effect of treatment should be monitored and documented in the patient's medical records at least every 6 months\" .1.2 Bruk av legemidler mot aldersde- prevalence (per 100) of anti-dementia drugs (N06D) prescriptions in men and women 65 years in Norway in the period 2007-20112,5 2,01,5 1,0 0,5 0Proportion (%) of the population 65 years Women Men Year 2007 2008 2009 2010 2011 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 19Figure 1.2.a shows the percentage (prevalence) of elderly 65 years who had at least one anti-dementia drug dispensed. The proportion has remained rela- tively stable in the period 2007-2011, around 2% for women and around 1.5% for men. 63% of all patients using anti-dementia drugs in 2011 were women. The high proportion of women is probably partly influenced by the fact that there are more elderly women than men in Norway. 95% of all patients using anti-dementia drugs in 2011 were 65 years or older. There were a total of 14 000 home-dwelling users of anti-dementia drugs in 2011 aged 65 years, of whom around 5000 individuals were new users. New users of anti-dementia drugs were defined as those who had not been dispensed drugs in this class in the preceding year, i.e. 2010. The annual number of new users and the total number of users have remained relatively unchanged in the period 2007-2011, implying that there is a balance between the numbers who start and stop treatment during a year. Lack of efficacy and adverse events can be reasons for stopping treatment. In addition, patients who are admitted to nursing homes or those who die in the course of the year will not be registered in the NorPD. Data on drug prescriptions to individuals in nursing home are not included in the figures presented in this report. Based on the sales in number of doses (DDD) in 2011, it is estimated that around 30% of total sales of anti-dementia drugs can be attributed to use in Figur %. 63 % Norge. 95 % av demensmidler 2011 var at rundt 30 % alt hypnotics/sedatives (N05C) and elderly population who were dispensed anti-dementia drugs in 2011 compared to the total Norwegian population aged 65 years40 35 30 25 20 15 10 5 0Proportion (%) of the population 65 years Women Men Total population Antipsychotics Total population Hypnotics and sedatives Total population Anxiolytics Total population Antidepressants Anti-dementia drug patientsAnti-dementia drug patients 20 Legemiddelstatistikk 2012:2 Folkehelseinstituttetnursing homes. This figure is calculated from the total sales of anti-dementia drugs from the Norwegian Drug Wholesale Statistics (4). Number of users for the various anti-dementia drugs are shown in table 3.13, p. 113. The highest increase in the number of users in 2011 is observed for memantine and this is probably due to the inclusion of memantine in the reimbursement scheme in December 2010. Figures from the NorPD show that patients using anti-dementia drugs also use many other drugs. Table 1.2.a shows the distribution of women and men according to the number of drugs that were dispensed in 2011, where at least one was an anti-dementia drug (N06D). Number of drugs is based on counting of the different ATC codes (active ingredient level) dispensed. Some of the drugs dispensed can be used for acute short-term disease e.g. antibacterials for treatment of infections, while other drugs are intended for chronic diseases. This implies that not all drugs are necessarily prescribed for concurrent use. Changes in drug therapy will also influence the total number of drugs dispensed to a patient during a year. Overall, around 30% of all dementia patients will have more than 10 drugs dispensed during 2011. The use of many drugs will increase the risk of drug-related problems. Figure 1.2.b shows the proportion who had at least one antipsychotic (N05A), anxiolytic (N05B), hypnotic and sedative (N05C) and/or antidepressant (N06A) among elderly users of anti-dementia drugs in 2011, compared to the total population aged 65 years or older. The use of Antall brukere for de ulike demenslegemidlene er 113. st\u00f8rst sammenheng ble i refusjonsordningen i desember 2010. Tall i midler mot depresjon mens Table1.2.a: Number of men and women (65 years) with at least one dementia drug dispensed in 2011, distributed according to the total number of drugs (ATC codes) dispensed during 2011. Gender1-5 drugs n (%)6-10 drugs n (%)11-15 drugs n (%)>15 drugs n (%)Total n (%) Men 1 535 (30) 2 277 (44) 1 013 (20) 337 (7) 5 162 (100) Women 2 310 (26) 3 807 (43) 1 916 (22) 779 (9) 8 812 (100) Total 3 845 (28) 6 084 (44) 2 929 (21) 1 116 (8) 13 974 (100)Legemiddelstatistikk 2012:2 Folkehelseinstituttet 21the specified drug groups was higher in the dementia population compared to the total population. The differences were particularly visible for the use of antidepressants and antipsychotics. In the dementia group, 36% of women used antidepressants compared to 14 % in the total population. For men, the corre - sponding figures for antidepressants were 24 and 7% (figure 1.2.b). It is not unexpected that the use of psychotropic drugs is higher in the dementia group as this is a particularly vulnerable group of patients with more anxiety and depression. Focus on the optimal use of psychotropics in dementia patients is of importance in order to achieve optimal treatment and reduce unfavorable over-treatment.gjennomsnittet i befolkningen var 14 %. For menn var tilsvarende andeler 24 og 7 % er en spesielt (www.aldringoghelse.no) 3. 2011 Alzheimer's disease facts and figures. Alzheimer's Association Report, Alzheimer's & Dementia 2011; of cardiovascular drugs in the elderly (ATC group C) Cardiovascular disease increases with age and this chapter will focus on the use of medicines among the elderly (aged 65 years or older). Drugs classified in ATC group C are used to treat different diseases such as hypertension, heart failure, angina pectoris and high cholesterol. The use of cardiovascular drugs in the general population has been presented in previous reports (1, 2). In 2011, a total of 520 591 elderly men and women had at least one prescription dispensed for a medicinal product in ATC group C. This corresponds to a one- year prevalence of 65% in women and 67% in men. This is an increase compared to 2005 where the prevalence was 60% in women and 61% in men (figure 1.3.a). The proportion using these drugs increases with age up to about 90 years (figure 1.3.b). In 2011, over 70% of the 75-89 year age group had at least one cardiovascular drug dispensed. Use of medicines to treat hypertension and other cardio - vascular disease Drugs in various groups such as diuretics (C03), beta blockers (C07), calcium channel inhibitors / angiotensin II blockers (C09) are used to treat different diseases. such as high blood pressure, angina, oedema and heart failure.1.3 \u00e5rs prevalens p\u00e5 65 % hos og 67 % hos menn. Dette er en \u00f8kning i forhold til 2005 hvor prevalensen var 60 % hos kvinner og 61 1.3.a: One-year prevalence (per 100) of cardiovascular prescriptions (ATC group C) in the Norwegian population aged 65 years or older 2005-2011100 90 807060 50 40302010 0Proportion (%) of the population 65 years Women Men Year 2005 2006 2007 2008 2009 2010 2011 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 23In 2011, over half of the elderly population had at least one prescription dispensed for a medicinal product in one of these groups (57% women and 60% men). Figure 1.3.c shows the prevalence of use of the various groups in the period 2005-2011 in women and men. The greatest increase in the proportion of users is seen in drugs acting on the renin-angiotensin system (C09). I 2011 fikk One-year prevalence (per 100) of cardiovascular prescriptions (ATC group C) in 2011 in the Norwegian population aged 65 years or older100 90 807060 50 40302010 0Proportion (%) of the 75-79 80-84 85-89 90+ (C07), calcium channel inhibitors (C09) in the period 2005-2011 in the Norwegian population aged 65 years or older45 40 35 302520 15 10 5 0Proportion (%) of the population 65 years ACE-inhibitors/ARBs Beta blocking agents Calcium channel blockers Diuretics Women Men 2005 2006 2007 2008 2009 2010 2011 2005 2006 2007 2008 2009 2010 2011 24 Legemiddelstatistikk 2012:2 FolkehelseinstituttetThe ATC group C09 includes ACE inhibitors and Angio - tensin II Receptor Blockers (ARBs), both plain and in combination products (e.g. combined with a diuretic such as hydrochlorothiazide). More women than men use plain diuretics (C03). The proportions have declined slightly in both genders from 2008 to 2011. The reduced use of diuretics should be seen in rela- tion to the increased use of combination products of thiazide with ACE-inhibitors or ARBs (data not shown). The proportion using beta blockers has remained fairly stable since 2007 with around 32% among men and 28% among women. Beta blockers are important in the treatment of heart failure but are no longer the drug of choice to treat essential hypertension (3,4). Initiation of antihypertensive therapy A recently published article based on data from the Norwegian Prescription Database showed that thiazides and ARBs were the most widely used first-line drugs in new patients with hypertension (5). This is in line with the new guidelines for the treatment of uncomplicated hypertension. The same study also showed that treat - ment of hypertension continued over time, with 80% of new users of thiazides or ARBs still using medicines after one year and around three-quarters still receiving treatment after four years. Over time there was little difference between the groups who initially received thiazides and ARBs, however more thiazide users switched to other antihypertensives during the four year follow up. The results show good persistence of treatment of hypertension among new users in Norway, higher than figures reported by other countries.ATC-gruppe C09 inkluderer b\u00e5de preparater og (med 2011. reduserte bruken av rene diuretika m\u00e5 ses at tiazider og ARB var de vanligste legemidlene som h\u00f8yt i av tiazidbrukerne Resultatene Figure 1.3.d: One-year prevalence (per 100) of prescriptions of statins in the Norwegian population aged 65 years or older in 201170 6050 40 30 2010 0Proporton (%) of the population Men Age (years) 65-69 Norway still has a high use of statins compared with other European countries (6,7). Among the elderly population, 33% women and 39% men in Norway were dispensed at least one statin prescription in 2011 (figure 1.3.d). The proportion using statins has increased steadily over time and men use more than women. Usage increases with age up to 80 years. In the 75-79 year age group , the proportion was 40% in women and 45% in men. The prevalence of statin use declines in the oldest age groups, implying that there is less secondary prevention with statins for reducing new cardiovascular events and mortality. It should also be emphasised that there is no adjustment for the number of elderly living in nursing homes which is highest among the oldest age groups. Usage in nursing homes is not included in the figures presented in this report. While the prevalence of statin use in the popula- tion has increased over time, the proportion of new users (i.e. the ratio between the number of new users and the number of people who did not receive a statin in the preceding year) has been fairly stable (figure 1.3.e). Annually, the proportion of new users of statins was around 4-5%. Since the annual prevalence is increasing, this means that the number of new users is higher than the numbers who cease statin use. This is as expected since statins are intended for long-term treatment. The viser god etterlevelse av blodtrykksbehandling hos nye bruker i Norge, bedre enn det som er beskrevet i andre land. Statiner har fortsatt et h\u00f8yt av statiner til andre land (6,7). I 2011 fikk 33 % av kvinner var henholdsvis 40 statinbehandling enn de som slutter. Figure 1.3.e: Yearly incidence rate of use of statins (%) in the Norwegian population aged 65 years or older6 5 4 321 0Incidence (%) in population 65 years Women Men Year 2005 2006 2007 2008 2009 2010 2011 26 Legemiddelstatistikk 2012:2 Folkehelseinstituttetdata show that 91% of all statin users in 2010 also had a statin dispensed in 2011, while for new statin users, the corresponding figure is 80%. It should be noted that these figures are not adjusted for deaths and change of residence to nursing homes during the year. Many statin users are also dispensed other cardiovas- cular drugs. In the elderly 82% had at least one other drug in the ATC group C dispensed in 2011.Dette har sammenheng med at statinbehandling er en kronisk behandling. alle statinbrukere i 2010, hentet statin ogs\u00e5 Database 2004-2007), Nasjonalt folkehelseinstitutt, rapport Reseptregisteret 2005-2008 (The A, Kristiansen IS, Th\u00fcrmer H and Flottorp S. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Medicine 2012, 10:33 5. Selmer R, Blix HS, Landmark K, Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use - a 4-year follow-up of 78,453 incident users. Eur J Clin Pharmacol 2012. 6. OECD Health Data: Pharmaceutical market, 2011. (www.oecd-ilibrary.org) 7. Medicine Consumption in the Nordic Countries 2004-2008, NOMESCO (www.nom-nos.dk)Legemiddelstatistikk 2012:2 Folkehelseinstituttet 271.4 Use of drugs for osteoporosis in the elderly population The incidence of osteoporotic fractures in the Norwe - gian population is among the highest ever reported (1-4). Annually, adult Norwegians suffer about 9 000 hip fractures and 15 000 forearm fractures, with 140 000 women experiencing vertebral fractures (1). At any time, approximately 250 surgical ward beds will be occupied by hip fracture patients and the mortality after hip fractures is high (5). One third of those 85 years or older who lived at home before the fracture, lived in nursing homes one year after the fracture (6). Prevention of these fractures is possible, both through lifestyle changes and drug therapy. This could poten- tially save unnecessary expenses for society and pain, suffering and loss of quality of life for each patient. Several types of drugs against osteoporosis have been introduced in the last 10-15 years. Until 1996, the only effective drug for osteoporotic patients was oestrogen. Since 1996, the following osteopo no longer recommended as first choice, and not for long periods of time because of serious side effects. Stron- tium ranelate has not been marketed in Norway, and is therefore not presented in the statistics.1.4 Bruk av midler mot osteoporose hos eldre i et underarmsbrudd. Vel 140 000 norske kvinner har ca. 250 sykehussenger vil en tid ha en hoftebruddpasient. D\u00f8delig-heten etter hoftebrudd grad brukes i behandlingen av osteoporose i andre land, er 1.4.a: One-year prevalence 100) of bisphosphonate drug use in the period 2005-2011 in Norwegian women aged 65 years or older12 11 10 98 7 65 4 3 2 1 0Proportion (%) of the female population 65 years Year 2005 2006 2007 2008 2009 2010 2011 Total bisphosphonates Alendronate Etidronate Zoledronate Other bisphosphonates 28 Legemiddelstatistikk 2012:2 FolkehelseinstituttetIn the time period covered in this report, reimburse - ment of these drugs has been available in Norway. The prerequisite for reimbursement is the diagnosis established osteoporosis, i.e. a bone mineral density T-score of -2.5 or lower with the presence of at least one fragility fracture. Table 1.4.a shows one-year prevalence in percent of anti-osteoporotic drug use in Norwegian women and men 65 years. Overall, use of these drugs has been stable since 2005, with a prevalence of 10% in women and 1% in men each year. A slight fall in the numbers using bisphosphonates and alendronate can be observed in women. For both men and women, bisphosphonates are the most commonly used anti- osteoporotic drug type, and alendronate is the most used bisphosphonate. The use of teriparatide, raloxi-fene and calcitonin is negligible and declining during this time period. Figure 1.4.a shows one-year prevalence in percent, of bisphosphonate use in the period 2005-2011 in Norwe - gian women aged 65 years or older. As we could observe in table 1.4.a the use of these drugs has been relatively stable, although we observe a slight decrease in the proportion of use, both in the total use and in most of the other bisphosphonates. The only increase observed is in the use of zoledronate. This is a new drug, available on the Norwegian market since 2005, with a new admin- istration form. Oral bisphosphonate therapy has been associated with caustic injury in the oesophagus and poor compliance because of a complex dosing regime. I den som har diagnosen etablert osteoporose, det vil gis \u00e5rlig. Oral bisfosfonatbehandling har incidence rate (per 100) of anti-osteoporosis drug use in the period 2005-2011 in the Norwegian population aged 65 years or older2,5 2,01,5 1,0 0,5 0Incidence (%) in population 65 years Women Men Year 2005 2006 2007 2008 2009 2010 2011 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 29However, zoledronate is an infusion administered once a year and is expected to improve compliance and to be free from potential caustic injuries. The same pattern in use is observed in men (results not shown). Figure 1.4.b illustrates annual incidence rates in percent, in women and men, of anti-osteoporosis drug use in the period 2005-2011 in the Norwegian popula- tion aged 65 years or older. In women, the incidence declines in the period 2005-2008, and stabilises in the time period 2009-2011. In men, the incidence rate is also declining, however not as obviously as for women. It is somewhat surprising that the incidence rate is declining, as there is no indication that the need for fracture preventive treatment in people with osteo - porosis has been smaller in this time period. The proportion of use increases with age (figure 1.4.c). This is expected, since age is an important risk factor for osteoporosis and that osteoporosis prevalence increases with age. A considerable proportion among those 85 years and older will reside in nursing homes or long-term care facilities (see table 1.1.a), and use of drugs in these institutions are not registered in NorPD at an individual level. The observed decline in preva- lence in the highest age groups may therefore not give a true picture of the use in these age groups. However, the use of these drugs in long-term care facilities or in-hospital use is limited. Of all anti-osteoporosis drugs prescribed in Norway, measured in defined daily doses, 3.6% were prescribed to nursing homes or for in-hospital use in 2011.for bruk av de som er 85 og 1.4.c: One-year prevalence (per 100) of bisphophonates drug use in the Norwegian population aged 65 years or older in 201120 18161412 10 8 6420Proportion (%) of the population Meyer HE. [Osteoporosis and fractures in Norway. Occurrence and risk factors] Osteoporose og brudd L, Stensvold I, Meyer HE. Epidemiology of hip fractures in Oslo, Norway. Bone 2001;29:413-18. 3. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: The European vertebral osteoporosis study. J Bone Miner Res 1996;11:1010-1018. 4. Lunt M, Felsenberg D, Adams J, Benevolenskaya KT, P , Pols H, Poor G, Reid D, Scheidt-Nave C, Weber K, Silman AJ, Reeve J. Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Nordsletten L, Cappelen I, Kristiansen IS. Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 2004;15:567-74. Table 1.4.a: Number of women and men 65 years and one-year prevalence (%) of users of anti-osteoporosis drugs in Norway 2005-2011 2005 2006 2007 2008 2009 2010 2011 Women Number % Number % Number % Number % Number % Number % Number % Population 403 114 403 584 406 021 410 131 418 219 425 553 437 091 All anti-osteoporosis drugs140 487 10.0 41 284 10.2 41 430 10.2 41 135 10.0 40 915 9.8 41 161 9.7 41 589 9.5 Bisphosphonates239 091 9.7 40 059 9.9 40 271 9.9 40 077 9.8 39 973 9.6 40 313 9.5 40 702 9.3 Alendronate331 370 7.8 34 344 8.5 36 380 9.0 36 467 8.9 36 509 8.7 36 830 8.7 37 026 8.5 Etidronate44 331 1.1 3 567 0.9 3 024 0.7 2 535 0.6 2 111 0.5 1 807 0.4 1 538 0.4 Zoledronate56<0.1 6<0.1 10 <0.1 100 <0.1 450 0.1 911 0.2 1 386 0.3 Other bisphosphonates64 318 1.1 4 961 1.2 1 766 0.4 1 400 0.3 1 312 0.3 1 232 0.3 1 157 0.3 Raloxifene71 505 0.4 1 334 0.3 1 188 0.3 1 084 0.3 951 0.2 845 0.2 742 0.2 Teriparatide870 <0.1 <0.1 57 <0.1 57 <0.1 Men Population 296 878 299 684 305 170 312 079 322 822 333 792 348 535 All anti-osteoporosis drugs13 728 1.3 3 949 1.3 4 022 1.3 4 017 1.3 4 123 1.3 4 245 1.3 4 466 1.3 Bisphosphonates23 710 1.2 3 931 1.3 4 004 1.3 4 005 1.3 4 115 1.3 4 230 1.3 4 409 1.3 Alendronate33 107 1.0 3 479 1.2 3 735 1.2 3 772 1.2 3 877 1.2 3 974 1.2 4 129 1.2 Etidronate4260 0.1 216 0.1 173 0.1 129 <0.1 111 <0.1 <0.1 in- flammatory drugs (NSAIDs) in the elderly Non-steroid anti-inflammatory drugs (NSAIDs) have both anti-inflammatory and analgesic effects. These drugs should be used with caution in patients who also take medicines that may increase bleeding risk, patients prone to ulcers, and patients taking other drugs which in combination with NSAIDs can cause serious side effects (increased gastrointestinal toxicity). Examples of such drugs are antithrombotic agents, proton pump inhibitors (PPIs), glucocorticoids and the class of antidepressant drugs called selective serotonin reuptake inhibitors (SSRIs). Many elderly people are prescribed NSAIDs for short- term use while others use them over a long time. In 2011, approximately 20% of individuals aged 65 or older were dispensed at least one NSAID (ATC code M01A), excluding glucosamine and nabumetone. Of all the NSAIDs dispensed to individuals x65 years, 54% were non-reimbursed whereas 46% were reimbursed. The most common reimbursement codes were rheumatic disorders such as arthritis, and various types of inflammation. In total, 14.2 million defined daily doses (DDD) were dispensed to more than 155 000 individuals aged 65 years in 2011. Approximately 41% of DDDs were 1.5 lang tid. I 2011 var det alderen 65 \u00e5r i l\u00f8pet av 2011. I underkant av 41 % av DDD var p\u00e5 Figure 1.5.a. One year prevalence (%) of NSAIDs prescriptions in men and women aged 65 years in 2011 according to active ingredient12 10 8 6 65 years Generic name Women Men Naproxen and esomeprazoleDiclofenac and misoprostol 32 Legemiddelstatistikk 2012:2 by ibuprofen (23%), and naproxen (14%). About 40% of users were men and they used 36% of DDDs. Use of other drugs in chronic elderly NSAIDs users Figure 1.5.b shows that 25% (38 964) were dispensed more than 100 DDD during the year. If everyone uses one DDD per day, this volume will correspond to approximately 3 months of treat - ment which, in most cases, indicates the treatment of a chronic illness. About 66% of these users were women, reflecting higher incidence of musculoskel- etal disorders in women than in men. Further analysis of the group receiving over 100 DDDs in 2011 showed that in the period 2 months before to 2 months after the last NSAID prescription, almost 60% (23 346) also received at least one drug from the following groups; and 64% were women. Antithrombotic agents were most frequently prescribed together with NSAIDs, followed by PPIs (figure 1.5.c). The most common antithrombotic was acetylsalicylic acid (B01AC06), followed by warfarin (B01AA03). Antithrombotic agents are used to treat or prevent blood clots. NSAIDs increase the risk of gastrointestinal bleeding and combination of these agents may increase this risk. Approximately 38% aged 65 years were dispensed both NSAIDs Omtrent % av alle brukere var menn og de fikk 36 % 25 % (38 964) fikk utlevert mer DDD behand- ling av en kronisk over 100 DDD i 2011, viste at nesten 60 % (23 346) Antitrombotika var Number of defined daily doses (DDD) dispensed for NSAIDs in the population aged 65 years in 2011 80 70605040302010 0Propotion (%) of users period. As exten- sive use of drugs may increase bleeding risk, it is important to closely monitor these patients. Fewer than 24% of individuals in our cohort were given PPIs and NSAIDs in the period. Individuals who receive PPIs for the treatment of oesophagal and stomach ulcers should not use NSAIDs over a long time period. Prescription of PPIs to prevent side effects of NSAIDs use, however, is in line with guidelines. More than 13% were dispensed glucocorticoids used in many inflammatory diseases. More than 9% received selective serotonin reuptake inhibitors (SSRIs) for anxiety and depression. Both of these drugs are shown to cause increased gastrointestinal toxicity in combination with NSAIDs. Data from the Norwegian Prescription Database show that many elderly also receive a number of drugs that may increase the risk of gastrointestinal side effects. NSAIDs should be used with caution in the elderly, especially in individuals with impaired cardiac and renal function. While drugs dispensed from a pharmacy within the same period are not necessarily used together, it still shows that these drug combinations are prescribed. Caution should be shown when individuals in this age group are prescribed drugs since complications of potential harmful combination therapy can be very serious and in some cases life-threatening so these indi- Proportion (%) of users aged 65 years who were dispensed the indicated drug groups in addition to NSAIDs 50 45403530 25 201510 50Proportion (%) of chronic NSAID 65 groupantithrombotics 34 Legemiddelstatistikk 2012:2 Folkehelseinstituttet1.6 Use of hypnotics in the elderly population Sleep problems increase with age (1). Insomnia among the elderly is not always resolved with non-medicinal treatments such as good sleep hygiene advice, so it is often treated with medicines. It is recommended that hypnotics should only be used for short periods. This is particularly important in older age groups because the elderly may have both altered drug metabolism and increased sensitivity to drugs. Therefore, lower doses and hypnotics with shorter half-life are recommended for the elderly. We have looked at drugs that can be used as hypnotics in the elderly. Z-hypnotics and benzodiazepines are the drugs most commonly used as hypnotics. Z-hypnotics, which dominate the market in general, are recom- mended as the first choice (2). We have chosen to include other agents indicated in sleep disturbances, apart from drugs with less than 300 users per year in the 65 age groups. The following drugs are included as hypnotics: ATC group N05BA som legemidler 1.6.a: One-year prevalence (%) of the population in primary care (i.e. outside institutions)1 who had at least one prescription of drugs used as hypnotics2 dispensed in 2011 in Norway by age groups 65 years and gender 1) Estimated population living at home (nursing home residents are subtracted from the total population) 2) 2010 0Proportion (%) of the population in primary care Women Men of the population in primary care (i.e. outside institutions) who had at least one prescription of benzodiazepines, z-hypnotics and other drugs used as hypnotics dispensed in 2011. Shown for the age groups 40-64 (red columns), 65-69, 70-74, 75-79, 80-84, 85-89, 90+ different axis!) 12 10 8 64 2 0Proportion (%) of the population in primary care Diazepam antipsychotics are not included. In calculating the percentage of users (prevalence) in the Norwegian Prescription Database (NorPD), the total population is used as the denominator. Drugs for patients in hospitals or nursing homes are not available at the individual level in the NorPD. For the older age groups, where a large proportion of the population live in nursing homes, this results in too low figures for the proportion (prevalence) of drug users. We have therefore chosen to present the preva- lence based on the population living at home. This will provide a more accurate picture of the prevalence of users in the oldest part of the population. Data is obtained from Statistics Norway about residents in institutions for 2010. The prevalence given in the figures are therefore based on the total population in these age groups minus the number of nursing home residents (see table 1.1.a). Overall, 32% of the population aged 65 years was dispensed sleeping medication from the pharmacy in 2011. The percentage increases from 23% in 65-69 year olds to 52% in those over 90 years. For all age groups included, More women than men used hypnotics (figure 1.6.a). The percentage increases from 30% in 65-69 year old women to 57% in women aged over 90 years; for men the corresponding figures were 15% and 41%. It is mainly 23 % hos 65-69 \u00e5ringene til 52 % hos de over 90 kvinner 57 % hos kvinner 90 \u00e5r, for menn er andelene henholdsvis 15 h\u00f8yest andel brukere Figure 1.6.c: One-year prevalence (%) of the population in primary care (i.e. outside institutions)3 who had at least one prescription of drugs used as hypnotics dispensed in 2004-2011 in Norway by age above 65 years and gender 3) Estimated population living at home (nursing home residents - around 6% - are subtracted from the total population 65 years)30 25 201510 50Proportion (%) of the population 65 years in primary care Women Men Benzodiazepines - anxiolytics (diazepam, oxazepam)Z-hypnotics alimemazine, promethiazine)2005 2007 2009 2011 2005 2007 2009 2011 2005 2007 2009 2011 2005 2007 2009 2011 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 37that contributes to the increased consumption of hypnotics with age (figure 1.6.b). From a ratio of about 14% of the population using zopiclone in the age group 65-69 years, the proportion is about 34% in the age group over 90 years. The highest proportion of users is for z-hypnotics (N05CF), whereas the anxiolytic benzodiazepines benzo - diazepine hypnotics (N05CD). For these three groups of addictive drugs, a slight decrease in the propor - tion of users is observed since 2004 (figure 1.6.c). For z-hypnotics the decline started later than that of the benzodiazepines and the decrease was first observed in men (a decrease from 2007) and later in women (down from 2009). For other agents than benzodiaz- epines and z-hypnotics, prevalence is low and, except clomethiazole, the prevalence for these agents does not increase with increasing age.av z-hypnotika (N05CF), og senere hos kvinner (nedgang fra 2009). For andre midler enn benzodiazepiner og z-hypnotika er prevalensen lav Folkehelseinstituttet1.7 Use of antibiotics in the elderly Use of antibiotics increases with increasing age (1). The total population is used as the denominator in the calculation of prevalence in the Norwegian Prescrip - tion Database (NorPD). Drugs dispensed to patients in hospitals or nursing homes are not available at the individual level in the NorPD. For the older age groups, where a large proportion of the population are living in nursing homes, this results in too low figures for the proportion (prevalence) of drug users. In this chapter on antibiotics, we have therefore chosen to present the prevalence based on the population living at home. This will provide a more accurate picture of the prevalence of users in the oldest part of the popu- lation. Data were obtained from Statistics Norway about residents in institutions in 2010 (see table 1.1.a) and the prevalence in the figures is based on the total population for each age group minus the number of nursing home residents. Overall, 34% of the population in the age group 65 years was dispensed antibiotics from the pharmacy in 2011. The percentage increased from 30% in 65-69 year olds to 46% in those over 90 years. For all age groups more women than men used antibiotics (figure 1.7.a). The percentage increased from 34% in 65-69 year old women to 48% in women aged over 90 years, for men the percentages were 25% and 43%, respec - tively. The trend is stable over the (figure 1.7.b).1.7 hos eldre forskrevet antibiotika fra 30 % hos 65-69 \u00e5ringene til 46 % hos de over 90 kvinner 48 % hos kvinner 90 \u00e5r, for menn er andelene henholdsvis 25 % og 43 %. og trenden er stabil over \u00e5r (figur 1.7.b). Figure 1.7.a: Use of antibiotics for systemic use (J01) in elderly men and women 65 in primary (i.e. living outside institutions), according to age groups in 2007, 2009 and 201160 5040 30 2010 0Proportion (%) of the population in primary care Women Men Age and the number of users of urinary tract antibiotics that increases with age, and the increase is greater among women than in men (figure 1.7.b). 14% of women in the 65-74 year age group and 26% in the > 85 years age group used antibiotics for urinary tract infections and for men the corresponding figures are 5% and 15%. Particularly in men an increase in the number who are prescribed penicillin is seen (figure 1.7.b). The percentage increases from 15% in 65-74 year olds to 20% in those over 85 years. It is not such a sharp increase with age in women, from 15% among 65-74 year olds to 17% in those over 85 years. For both sexes, phenoxymetylpenicillin is most commonly prescribed, followed by amoxicillin. These are the drugs of choice for respiratory infections and bacterial pneumonia.Det er f\u00f8rst og 85 \u00e5r, for menn er tilsvarende tall 5 % og 15 %. Is\u00e6r hos menn ses en % hos 65-74 \u00e5ringene til 20 % hos de over 85 \u00e5r. er ikke like kraftig \u00f8kning fra 15 % hos 65-74 \u00e5ringene til 17 % hos de over 85 riell Figure 1.7.b: Use of antibiotics for systemic use (J01) in men and women 65 year in primary care (i.e. living outside institutions), by different age groups in 2011. Grouped as; antibiotics used in urinary tract infections (UTIs), penicillins, tetracyclines and all other antibiotics for systemic use. 30 25201510 5 0Incidence (%) in population Women Men Antibiotics for UTI (pivmecillinam, trimethoprim, sulfamethoxazole about the Norwegian Prescription Databa-se and drug statistics 2.1 About the NorPD Data collection and variables in NorPD New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescrip - tion data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to: 1. describe drug use patterns, highlighting changes over time 2. promote and form a basis for research and review of the safety and effectiveness of drug use 3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning 4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and admin- istrative registers. 2. Generelt tr\u00e5dte kraft 1. mars 2001, og loven ble apotek utredning inn fra apotek og administrative registre. Part 2 Del 2 42 Legemiddelstatistikk 2012:2 Folkehelseinstituttet The NorPD contains the following variables: Patient Person -identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county) Prescriber Person -identifier (encrypted), year of birth, gender, profession, speciality Drug Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC codes or codes defined by the Norwegian Medi- cines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price) Pharmacy Name , licence number, municipality and county The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009. Since 1 st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD. However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database. The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veter - inarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate m\u00e5nedlig informasjon protection As illustrated in figure 2.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called \"trusted third party centre\" and is a part of the data protection to ensure confi- dentiality of personal information. Statistics Norway only has access to the patient personal identification number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term \"Pseud- onymous health data\" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregister - loven): \"personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed\" (3). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries. Quality checks For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated aggregerte prescriptionsencryptedPrescriptionswith pseudo-nymised pseudonyms *Trusted third Institute of Public Health NorPD 44 Legemiddelstatistikk 2012:2 Folkehelseinstituttet ATC codes and DDD values (4). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identifica-tion Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordina- tions and DDDs can be included in the total statistics. 2.2 Prescription statistic in the other Nordic countries During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, inde - pendent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 25 million inhabitants (Denmark: 5.5 million; and Sweden: 9.2 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection proce - dures and content of the Nordic countries' prescription databases (5). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.kontroller p\u00e5 data 2004 Norge, siden 2005 i Folkehelseinstituttet 45 2.3 The Norwegian Drug Wholesales Statistics Statistics based on total sales of drugs from whole - salers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwe - gian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user. Drug Consumption in Norway - published annually Data from the Norwegian Drug Wholesales Statis- tics Database have been published annually in Drug Consumption in Norway (6) since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugcon- sumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no. 2.4 The Anatomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmaco - logical/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/ thera- peutic sub-groups and the 5th level is the chemical substance. The ATC code A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic plain spironolac - tone (Aldactone\u00ae and Spirix\u00ae) are thus assigned the code C03DA01. The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C - Cardiovas - cular system (1st level), figures for the various sub- groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from the pharmacy medicinal product register and in the monographs of the national drug catalogue \"Felleskatalogen\" . The yellow section of the latter, entitled The Anatomical Therapeutic Chemical Medicines Register, lists all medicinal products belonging to each of the ATC 5th level codes. 2.5 The Defined Daily Dose (DDD) In some tables in part 1 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults. The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should there - fore be regarded as a technical measuring unit. Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their admin-istration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller main- tenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. Alle spironolakton niv\u00e5), tall for de ulike under - gruppene (2., 3. og 4. niv\u00e5) og ned til tall preparater as is the case with combi- nation preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evalu- ating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows: Total consumption measured in number of DDDs x 1000 365 x number of inhabitants This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose. 2.6 The WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (7). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (8). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no.ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2012 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.DDD representer ikke tallet gi som faktisk brukes. 2.6 WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av for ATC classifica- tion and DDD assignment (7). ATC Index with DDDs, som inneholder en liste over alle - nene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology. Referanser/References: 1. Forskrift om Filing Lov av 18.mai 2001 4. R\u00f8nning M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. Italian J Public Health 2006;3(1):30-35. 5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic countries as cohort pharmacoepi-demiological research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94. 6. Sakshaug S Norway 2007-2011. [Legemiddelforbruket i Norge 2007-2011] Oslo: Norwegian Institute of Public Health, 2012. 7. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011. 8. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2007-2011 3.1 Selected key figures from NorPD NorPD contains information from all Norwegian phar - macies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2011, almost 95% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4.7% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 15% of total sales of pharmaceuticals in Norway in 2011, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health). 3. Reseptregisteret 2007-2011 n\u00e6rmere % av legemidlene i Number of individuals and one-year prevalence (%) of the population who had at least one prescrip - tion dispensed in Norway 2007-2011 Women n (%)Men n (%)Both genders n (%) 2007 1 774 835 (75.0) 1 440 441 (61.5) 3 215 276 (68.3) 2008 1 800 432 (75.3) 1 470 133 (61.8) 3 270 565 (68.6) 2009 1 839 804 (76.1) 1 522 917 (63.2) 3 362 721 (69.6) 2010 1 842 423 (75.3) 1 510 043 (61.8) 3 352 466 (68.6) 2011 1 879 188 (76.0) 1 551 319 (62.6) 3 430 507 (69.3)Part 3 Del 3 50 Legemiddelstatistikk 2012:2 FolkehelseinstituttetSince January 2004 more than 4.9 million individuals have been included in NorPD with at least one prescrip - tion medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period (2004-2011) is 285 million. In 2011, 69.3% of the Norwegian population had at least one prescription dispensed, 76% of women and 62.6% of men (table 3.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identification number was 3.7%. In the period 2005-2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identification number has declined further to just below 1.4 % in 2008 and 2009. In 2010 and 2011 the propor - tion was less than 1% (0.87% in 2011). The age-specific one year prevalence for having a drug dispensed in 2011 was lowest in both genders at about 10-14 years of age (figure 3.1). About 90 % of individuals aged 70 years and older received prescrip - tion medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10-15 % in women aged 15-29, although the proportion of drug users among women over 15 years of age was still higher than in men.Reseptregisteret ble opprettet 1. januar 2004 og 2009 har den ligget p\u00e5 i underkant av 1,4 %. I 2010 og var andelen uten gyldig f\u00f8dselsnummer under 1 3.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2011 in Norway according to age and gender Women 40 20 0 Age Legemiddelstatistikk 2012:2 Folkehelseinstituttet 51Table 3.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R). Table 3.1.c lists the medicines with most users in Norway in 2011. The medicines (defined as ATC 5th levels) used by most individuals are analgesics (diclof- enac, and the combination of codeine / paracetamol). Phenoxymethylpenicillin (antibacterial) has for the last three years been number two on the list. Paracetamol (analgesic) is number five on the list in 2011 as compared to number 7 and 8 in the two previous years. Paracetamol is also used by many individuals without prescription and this use is not covered by NorPD. Erythromycine (antibacterial), used e.g. for treatment of mycoplasma infections, has shown a significant increase in number of users in 2011 and is number 16 on the list as compared to number 21 in 2010. In general the list comprises mainly the same medicines as previous years but with some changes in the sequence. Tabell 3.1.b i 2011. De legemidlene som 5. niv\u00e5er) som og er nummer p\u00e5 listen (nr. 21 i 2010). For 3.1.b: One-year prevalence, or % of the population having at least one prescription dispensed, in Norway in 2011 according to the main ATC groups ATC Women %Men %Both genders % A Alimentary tract and metabolism 17.1 12.9 15.0 B Blood and blood forming organs 12.0 12.2 12.1 C Cardiovascular system 20.7 19.6 20.2 D Dermatologicals 13.8 11.5 12.6 G Genito urinary system and sex hormones 24.6 5.5 15.0 H Systemic hormonal preparations, excl. sex hormones and insulins 11.0 5.3 8.1 J Anti-infectives for systemic use 31.7 21.9 26.8 L Anti-neoplastic and immunomodulating agents 1.8 1.5 1.6 M Musculo-skeletal system 21.5 16.0 18.7 N Nervous system 30.7 21.0 25.8 P Anti-parasitic products, insecticides and repellents 2.4 1.4 1.9 R Respiratory system 27.7 21.7 24.7 S Sensory organs 14.2 10.8 12.5 V Various 0.4 0.4 0.4 52 Legemiddelstatistikk 2012:2 FolkehelseinstituttetTable 3.1.c: Legemidler with the highest number of users i Norway 2011 ATC code Active ingredient UseNumber of individualsProportion (%) of the population 1 M01AB05 diclofenac NSAID/analgesic 483 075 9.8 2 J01CE02 3 N02AA59 387 870 7.8 acid 377 732 7.6 5 336 593 6.8 6 C10AA01 375 5.5 10 C07AB02 metoprolol Antihypertensive/cardiac disease 261 240 5.3 11 M01AE01 ibuprofen Analgesic 226 784 4.6 12 R03AC02 507 4.2 13 684 4.1 534 3.8 15 H03AA01 levothyroxine supplement 181 635 3.7 16 Antibacterial 170 300 3.4 17 H02AB06 159 500 3.2 18 148 562 3.0 19 R01AD09 mometasone Anti-allergic nose spray 144 388 2.9 20 C10AA05 atorvastatin Cholesterol lowering 140 846 2.8 21 R05CB01 acetylcysteine Mucolytic 139 313 2.8 22 N02AX02 tramadol Analgesic 138 458 2.8 23 N05BA04 oxazepam Anxiolytic 131 920 2.7 24 J01CA04 amoxicillin Antibacterial 131 884 2.7 25 N05BA01 diazepam Anxiolytic 128 251 2.6 26 A02BC05 esomeprazole Reflux oesofagitis 125 625 2.5 27 125 071 2.5 28 disease 121 600 2.5 29 N06AB10 escitalopram Antidepressant 107 161 2.2 30 A10BA02 og spesielt for utenom apotek, er med i den 3.2 Description of the main tables The tables in Section 3 of this book provide an over - view of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for 0.87% of the dispensed medicines to individuals in 2011. The tables contain figures for the period 2007-2011. In addition, the following information for 2011 includes: Share of women (%) of the total number of indi-viduals who have had at least one prescription dispensed The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15-44, 45-69, 70 Sales in million Norwegian kroner (mNOK), i.e. for prescriptions dispensed to individuals with a personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy. The tables are arranged according to the ATC system (see further description in p. 45). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institu- tions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institu- tions. The following ATC groups have been omitted: B05 Blood substitutes and perfusion solutions S01J Diagnostic agents S01L Ocular vascular disorder agents V Various (ATC group V01 Allergens is included in (se ogs\u00e5 s. 45). I tabellene i del 3 i denne minst ett av Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in \"Drug Consumption in Norway\" (see also page p. 45). A footnote is used in the tables in part 3 of this book in the various ATC codes where OTC medicines are available in Norway. In 2011, OTC medicines had a share of 15% of total sales measured in DDDs. These shares have remained almost unchanged over time. Most prescribed medicines have an approved marketing authorisation in Norway. However, physi- cians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called \"negative list\" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables. Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the Figure 3.2: The report generator at www.reseptregisteret.no (English version kroner som filbe - handling m\u00e5 p\u00e5regnes.tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another. The NorPD website: www.norpd.no The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 3.2), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name. The following data on drug use can be extracted from the website: Number of users, split by gender, 10-year age groups, county or health region Number of users per 1 000 population (prevalence per 1 000) Turnover in NOK (pharmacy retail price) Turnover in doses (DDD - defined daily doses) Population base for the statistics, split by gender, age, county or health region Data are available from 2004 with an annual update for the preceding year. The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at another date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website. Access to data from NorPD It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to Datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required. 56 Legemiddelstatistikk 2012:2 FolkehelseinstituttetBeregning av \u00e5ret (utleve - rings\u00e5r minus f\u00f8dsels\u00e5r).Calculation of prevalence per 1000 inhabitants Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescrip - tion dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example: The population in Norway for the years 2007-2011 is shown on p. 127. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year). Antall individer x 1000 998 419 x 1000 Antall innbyggere = 4 953 216 = 201,6 individer som i 2011: 419 Antall innbyggere i Norge per 1. juli 2011: 4 953 av prevalens (per 1000) for av hjerte-/ karmidler i Norge i 2011: The number of individuals x 1000 998 419 x 1000 The number of inhabitants = 4 953 216 = 201.6 individuals per 1000 inhabitantsThe number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2011: 998 419 The number of inhabitants in Norway as of 1st July 2011: 4 953 216Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2011: Legemiddelstatistikk 2012:2 Folkehelseinstituttet 573.3 ATC main groups ATC level2007 2008 2009 2010 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 A ALIMENTARY TRACT AND METABOLISM 610 766 647 848 678 424 702 527 742 144 57 21 630 169 883 332 767 217 864 1 441 744 B BLOOD AND BLOOD FORMING ORGANS 523 020 541 141 562 343 581 346 597 870 50 2 762 55 054 260 062 279 992 702 960 C CARDIOVASCULAR SYSTEM 883 033 917 229 945 884 975 140 998 419 51 5 529 94 538 522 767 375 585 1 879 102 D DERMATOLOGICALS 582 681 589 450 587 812 611 440 624 324 54 79 383 234 254 210 351 100 336 228 140 G GENITO URINARY SYSTEM AND SEX HORMONES 678 886 692 715 703 423 721 846 745 296 82 3 276 415 107 230 716 96 197 842 612 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 342 524 357 070 375 464 387 820 402 895 67 16 472 108 182 172 886 105 355 418 533 J ANTIINFECTIVES FOR SYSTEMIC USE 1 236 736 1 247 164 1 394 472 1 252 356 1 326 119 59 176 429 536 866 423 376 189 448 699 249 L ANTINEOPLASTIC AND IMMU-NOMODULATING AGENTS 65 309 70 154 72 795 76 656 81 605 54 1 180 17 972 38 192 24 261 2 168 965 M MUSCULO-SKELETAL SYSTEM 915 415 907 360 891 127 901 910 927 190 57 14 195 334 035 421 567 157 393 286 442 N NERVOUS SYSTEM 1 181 693 1 208 796 1 230 916 1 248 502 1 279 567 59 30 739 407 577 554 377 286 874 2 554 961 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 88 000 89 343 86 714 88 743 92 281 63 3 186 42 467 36 347 10 281 33 169 R RESPIRATORY SYSTEM 1 153 020 1 151 929 1 183 767 1 183 735 1 223 304 56 182 251 448 141 430 104 162 808 1 478 331 S SENSORY ORGANS 585 905 596 101 596 290 609 467 617 591 57 118 923 181 573 188 647 128 448 308 635 V VARIOUS 10 023 11 571 13 317 15 900 18 601 49 2 926 6 862 5641 3 172 71 097 58 Legemiddelstatistikk 2012:2 Folkehelseinstituttet3.4 ATC group A - Alimentary tract and metabolism ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 A ALIMENTARY TRACT AND METABOLISM 610 766 647 848 678 424 702 527 742 144 57 21 630 169 883 332 767 217 864 1 441 744 A01 STOMATOLOGICAL PREPARATIONS 18 366 18 177 11 205 6 463 9 154 57 356 3 570 3 210 2 018 1 440 A01A STOMATOLOGICAL PREPARATIONS 18 366 18 177 11 205 6 463 9 154 57 356 3 570 3 210 2 018 1 440 A01AA Caries prophylactic agents 601 618 665 776 4 791 58 34 1 722 1 706 1 329 674 A01AA01 sodium fluoride 1)601 618 665 776 4 791 58 34 1 722 1 706 1 329 674 A01AB Antiinfectives and antisep - tics for local oral treatment 8 913 8 944 8 998 4 088 2 553 53 171 1 023 884 475 269 A01AB02 hydrogen peroxide 1)53 <5 0 <5 A01AB03 chlorhexidine 1)2 283 2 312 2 293 2 540 2 482 53 168 1 000 858 456 206 A01AB04 amphotericin B 6 514 6 554 6 690 1 529 52 71 0 17 19 16 52 A01AB09 miconazole 12 <5 5 <5 5 60 <5 <5 0 0 9 A01AB11 various 1)11 18 22 26 14 86 0 <5 7 <5 2 A01AB17 metronidazole 106 108 45 0 0 - 0 0 0 0 0 A01AC Corticosteroids for local oral treatment 8 821 8 434 1 026 1 155 1 379 63 128 485 554 212 344 A01AC01 triamcinolone 8 821 8 434 1 026 1 155 1 379 63 128 485 554 212 344 A01AD Other agents for local oral treatment 402 550 598 508 516 58 26 360 97 33 152 A01AD01 epinephrine 6 7 6 9 10 40 0 <5 6 <5 7 A01AD02 benzydamine 368 515 562 475 494 59 21 353 89 31 143 A01AD11 various 28 28 30 24 12 50 5 <5 <5 <5 2 A02 DRUGS FOR ACID RELATED DISORDERS 277 446 298 397 316 609 338 746 366 428 54 6 669 81 415 175 643 102 701 368 198 A02A ANTACIDS 4 499 4 296 4 537 4 691 4 777 44 146 1 079 1 683 1 869 5 827 A02AA Magnesium compounds 0 0 0 0 5 40 0 0 <5 <5 2 A02AA02 magnesium oxide 0 0 0 0 5 40 0 0 <5 <5 2 A02AC Calcium compounds 1 414 1 398 1 293 1 229 1 085 36 11 135 413 526 800 A02AC01 calcium carbonate 1)1 414 1 398 1 293 1 229 1 085 36 11 135 413 526 800 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1 547 1 240 1 495 1 485 1 526 60 52 696 487 291 216 A02AD01 ordinary salt combinations 1)1 547 1 240 1 495 1 485 1 526 60 52 696 487 291 216 A02AH Antacids with sodium bicarbonate 2 107 2 166 2 187 2 341 2 471 34 41 269 925 1 236 4 560 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPH-AGEAL REFLUX DISEASE (GORD) 274 929 296 148 314 287 336 339 364 136 54 6 570 80 951 174 927 101 688 362 371 A02BA H2-receptor antagonists 60 233 59 188 58 630 57 804 57 041 59 1 225 15 671 25 984 14 161 18 437 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 59A02BA01 cimetidine 6 270 356 56 46 62 0 <5 17 14 17 A02BA02 ranitidine 1)50 376 55 440 55 484 54 984 54 639 59 1 213 15 330 24 862 13 234 16 187 A02BA03 famotidine 1)3 920 3 448 2 878 2 547 2 313 56 11 284 1 115 903 2 186 A02BA07 ranitidine bismuth citrate 247 <5 0 0 0 - 0 0 0 0 0 A02BA53 famotidine, combinations 1)306 351 378 367 221 65 <5 82 74 63 47 A02BB Prostaglandins 237 267 248 259 255 80 0 135 78 42 191 A02BB01 misoprostol 237 267 248 259 255 80 0 135 78 42 191 A02BC Proton pump inhibitors 227 639 250 321 269 754 292 835 321 935 54 5 494 69 299 156 197 90 945 343 128 A02BC01 omeprazole 40 041 44 880 46 873 47 082 48 114 55 3 238 9 790 21 375 13 711 49 264 A02BC02 pantoprazole 1)57 054 74 965 85 176 102 237 125 071 54 488 28 819 59 780 35 984 48 404 A02BC03 lansoprazole 48 545 50 410 50 018 48 809 47 345 51 404 8 911 24 020 14 010 32 300 A02BC05 esomeprazole 117 306 108 181 111 446 117 963 125 625 55 1 785 27 991 62 695 33 154 213 160 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 1 685 1 837 1 807 1 909 2 140 61 233 670 734 503 614 A02BX02 sucralfate 378 424 403 366 416 56 <5 106 178 130 309 A02BX13 alginic acid 1 312 1 424 1 414 1 549 1 739 62 232 571 560 376 305 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 54 638 58 719 60 485 62 554 65 496 71 1 551 22 681 24 443 16 821 13 974 A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS 3 450 3 365 3 471 3 623 3 148 57 172 669 1 075 1 232 1 397 A03AA Synthetic anticholinergics, esters with tertiary amino group 34 45 28 29 26 81 0 10 14 <5 42 A03AA04 mebeverine 34 42 27 29 26 81 0 10 14 <5 42 A03AA07 dicycloverine 0 <5 <5 0 0 - 0 0 0 0 0 A03AB Synthetic anticholinergics, quaternary ammonium compounds 41 32 112 132 159 41 <5 20 68 69 142 A03AB02 glycopyrronium 28 25 105 128 154 42 <5 16 67 69 140 A03AB05 propantheline 13 7 7 <5 5 0 0 <5 <5 0 3 A03AD Papaverine and derivatives 71 48 37 59 47 19 0 <5 30 13 88 A03AD01 papaverine 71 48 37 59 47 19 0 <5 30 13 88 A03AE Drugs acting on serotonin receptors 19 <5 0 0 0 - 0 0 0 0 0 A03AE02 tegaserod 19 <5 0 0 0 - 0 0 0 0 0 A03AX Other drugs for functional bowel disorders 3 290 3 239 3 302 3 405 2 923 58 170 636 965 1 152 1 125 A03AX13 silicones 3 290 3 239 3 302 3 405 2 923 58 170 636 965 1 152 1 125 A03B BELLADONNA AND DERIVATIVES, PLAIN 1 305 1 101 1 382 1 617 1 910 59 9 786 808 307 712ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 60 Legemiddelstatistikk 2012:2 FolkehelseinstituttetA03BA Belladonna alkaloids, tertiary amines 1 050 861 098 1 297 1 510 56 6 627 638 239 501 A03BA01 atropine 33 27 26 22 23 35 0 5 13 5 22 A03BA03 hyoscyamine 1 017 834 1 072 1 276 1 487 57 6 622 625 234 479 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 259 242 285 321 406 69 <5 162 173 68 210 A03BB01 butylscopolamine 238 223 267 300 386 69 <5 155 163 65 207 A03BB03 methylscopolamine 21 19 18 23 21 71 0 7 11 <5 4 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 30 27 18 19 20 45 0 <5 14 <5 23 A03CA Synthetic anticholinergic agents in combination with psycholeptics 30 27 18 19 20 45 0 <5 14 <5 23 A03CA02 clidinium and psycholeptics 30 27 18 19 20 45 0 <5 14 <5 23 A03F PROPULSIVES 50 518 54 797 56 321 58 104 61 210 72 1 377 21 395 22 879 15 559 11 842 A03FA Propulsives 50 518 54 797 56 321 58 104 61 210 72 1 377 21 395 22 879 15 559 11 842 A03FA01 metoclopramide 50 382 54 676 56 214 57 999 61 088 72 1 359 21 363 22 835 15 531 11 187 A03FA02 cisapride 134 116 93 83 79 63 15 21 30 13 541 A03FA03 domperidone 35 39 44 55 71 65 5 20 27 19 115 A04 ANTIEMETICS AND ANTINAUSEANTS 12 190 12 918 13 054 13 797 14 668 59 269 2 491 8 112 3 796 31 189 A04A ANTIEMETICS AND ANTINAUSEANTS 12 190 12 918 13 054 13 797 14 668 59 269 2 491 8 112 3 796 31 189 A04AA Serotonin (5HT 3) antagonists 9 738 10 498 10 867 11 434 11 985 58 200 1 576 6 811 3 398 25 277 A04AA01 ondansetron 9 013 10 010 10 437 11 150 11 783 58 200 1 570 6 688 3 325 24 A04AA02 granisetron <5 <5 0 15 A04AA03 tropisetron 1 050 755 613 440 324 60 0 20 206 98 1 006 A04AA05 palonosetron 82 6 <5 5 <5 50 0 <5 <5 0 4 A04AD Other antiemetics 3 105 3 138 3 193 3 887 4 658 67 72 1 302 2 668 616 5 912 A04AD01 scopolamine 2 446 2 412 2 111 2 135 2 400 59 69 862 1 077 392 671 A04AD05 metopimazine 23 <5 0 0 0 - 0 0 0 0 0 A04AD10 dronabinol <5 7 5 <5 5 0 34 A04AD12 aprepitant 642 719 1 078 1 761 2 269 77 <5 441 1 596 229 5 207 A05 BILE AND LIVER THERAPY 1 457 1 752 1 913 2 020 2 308 73 85 805 1 076 342 8 803 A05A BILE THERAPY 1 457 1 752 1 913 2 020 2 308 73 85 805 1 076 342 8 803 A05AA Bile acid preparations 1 445 1 749 1 909 2 015 2 303 73 85 804 1 075 339 8 801 A05AA02 ursodeoxycholic acid 1 445 1 749 1 909 2 015 2 303 73 85 804 1 075 339 8 801 A05AX Other drugs for bile therapy 12 5 100 0 <5 <5 <5 2ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 61A06 LAXATIVES 26 333 28 855 31 408 44 230 50 562 57 4 796 7 115 17 868 20 783 25 231 A06A LAXATIVES 26 333 28 855 31 408 44 230 50 562 57 4 796 7 115 17 868 20 783 25 231 A06AA Softeners, emollients 88 69 105 112 208 51 53 32 58 65 128 A06AA01 liquid paraffin 1)88 69 105 112 194 53 48 30 54 62 72 A06AB Contact laxatives 11 941 12 341 13 383 15 058 21 751 60 357 2 282 7 964 11 148 6 177 A06AB02 bisacodyl 1)3 843 3 847 3 858 4 056 6 512 64 96 804 2 157 3 455 1 731 A06AB06 senna glycosides 1)2 138 2 002 2 020 2 120 4 323 66 19 238 1 356 2 710 1 656 A06AB08 sodium picosulfate 1)7 092 7 574 8 584 10 082 10 944 55 247 1 155 4 129 5 413 2 251 A06AB20 contact laxatives in combination 1)11 6 <5 6 8 0 0 A06AB56 senna glycosides, combinations 1)10 17 17 10 12 83 <5 <5 8 2 A06AB58 sodium picosulfate, combinations 1)0 0 0 31 1 579 59 0 219 891 469 532 A06AC Bulk producers 1 586 1 508 1 772 1 996 2 054 61 42 537 782 693 561 A06AC01 ispaghula (psylla seeds) 1)1 575 1 505 1 772 1 996 2 054 61 42 537 782 693 561 A06AC51 ispaghula, combinations 1)11 <5 0 0 0 - 0 0 0 0 0 A06AD Osmotically acting laxatives 14 700 17 176 18 687 30 442 30 635 55 4 257 4 139 10 986 11 253 10 662 A06AD11 lactulose 1)12 320 13 475 13 507 14 464 14 508 52 683 1 821 5 239 6 765 3 856 A06AD12 lactitol 58 68 78 59 58 55 43 7 <5 <5 48 A06AD15 macrogol 0 0 0 45 79 54 76 <5 0 0 69 A06AD17 sodium phosphate 1)602 923 847 9 665 7 332 58 13 1 137 4 079 2 103 1 405 A06AD65 macrogol, combinations 1)2 086 3 327 4 947 7 273 9 941 56 3 590 1 289 2 183 2 879 5 283 A06AG Enemas 4 453 4 522 4 649 4 892 5 457 50 530 1 226 1 840 1 861 6 724 A06AG02 bisacodyl 1)1 574 1 468 1 475 1 410 1 680 46 37 472 670 501 711 A06AG04 glycerol 1)649 689 772 827 905 49 210 218 242 2 809 A06AG10 docusate sodium, incl. combinations 1)1 137 1 213 1 217 1 394 1 484 52 83 335 526 540 1 695 A06AG11 laurilsulfate, incl. combinations 1)1 475 1 511 1 567 1 647 1 825 51 220 285 585 735 1 508 A06AH Peripheral opioid receptor antagonists 0 18 164 197 195 49 0 21 98 76 979 A06AH01 methylnaltrexone bromide 0 18 164 197 195 49 0 21 98 76 979 A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAM - MATORY/ANTIINFECTIVE AGENTS 55 487 60 734 62 602 69 830 72 486 58 6 623 20 118 29 671 16 074 123 082 A07A INTESTINAL ANTIINFECTIVES 21 049 24 718 25 617 31 199 32 188 64 6 105 8 035 11 059 6 989 12 285ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 62 Legemiddelstatistikk 2012:2 FolkehelseinstituttetA07AA Antibiotics 21 049 24 718 25 617 31 199 32 188 64 6 105 8 035 11 059 6 989 12 285 A07AA02 nystatin 20 894 24 493 25 375 30 730 31 528 63 6 099 7 732 10 793 6 904 10 938 A07AA06 paromomycin 49 90 81 154 316 74 5 189 117 5 328 A07AA09 vancomycin 123 158 177 182 200 65 <5 41 78 79 659 A07AA11 rifaximin 0 0 <5 184 211 79 <5 101 99 10 360 A07B INTESTINAL ADSORBENTS 134 146 95 80 84 44 6 29 30 19 10 A07BA Charcoal preparations 134 146 95 80 84 44 6 29 30 19 10 A07BA01 medicinal charcoal 1)134 146 95 80 84 44 6 29 30 19 10 A07C ELECTROLYTES WITH CARBOHYDRATES 281 118 182 259 279 53 129 81 46 23 174 A07CA Oral rehydration salt formulations 1)281 118 182 259 279 53 129 81 46 23 174 A07D ANTIPROPULSIVES 15 085 15 925 16 124 16 735 17 206 56 135 3 452 7 704 5 915 7 034 A07DA Antipropulsives 15 085 15 925 16 124 16 735 17 206 56 135 3 452 7 704 5 915 7 034 A07DA01 12 A07DA02 opium 41 99 94 124 112 57 0 8 56 48 192 A07DA03 loperamide 1)15 017 15 718 15 829 16 464 16 931 56 133 3 346 7 601 5 851 6 740 A07DA53 loperamide, combinations 1)76 221 326 294 282 54 <5 108 104 68 90 A07E INTESTINAL ANTIINFLAM - MATORY AGENTS 20 618 21 365 21 914 22 753 23 690 52 230 8 320 11 512 3 628 100 098 A07EA Corticosteroids acting locally 4 407 4 806 5 014 5 212 5 155 60 53 1 809 2 420 873 15 551 A07EA01 prednisolone 975 1 002 1 011 1 175 1 292 51 11 528 592 161 1 379 A07EA02 hydrocortisone 1 159 1 195 1 233 1 154 408 67 <5 150 209 46 652 A07EA06 budesonide 2 480 2 820 2 972 3 190 3 583 62 42 1 189 1 677 675 13 521 A07EB Antiallergic agents, excl. corticosteroids 71 63 54 53 64 75 22 16 24 <5 416 A07EB01 cromoglicic acid 71 63 54 53 64 75 22 16 24 <5 416 A07EC Aminosalicylic acid and similar agents 18 442 18 950 19 275 19 918 20 669 50 187 7 452 10 042 2 988 84 130 A07EC01 sulfasalazine 6 613 6 461 6 194 6 104 5 966 54 6 1 446 3 414 1 100 7 138 A07EC02 mesalazine 11 301 11 965 12 549 13 330 14 229 48 181 5 834 6 406 1 808 72 79 1 649 A07EC04 balsalazide 890 859 809 750 687 45 <5 276 321 89 2 665 A07F ANTIDIARRHEAL MICROORGANISMS 63 302 694 1 252 1 507 74 39 861 529 78 2 779 A07FA Antidiarrheal microorganisms 63 302 694 1 252 1 507 74 39 861 529 78 2 779 A07FA01 lactic acid producing organisms 0 204 581 918 912 74 10 540 341 21 1 963 A07FA02 saccharomyces boulardii 63 98 116 283 381 73 22 175 130 54 254ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 63A07X OTHER ANTIDIARRHEALS 64 107 139 99 117 80 0 66 45 6 87 A07XA Other antidiarrheals 64 107 139 99 117 80 0 66 45 6 87 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 36 776 37 873 38 343 19 168 10 367 77 <5 4 158 5 463 743 18 451 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 36 776 37 873 38 343 19 168 10 367 77 <5 4 158 5 463 743 18 451 A08AA Centrally acting antiobesity products 17 850 22 024 25 710 5 782 0 - 0 0 0 0 0 A08AA10 sibutramine 17 850 22 024 25 710 5 782 0 - 0 0 0 0 0 A08AB Peripherally acting antiobesity products 16 710 14 563 14 540 14 575 10 367 77 <5 4 158 5 463 743 18 451 A08AB01 orlistat 1)16 710 14 563 14 540 14 575 10 367 77 <5 4 158 5 463 743 18 451 A08AX Other antiobesity drugs 5 242 4 206 <5 <5 0 - 0 0 0 0 0 A08AX01 rimonabant 5 242 4 206 <5 <5 0 - 0 0 0 0 0 A09 DIGESTIVES, INCL. ENZYMES 5 027 5 053 5 126 5 479 5 758 58 123 1 023 2 739 1 873 15 924 A09A DIGESTIVES, INCL. ENZYMES 5 027 5 053 5 126 5 479 5 758 58 123 1 023 2 739 1 873 15 924 A09AA Enzyme preparations 4 962 4 965 5 070 5 441 5 699 58 123 1 011 2 721 1 844 15 886 A09AA02 multienzymes (lipase, protease etc.) 4 962 4 965 5 070 5 441 5 699 58 123 1 011 2 721 1 844 15 886 A09AB Acid preparations 76 104 65 50 61 75 0 9 21 31 31 A09AB01 glutamic acid hydrochloride 1)58 66 52 44 54 74 0 7 18 29 28 A09AB02 betaine hydrochloride 0 0 0 0 <5 100 0 0 0 3 A09AB03 hydrochloric <5 0 A09AB04 citric acid 15 35 10 0 0 - 0 0 0 0 0 A09AC Enzyme and acid prepara-tions, combinations 0 0 0 15 17 94 0 10 6 <5 7 A09AC02 multienzymes and acid preparations 0 0 0 15 17 94 0 10 6 <5 7 A10 DRUGS USED IN DIABETES 131 977 139 101 145 677 152 065 156 540 44 1 834 22 798 80 460 51 448 548 675 A10A INSULINS AND ANALOGUES 49 356 51 156 52 603 54 014 54 993 43 1 811 13 852 24 774 14 556 348 231 A10AB Insulins and analogues for injection, fast-acting 30 993 32 514 33 562 34 874 35 656 43 1 803 12 551 15 459 5 843 125 808 A10AB01 insulin (human) 2 536 2 184 1 823 1 604 1 403 41 13 260 751 379 3 073 A10AB03 insulin (pork) <5 <5 0 0 0 - 0 0 0 0 0 A10AB04 insulin lispro 8 632 8 672 8 615 8 835 9 021 42 156 4 085 3 897 883 36 434 A10AB05 insulin aspart 21 086 22 740 23 900 25 159 25 857 43 1 680 8 456 11 077 4 644 85 140 A10AB06 insulin glulisine <5 145 270 375 404 46 <5 165 192 45 1 162ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 64 Legemiddelstatistikk 2012:2 FolkehelseinstituttetA10AC Insulins and analogues for injection, intermediate-acting 34 030 33 505 33 129 32 520 31 915 42 661 5 824 15 187 10 243 106 182 A10AC01 insulin (human) 34 025 33 503 33 129 32 520 31 915 42 661 5 824 15 187 10 243 106 182 A10AC03 insulin (pork) 7 <5 0 0 0 - 0 0 0 0 0 A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting 10 253 10 261 9 736 9 112 8 303 43 7 587 3 970 3 739 39 123 A10AD01 insulin (human) 43 33 17 <5 <5 0 0 0 0 <5 31 A10AD03 insulin (pork) 0 0 0 0 <5 0 0 0 0 <5 1 A10AD04 Insulin lispro 763 750 672 647 643 45 <5 124 333 183 2 891 A10AD05 insulin aspart 9 482 9 506 9 075 8 476 7 671 43 <5 464 3 645 3 558 36 199 A10AE Insulins and analogues for injection, long-acting 8 144 9 845 11 310 13 695 15 222 45 720 6 307 6 502 1 693 77 119 A10AE03 insulin (pork) 0 <5 <5 <5 0 0 <5 0 0 15 A10AE04 insulin glargine 5 137 6 167 6 958 8 433 9 559 45 250 4 033 4 173 1 103 44 242 A10AE05 insulin detemir 3 102 3 802 4 493 5 526 5 927 46 494 2 396 2 426 611 32 862 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 98 919 105 413 111 436 117 293 121 206 45 24 10 456 67 132 43 594 200 444 A10BA Biguanides 81 208 88 638 95 537 101 637 103 521 45 16 9 510 58 818 35 177 52 597 A10BA02 metformin 81 208 88 638 95 537 101 637 103 521 45 16 9 510 58 818 35 177 52 597 A10BB Sulfonamides, urea derivatives 46 457 47 057 47 349 46 112 43 114 42 8 2 034 22 141 18 931 19 543 A10BB01 glibenclamide 2 127 1 912 1 738 1 539 1 343 43 6 3 A10BB07 glipizide 6 094 5 707 5 229 4 807 4 281 43 0 122 1 782 2 377 2 509 A10BB12 glimepiride 38 632 39 867 40 684 40 028 37 731 41 <5 1 870 19 873 15 986 16 310 A10BD Combinations of oral blood glucose lowering drugs 2 680 2 652 3 852 8 219 10 972 37 0 909 7 471 2 592 49 241 A10BD03 metformin and rosiglitazone 2 680 2 641 2 575 2 284 0 - 0 0 0 0 0 A10BD04 glimepiride and rosiglitazone 0 <5 <5 0 0 - 0 0 0 0 0 A10BD05 metformin and pioglitazone 0 <5 27 32 35 49 0 <5 24 7 164 A10BD07 metformin and sitagliptin 0 0 318 2 187 4 053 36 0 309 2 778 966 17 942 A10BD08 metformin and vildagliptin 0 10 1 068 4 791 7 028 38 0 608 4 770 1 650 31 135 A10BF Alpha glucosidase inhibitors 1 100 988 922 813 701 43 0 30 341 330 1 062 A10BF01 acarbose 1 100 988 922 813 701 43 0 30 341 330 1 062 A10BG Thiazolidinediones 6 461 5 719 5 401 4 672 1 912 40 0 146 1 274 492 8 543 A10BG02 rosiglitazone 5 008 4 193 3 798 3 104 20 65 0 <5 10 9 20 A10BG03 pioglitazone 1 515 1 568 1 641 1 779 1 894 39 0 145 1 266 483 8 522ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 1 752 6 478 9 436 42 0 711 5 976 2 749 40 780 A10BH01 sitagliptin 143 793 1 491 4 799 6 711 42 0 518 4 269 1 924 30 171 A10BH02 vildagliptin 0 6 288 935 1 274 44 0 82 767 425 3 827 A10BH03 saxagliptin 0 0 0 854 1 616 41 0 119 1 041 456 6 783 A10BX Other blood glucose lowering drugs, excl. insulins 530 725 847 1 335 3 523 47 0 543 2 534 446 28 679 A10BX02 repaglinide 435 399 330 283 252 38 0 10 137 105 515 A10BX03 nateglinide 12 13 13 11 9 33 0 <5 7 <5 20 A10BX04 exenatide 85 314 491 554 795 48 0 125 581 89 5 452 A10BX07 liraglutide 0 0 19 535 2 605 47 0 430 1 910 265 22 693 A11 VITAMINS 75 652 79 347 91 052 93 046 102 130 61 698 24 268 38 681 38 483 60 711 A11A MUL TIVITAMINS, COMBINATIONS 0 0 0 0 28 39 24 <5 0 0 99 A11AA Multivitamins with minerals 0 0 0 0 28 39 24 <5 0 0 99 A11AA03 multivitamins and other minerals, incl. combinations 0 0 0 0 28 39 24 <5 0 0 99 A11B MUL TIVITAMINS, PLAIN 31 39 78 100 74 77 34 40 0 0 65 A11BA Multivitamins, plain 31 39 78 100 74 77 34 40 0 0 65 A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO 6 742 7 962 9 836 11 360 17 025 58 284 5 917 6 971 3 853 13 570 A11CA Vitamin A, plain 31 38 29 30 42 60 <5 18 16 5 147 A11CA01 retinol (vit A) 18 22 13 14 20 65 0 7 10 <5 27 A11CA02 betacarotene 13 16 16 16 22 55 <5 11 6 <5 121 A11CC Vitamin D and analogues 6 714 7 931 9 815 11 337 16 991 58 281 5 902 6 960 3 848 13 422 A11CC01 ergocalciferol 1 477 2 034 3 096 4 250 8 653 66 115 4 164 3 507 867 3 483 A11CC03 alfacalcidol 3 190 3 526 3 790 3 884 4 123 45 126 598 1 634 1 765 6 320 A11CC04 calcitriol 1 911 2 085 2 297 2 396 2 632 45 10 412 1 121 1 089 3 261 A11CC05 colecalciferol 221 367 753 939 1 733 73 32 771 773 157 359 A11D VITAMIN B1, PLAIN AND IN WITH VITAMIN B6 AND B12 1)624 697 762 790 749 36 7 105 467 170 509 A11DA Vitamin B1, plain 624 677 745 782 739 35 7 101 466 165 501 A11DA01 thiamine (vit B1) 1)624 677 745 782 739 35 7 101 466 165 501 A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12 0 20 17 8 10 70 0 <5 <5 5 9 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 65 855 68 574 78 387 78 352 82 342 61 244 17 552 31 337 33 209 43 403 A11EA Vitamin B-complex, plain 1)65 084 67 559 77 313 77 144 80 803 61 198 17 153 30 762 32 690 41 999 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 15-44 45-69 70 66 Legemiddelstatistikk 2012:2 FolkehelseinstituttetA11EB Vitamin B-complex with vitamin C 0 58 114 92 155 55 <5 50 48 53 45 A11EX Vitamin B-complex, other combinations 793 986 1 008 1 155 1 443 45 42 357 545 499 1 359 A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS 3 307 3 410 3 507 3 677 3 758 66 9 400 767 2 582 1 097 A11GA Ascorbic acid (vitamin C), plain 3 307 3 410 3 507 3 677 3 758 66 9 400 767 2 582 1 097 A11GA01 ascorbic acid (vit C) 1)3 307 3 410 3 507 3 677 3 758 66 9 400 767 2 582 1 097 A11H OTHER PLAIN VITAMIN PREPARATIONS 1 249 1 181 1 462 1 604 1 730 64 162 939 447 182 981 A11HA Other plain vitamin preparations 1 249 1 181 1 462 1 604 1 730 64 162 939 447 182 981 A11HA01 nicotinamide 14 14 5 65 54 705 281 94 413 A11HA03 tocopherol (vit E) 1)650 590 572 442 412 52 97 132 103 80 478 A11HA04 riboflavin (vit B2) 14 13 16 12 11 55 <5 6 <5 <5 5 A11HA06 pyridoxal phosphate 0 0 0 66 161 87 7 94 58 <5 61 A11HA08 tocofersolan 0 0 0 0 <5 0 <5 0 0 0 12 A11J OTHER VITAMIN PROD - UCTS, COMBINATIONS 51 63 59 61 91 70 43 38 10 0 118 A11JA Combinations of vitamins 51 63 59 48 53 55 42 10 <5 0 91 A11JB Vitamins with minerals 0 0 0 13 38 92 <5 28 9 0 27 A12 MINERAL SUPPLEMENTS 76 580 83 210 91 599 100 956 111 506 79 380 9 813 44 718 56 595 72 609 A12A CALCIUM 56 470 62 611 70 986 80 569 91 198 82 192 8 581 37 947 44 478 57 093 A12AA Calcium 1 449 1 515 1 467 1 417 1 137 69 62 173 455 447 1 155 A12AA02 calcium glubionate <5 <5 9 A12AA04 calcium carbonate 1)371 397 371 412 188 73 <5 21 63 102 51 A12AA06 calcium lactate gluconate 1)1 078 1 123 1 090 984 928 69 58 149 385 336 1 074 A12AA12 calcium acetate anhydrous 11 22 12 28 24 46 0 <5 9 12 22 A12AX Calcium, combinations with other drugs 55 193 61 293 69 722 79 351 90 231 83 130 8 432 37 561 44 108 55 938 A12B POTASSIUM 19 749 20 403 20 533 20 544 20 026 65 83 936 6 421 12 586 12 714 A12BA Potassium 19 749 20 403 20 533 20 544 20 026 65 83 936 6 421 12 586 12 714 A12BA01 potassium chloride 18 225 18 834 18 968 18 800 18 292 66 16 775 5 851 11 650 10 068 A12BA02 potassium citrate 1 799 1 860 1 828 2 055 2 034 64 70 186 666 1 112 2 627 A12BA30 combinations 5 5 <5 <5 <5 50 0 <5 <5 0 19 A12C OTHER MINERAL SUPPLEMENTS 3 345 3 628 3 773 4 004 4 806 60 102 544 1 737 2 423 2 598 A12CA Sodium 379 464 622 715 878 68 <5 58 265 552 438 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 58 265 552 438 A12CB Zinc 904 909 865 767 697 66 55 129 202 311 301 A12CB01 zinc sulfate 904 909 865 767 697 66 55 129 202 311 301 A12CC Magnesium 2 096 2 292 2 338 2 591 3 297 57 44 364 1 298 858 A12CC04 magnesium citrate 24 19 <5 0 0 - 0 0 0 0 0 A12CC10 magnesium oxide 0 9 13 18 101 56 <5 11 39 49 61 A12CC30 magnesium (different salts in combination) 1)2 077 2 272 2 328 2 573 3 211 57 40 356 1 266 1 549 1 762 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 710 660 728 847 866 81 0 242 563 61 591 A14A ANABOLIC STEROIDS 710 660 728 847 866 81 242 563 61 591 A14AA Androstan derivatives 595 561 645 827 841 82 0 231 553 57 475 A14AA07 prasterone 593 560 644 827 841 82 0 231 553 57 475 A14AA08 oxandrolone <5 <5 <5 0 0 - 0 0 0 0 0 A14AB Estren derivatives 117 100 84 21 25 20 0 10 11 <5 112 A14AB01 nandrolone 117 100 84 21 25 20 0 10 11 <5 112 A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 197 329 293 548 663 69 90 329 219 25 152 584 A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 197 329 293 317 335 55 75 125 113 22 152 302 A16AA Amino acids and derivatives 73 93 107 123 131 48 52 48 27 <5 2 824 A16AA01 levocarnitine 56 63 73 87 79 42 44 23 9 <5 1 270 A16AA03 glutamine <5 13 17 12 19 68 0 8 10 <5 23 A16AA04 mercaptamine 8 8 7 10 8 38 5 <5 0 0 645 A16AA06 betaine 6 10 11 16 20 45 5 11 <5 0 883 A16AB Enzymes 44 44 51 50 56 38 <5 25 24 <5 120 213 A16AB02 imiglucerase 9 9 10 7 7 71 0 <5 5 0 14 818 A16AB03 agalsidase alfa 17 17 16 32 33 33 <5 15 12 <5 62 805 A16AB04 agalsidase beta 19 19 23 18 7 57 0 <5 5 0 8 812 A16AB05 laronidase 0 0 0 <5 <5 100 0 <5 <5 0 12 922 A16AB10 velaglucerase alfa 0 0 0 0 6 33 0 <5 <5 0 13 200 A16AX Various alimentary tract and metabolism products 81 198 139 149 151 67 21 53 63 14 29 265 A16AX01 thioctic acid 66 180 122 121 109 72 <5 33 60 14 137 279ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 68 Legemiddelstatistikk 2012:2 FolkehelseinstituttetA16AX04 nitisinone 11 12 12 13 14 21 11 <5 0 0 11 222 A16AX05 zinc acetate <5 <5 <5 7 8 50 0 miglustat <5 0 0 0 1 833 A16AX07 sapropterin 0 0 0 5 15 87 <5 11 <5 0 15 711 ATC group A ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 69B BLOOD AND BLOOD FORMING ORGANS 523 020 541 141 562 343 581 346 597 870 50 2 762 55 054 260 062 279 992 702 960 B01 ANTITHROMBOTIC AGENTS 437 916 455 766 472 409 485 780 497 162 45 418 21 256 217 828 257 660 393 628 B01A ANTITHROMBOTIC AGENTS 437 916 455 766 472 409 485 780 497 162 45 418 21 256 217 828 257 660 393 628 B01AA Vitamin K antagonists 82 073 84 246 86 426 88 728 92 217 40 62 3 426 28 525 60 204 77 571 B01AA01 dicoumarol 70 88 93 90 93 47 0 13 36 44 491 B01AA02 phenindione 45 33 27 24 15 67 0 <5 6 6 65 B01AA03 warfarin 81 970 84 154 86 321 88 629 92 128 40 62 3 411 28 495 60 160 77 015 B01AB Heparin group 25 390 28 157 32 041 36 948 42 023 58 181 9 123 18 639 14 080 96 800 B01AB01 heparin 748 789 826 926 943 54 111 268 B01AB02 antithrombin III 0 <5 <5 0 - 0 0 0 0 0 B01AB04 dalteparin 13 379 15 439 15 917 21 249 25 587 59 47 5 368 11 519 8 653 57 752 B01AB05 enoxaparin 11 591 12 275 15 744 15 362 16 075 57 25 3 677 6 952 5 421 36 751 B01AB10 tinzaparin 0 0 0 0 6 67 0 <5 0 28 B01AC Platelet aggregation inhibitors excl. heparin 353 151 368 206 380 882 390 080 394 903 44 186 10 324 182 588 201 805 211 234 B01AC04 clopidogrel 23 296 25 178 26 429 28 372 29 470 34 <5 1 002 15 285 13 180 49 084 B01AC05 ticlopidine 432 429 420 327 273 47 0 <5 115 155 750 B01AC06 acetylsalicylic acid 344 984 359 578 370 132 376 010 377 732 44 185 9 935 175 242 192 370 104 653 B01AC07 dipyridamole 15 554 18 072 18 755 19 310 19 499 44 0 327 7 490 11 682 21 069 B01AC09 epoprostenol 7 9 7 <5 <5 50 0 4 484 1 996 B01AC21 treprostinil 8 9 9 9 8 75 0 <5 <5 0 14 376 B01AC22 prasugrel 0 0 31 214 487 25 0 28 317 142 2 152 B01AC24 ticagrelor 0 0 0 0 26 38 0 <5 9 16 81 B01AC30 combinations 1 331 2 230 5 557 8 787 11 323 44 0 253 4 764 6 306 12 Direct thrombin inhibitors 0 <5 9 187 1 168 43 <5 35 426 705 5 885 B01AE07 dabigatran etexilate 0 <5 9 187 1 168 43 <5 35 426 705 5 885 B01AX Other antithrombotic agents 7 7 61 208 906 59 <5 103 413 388 1 422 B01AX05 fondaparinux 7 7 75 0 <5 <5 <5 70 B01AX06 rivaroxaban 0 0 45 191 899 59 <5 100 411 386 1 351 B02 ANTIHEMORRHAGICS 12 236 12 621 12 470 12 218 12 951 93 248 6 365 5 760 578 152 853 B02A ANTIFIBRINOLYTICS 11 882 12 227 12 065 11 854 12 574 94 181 6 200 5 680 513 5 295 B02AA Amino acids 11 858 12 204 12 033 11 845 12 572 94 181 6 198 5 680 513 4 578 B02AA02 tranexamic acid 11 858 12 204 12 033 11 845 12 572 94 181 6 198 5 680 513 4 578 B02AB Proteinase inhibitors <5 0 7173.5 ATC group B - Blood and bloodforming organs ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 AND OTHER HEMOSTATICS 398 451 468 419 427 39 77 187 95 68 147 558 B02BA Vitamin K 226 263 275 212 208 65 51 73 33 51 151 B02BA01 phytomenadione 226 263 275 212 208 65 51 73 33 51 151 B02BB Fibrinogen 0 0 0 0 <5 100 0 0 <5 0 43 B02BB01 human fibrinogen 0 0 0 0 <5 100 0 0 <5 0 43 B02BD Blood coagulation factors 172 188 187 189 190 7 26 111 47 6 140 296 B02BD01 coagulation factor IX, II, VII and X in 0 <5 <5 <5 <5 coagulation factor VIII 122 138 129 134 132 1 22 74 34 <5 104 468 B02BD03 factor VIII inhibitor bypassing activity 6 0 0 <5 <5 <5 11 356 B02BD04 coagulation factor IX 26 23 30 28 30 0 <5 21 <5 <5 10 999 B02BD06 von Willebrand factor and coagulation factor VIII in combination 8 14 15 12 9 67 0 6 <5 <5 5 533 B02BD08 eptacog alfa <5 <5 0 B02BD09 <5 <5 0 488 B02BD10 0 0 <5 50 <5 0 0 3 038 B02BX Other systemic hemostatics 0 0 6 18 28 61 0 <5 14 11 7 068 B02BX04 romiplostim 0 0 6 14 15 47 0 <5 6 7 5 328 B02BX05 eltrombopag 0 0 0 <5 15 73 0 <5 9 <5 1 740 B03 ANTIANEMIC PREPARATIONS 112 845 113 447 120 950 129 327 135 589 65 1 961 29 566 49 706 54 356 123 172 B03A IRON PREPARATIONS 18 685 20 058 22 178 24 019 25 066 67 1 250 6 666 5 315 11 835 7 362 B03AA Iron bivalent, oral preparations 17 495 18 754 20 801 22 588 23 591 66 1 248 5 888 4 853 11 602 5 660 B03AA01 ferrous glycine sulfate 1)1 708 2 024 2 892 3 574 4 189 69 63 1 292 1 006 1 828 2 119 B03AA02 ferrous fumarate1)1 208 1 337 1 333 1 320 1 323 50 963 151 60 149 190 B03AA03 ferrous gluconate 0 10 112 101 52 50 6 12 15 19 13 B03AA07 ferrous sulfate1)14 691 15 544 16 693 17 767 18 250 67 222 4 474 3 810 9 744 3 338 B03AC Iron trivalent, parenteral preparations 1 257 1 395 1 461 1 524 1 577 85 <5 818 486 270 1 702 B03AC01 ferric oxide polymaltose complexes 0 0 0 0 <5 100 0 <5 0 0 6 B03AC02 saccharated iron oxide 302 297 288 280 325 79 0 151 108 66 464 B03AC06 ferric oxide dextran complexes 965 1 113 1 189 1 254 1 267 87 <5 673 383 208 1 232 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group B ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales FOLIC ACID 95 348 94 766 100 602 107 726 113 290 65 747 23 988 44 635 43 920 31 048 B03BA Vitamin B12 (cyanocobal-amin and analogues) 67 011 65 577 69 156 76 095 78 958 67 149 16 873 28 616 33 320 18 047 B03BA01 cyanocobalamin 5 378 5 696 6 558 7 389 7 466 68 21 2 206 2 792 2 447 1 628 B03BA02 cyanocobalamin tannin complex 35 668 34 254 36 404 39 772 40 802 66 38 8 733 14 643 17 388 8 999 B03BA03 hydroxocobalamin 27 756 27 457 28 055 31 131 32 945 67 87 6 495 12 007 14 356 7 306 B03BA05 mecobalamin 26 26 16 38 91 82 7 53 28 <5 114 B03BB Folic acid and derivatives 33 592 34 058 36 595 36 320 39 071 61 609 7 773 17 567 13 122 13 001 B03BB01 folic acid1) 33 592 34 058 36 595 36 320 39 071 61 609 7 773 17 567 13 122 13 001 B03X OTHER ANTIANEMIC PREPARATIONS 3 511 3 520 3 639 3 485 3 456 39 26 316 1 260 1 854 84 762 B03XA Other antianemic preparations 3 511 3 520 3 639 3 485 3 456 39 26 316 1 260 1 854 84 762 B03XA01 erythropoietin 867 681 470 334 279 42 <5 28 106 142 6 549 B03XA02 darbepoetin alfa 2 683 2 716 2 785 2 714 2 704 39 23 250 980 1 451 66 885 B03XA03 methoxy polyethylene glycol-epoetin beta 7 230 452 475 516 37 <5 42 194 279 11 328 B06 OTHER HEMATOLOGICAL AGENTS 32 29 45 45 46 65 <5 26 17 <5 15 564 B06A OTHER HEMATOLOGICAL AGENTS 32 29 45 45 46 65 <5 26 17 <5 15 564 B06AC Drugs used in hereditary angioedema 32 29 45 45 46 65 <5 26 17 <5 15 564 B06AC01 c1-inhibitor, plasma derived 32 29 39 35 29 66 <5 15 12 <5 12 189 B06AC02 icatibant 0 0 6 14 23 74 <5 14 8 0 3 375ATC group B ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 72 Legemiddelstatistikk 2012:2 FolkehelseinstituttetC CARDIOVASCULAR SYSTEM 883 033 917 229 945 884 975 140 998 419 51 5 529 94 538 522 767 375 585 1 879 102 C01 CARDIAC THERAPY 130 333 129 659 124 929 122 995 120 507 48 3 706 7 485 40 100 69 216 80 504 C01A CARDIAC GLYCOSIDES 28 141 27 042 25 819 24 749 23 213 48 38 143 4 349 18 683 4 393 C01AA Digitalis glycosides 28 141 27 042 25 819 24 749 23 213 48 38 143 4 349 18 683 4 393 C01AA04 digitoxin 26 937 25 925 24 735 23 709 22 196 48 0 110 4 131 17 955 4 227 C01AA05 digoxin 1 223 1 144 1 123 1 068 1 084 49 38 33 233 780 166 C01B ANTIARRHYTHMICS, CLASS I AND III 9 190 9 879 10 321 11 688 12 398 35 36 577 6 806 4 979 25 732 C01BA Antiarrhythmics, class Ia 202 184 173 159 131 54 0 6 52 73 326 C01BA01 quinidine 9 5 <5 <5 5 100 0 0 <5 <5 27 C01BA03 disopyramide 193 179 170 156 126 52 0 6 50 70 299 C01BB Antiarrhythmics, class Ib 33 26 23 17 17 24 0 <5 9 <5 281 C01BB02 mexiletine 33 26 23 17 17 24 0 <5 9 <5 281 C01BC Antiarrhythmics, class Ic 5 112 5 517 5 783 6 393 6 734 39 34 447 4 306 947 13 966 C01BC04 flecainide 5 111 5 515 5 780 6 390 6 729 39 34 446 4 303 1 946 13 950 C01BD Antiarrhythmics, class III 3 967 4 273 4 475 5 432 5 808 29 <5 131 2 658 3 016 11 159 C01BD01 amiodarone 3 967 4 273 4 475 4 853 4 911 29 <5 107 2 112 2 689 4 064 C01BD07 dronedarone 0 0 0 767 1 034 33 0 27 629 378 7 094 C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES 9 479 12 191 12 217 14 121 15 608 59 3 632 5 582 5 296 1 098 10 455 C01CA Adrenergic and dopaminergic agents 9 479 12 191 12 217 14 121 15 608 59 3 632 5 582 5 296 1 098 10 455 C01CA01 etilefrine 131 115 114 95 112 61 0 33 46 33 242 C01CA03 norepinephrine 0 <5 0 0 0 - 0 0 0 0 0 C01CA17 midodrine 18 14 14 16 20 65 0 12 6 <5 160 C01CA24 epinephrine 9 322 12 058 12 082 14 006 15 470 59 3 632 5 535 5 240 1 063 10 027 C01CA26 ephedrine 11 6 7 6 8 0 0 <5 5 0 26 C01D VASODILATORS USED IN CARDIAC DISEASES 91 790 88 490 83 930 79 479 75 819 47 <5 1 197 24 992 49 629 39 802 C01DA Organic nitrates 91 790 88 490 83 930 79 479 75 819 47 <5 1 197 24 992 49 629 39 802 C01DA02 glyceryl trinitrate 70 702 68 613 65 060 60 717 58 255 46 <5 1 127 21 771 35 356 12 609 C01DA08 isosorbide dinitrate 3 820 3 257 2 787 2 311 1 950 53 0 9 267 1 674 1 551 C01DA14 isosorbide mononitrate 40 190 38 046 35 905 34 145 31 871 51 0 140 6 503 25 228 25 642 C01E OTHER CARDIAC PREPARATIONS 145 133 138 138 67 75 <5 12 43 11 122 C01EB Other cardiac preparations 145 133 138 138 67 75 <5 12 43 11 122 C01EB09 ubidecarenone 132 123 129 126 59 73 <5 10 37 11 110 C01EB15 trimetazidine 13 10 9 10 6 83 0 <5 <5 0 113.6 ATC group C - Cardiovascular system ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 17 689 17 442 17 596 27 18 723 8 290 8 565 56 463 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 6 879 7 114 6 702 6 469 6 520 41 <5 347 3 677 2 495 6 312 C02AB Methyldopa 1 130 1 084 410 141 107 71 0 53 32 22 313 C02AB01 methyldopa (levorotatory) 1 130 1 084 410 141 107 71 0 53 32 22 313 C02AC Imidazoline receptor agonists 5 817 6 119 6 347 6 340 6 426 41 <5 295 3 653 2 477 5 999 C02AC01 clonidine 72 74 78 64 85 48 <5 27 45 12 108 C02AC05 moxonidine 5 746 6 045 6 269 6 276 6 341 41 0 268 3 608 2 465 5 890 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 10 575 10 920 11 234 11 221 11 285 18 <5 340 4 822 6 122 14 476 C02CA Alpha-adrenoreceptor antagonists 10 575 10 920 11 233 11 221 11 285 18 <5 340 4 822 6 122 14 476 C02CA04 doxazosin 10 575 10 920 11 233 11 221 11 285 18 <5 340 4 822 6 122 14 476 C02CC Guanidine derivatives 0 0 <5 0 0 - 0 0 0 0 0 C02CC02 guanethidine 0 0 <5 0 0 - 0 0 0 0 0 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 339 331 319 301 317 33 <5 15 139 159 346 C02DB Hydrazinophthalazine derivatives 302 300 285 270 288 34 <5 11 118 156 195 C02DB02 hydralazine 302 300 285 270 288 34 <5 11 118 156 195 C02DC Pyrimidine derivatives 40 31 34 32 29 24 <5 <5 21 <5 151 C02DC01 minoxidil 40 31 24 <5 <5 21 <5 151 C02K OTHER ANTIHYPERTENSIVES 89 106 119 142 161 67 12 53 68 28 35 328 C02KD Serotonin antagonists 21 22 18 19 20 90 0 6 11 <5 514 C02KD01 ketanserin 21 22 18 19 20 90 0 6 11 <5 514 C02KX Other antihypertensives 69 85 102 124 142 64 12 48 57 25 34 814 C02KX01 bosentan 69 83 91 103 114 61 12 38 44 20 25 315 C02KX02 ambrisentan 0 <5 12 19 33 76 0 11 14 8 9 499 C02KX03 sitaxentan 0 <5 0 <5 0 - 0 0 0 0 0 C03 DIURETICS 225 203 233 975 235 553 223 840 208 881 61 207 9 214 80 919 118 541 90 932 C03A LOW-CEILING DIURETICS, THIAZIDES 61 870 71 861 74 216 66 001 53 884 60 <5 2 615 27 914 23 351 25 445 C03AA Thiazides, plain 38 198 44 489 45 271 36 364 16 030 58 <5 875 8 391 6 761 4 620 C03AA01 bendroflumethiazide 26 172 30 790 31 710 22 807 <5 0 0 0 0 <5 0 C03AA03 hydrochlorothiazide 12 097 13 766 13 625 16 731 16 029 58 <5 875 8 391 6 760 4 620 C03AB Thiazides and potassium in combination 24 868 28 814 30 363 41 642 38 128 62 <5 1 764 19 656 16 707 20 826 C03AB01 bendroflumethiazide and potassium 24 868 28 814 30 363 41 642 38 128 62 <5 1 764 19 656 16 707 20 826ATC group C ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 0 0 <5 <5 27 C03BA Sulfonamides, plain 5 6 6 5 6 50 0 0 <5 <5 27 C03BA04 chlortalidone 5 6 6 5 0 0 <5 <5 27 C03C HIGH-CEILING DIURETICS 128 628 128 686 127 995 127 389 125 502 60 190 5 303 38 249 81 760 48 483 C03CA Sulfonamides, plain 128 628 128 686 127 995 127 389 125 502 60 190 5 303 38 249 81 760 48 483 C03CA01 furosemide 106 983 104 728 101 619 99 007 95 647 62 189 4 551 30 655 60 252 21 325 C03CA02 bumetanide 26 396 28 833 31 193 33 444 34 786 54 <5 864 8 671 25 torasemide <5 C03CB Sulfonamides and potassium in combination <5 0 0 0 0 - 0 0 0 0 0 C03CB02 bumetanide and potassium <5 0 0 0 0 - 0 0 0 0 0 C03D POTASSIUM-SPARING AGENTS 16 818 17 302 17 602 17 636 17 866 49 19 912 6 883 10 052 11 792 C03DA Aldosterone antagonists 16 805 17 287 17 589 17 623 17 849 49 17 909 6 877 10 046 11 601 C03DA01 spironolactone 16 399 16 795 17 028 17 038 17 158 50 17 844 6 458 9 839 6 996 C03DA02 potassium canrenoate <5 0 0 <5 <5 100 0 4 C03DA04 eplerenone 453 579 658 678 798 15 0 71 474 253 4 601 C03DB Other potassium-sparing agents 16 15 18 18 22 41 <5 5 9 6 191 C03DB01 amiloride 16 15 18 18 22 41 <5 5 9 6 191 C03E DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION 36 317 35 388 34 026 31 692 28 447 66 11 840 13 231 14 365 5 044 C03EA Low-ceiling diuretics and potassium-sparing agents 36 317 35 388 34 026 31 692 28 447 66 11 840 13 231 14 365 5 044 C03EA01 hydrochlorothiazide and potassium-sparing agents 36 317 35 388 34 026 31 692 28 447 66 11 840 13 231 14 365 5 044 C03X OTHER DIURETICS 0 0 0 140 C04 PERIPHERAL VASODILATORS 1 719 1 524 1 340 1 165 1 019 46 0 28 264 727 1 084 C04A PERIPHERAL V ASODILATORS 1 719 1 524 1 340 1 165 1 019 46 0 28 264 727 1 084 C04AD Purine derivatives 1 715 1 520 1 334 1 160 1 018 46 0 28 263 727 1 079 C04AD03 pentoxifylline 1 715 1 520 1 334 1 160 1 018 46 0 28 263 727 1 079 C04AX Other peripheral vasodilators <5 <5 6 0 <5 0 5 C04AX01 cyclandelate <5 0 0 0 0 - 0 0 0 0 0 C04AX02 phenoxybenzamine <5 <5 6 5 <5 100 0 0 <5 0 5 C05 VASOPROTECTIVES 54 309 55 015 56 622 59 372 62 324 57 860 25 335 25 024 11 105 11 303ATC group C ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE 48 819 49 681 51 350 54 315 56 889 56 821 24 369 22 774 8 925 9 499 C05AA Corticosteroids 48 021 48 507 49 667 52 387 54 728 56 787 23 325 21 933 8 683 7 121 C05AA01 hydrocortisone 1)11 920 9 924 9 649 9 749 9 661 56 246 3 848 3 961 1 606 1 908 C05AA04 prednisolone1)38 325 40 337 41 682 44 303 46 723 56 554 20 257 18 589 7 323 5 213 C05AE Muscle relaxants 663 1 360 2 137 2 732 2 892 51 17 1 451 1 184 240 2 208 C05AE01 glyceryl trinitrate 663 1 360 2 137 2 732 2 892 51 17 1 451 1 184 240 2 208 C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use 992 993 901 826 852 49 20 390 287 155 170 C05AX03 other preparations, combi-nations 973 963 885 807 832 49 20 377 282 153 135 C05B ANTIVARICOSE THERAPY 5 656 5 555 5 490 5 250 5 664 68 39 1 013 2 339 2 273 1 804 C05BA Heparins or heparinoids for topical use 5 647 5 551 5 486 5 245 5 654 69 39 1 010 2 332 2 273 1 787 C05BA01 organo-heparinoid 1)5 620 5 525 5 462 5 211 5 627 68 39 1 007 2 321 2 260 723 C05BA04 pentosan polysulfate sodium 27 26 25 34 27 93 0 <5 11 13 1 065 C05BB Sclerosing agents for local injection 9 <5 <5 5 10 60 0 <5 7 0 17 C05BB02 polidocanol 9 <5 <5 5 10 60 0 <5 7 0 17 C07 BETA BLOCKING AGENTS 343 799 351 983 356 313 361 076 364 230 49 371 19 922 165 749 178 188 177 206 C07A BETA BLOCKING AGENTS 338 456 346 545 350 748 355 651 359 124 49 371 19 630 162 596 176 527 173 843 C07AA Beta blocking agents, non-selective 28 174 27 359 25 833 24 967 24 719 58 133 4 509 10 863 9 214 10 987 C07AA03 pindolol 35 31 28 28 26 69 0 <5 11 13 53 C07AA05 propranolol 15 992 16 403 16 540 16 856 17 412 64 125 4 310 8 174 4 803 6 366 C07AA06 timolol 1 462 1 337 636 13 9 67 0 0 7 <5 29 C07AA07 sotalol 10 750 9 646 8 818 8 082 7 269 46 6 178 2 681 4 404 4 480 C07AA12 nadolol 8 12 13 17 29 48 <5 21 5 0 60 C07AB Beta blocking agents, selective 290 513 299 225 305 475 311 150 315 089 49 223 13 197 142 205 159 464 145 415 C07AB02 metoprolol 235 349 244 333 250 953 256 753 261 240 48 204 10 995 118 601 131 440 124 326 C07AB03 atenolol 46 631 42 914 39 561 36 754 33 972 59 18 1 443 14 620 17 891 9 209 C07AB07 bisoprolol 12 020 15 502 18 388 21 004 23 114 46 <5 896 10 401 11 815 11 881 C07AG Alpha and beta blocking agents 24 757 24 683 24 389 23 887 23 377 45 19 2 254 11 324 9 780 17 440 C07AG01 labetalol 2 158 2 173 2 324 2 392 2 447 80 <5 1 475 601 368 2 353 C07AG02 carvedilol 22 634 22 530 22 092 21 525 20 957 41 16 782 10 742 9 417 15 087 C07B BETA BLOCKING AGENTS AND THIAZIDES 5 875 5 991 6 057 5 815 5 485 55 0 310 3 356 1 819 3 364 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group C ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 76 Legemiddelstatistikk 2012:2 FolkehelseinstituttetC07BB Beta blocking agents, selective, and thiazides 5 875 5 991 6 057 5 815 5 485 55 0 310 3 356 1 819 3 364 C07BB07 bisoprolol and thiazides 5 875 5 991 6 057 5 815 5 485 55 0 310 3 356 1 819 3 364 C08 CALCIUM CHANNEL BLOCKERS 200 902 208 610 214 671 221 256 224 226 48 72 8 836 107 469 107 849 155 748 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS 176 033 185 199 192 742 200 625 205 158 48 59 8 079 100 275 96 745 135 985 C08CA Dihydropyridine derivatives 176 033 185 199 192 742 200 625 205 158 48 59 8 079 100 275 96 745 135 985 C08CA01 amlodipine 111 182 113 649 115 250 119 283 121 600 46 36 4 049 59 008 58 507 56 063 C08CA02 felodipine 17 749 17 106 16 692 16 309 16 008 51 0 387 7 024 8 597 11 986 C08CA03 isradipine 693 683 664 620 312 1 054 C08CA05 nifedipine 26 450 28 302 29 940 31 649 32 708 49 24 2 475 15 949 14 260 43 213 C08CA06 nimodipine 35 36 32 44 51 73 0 15 31 5 42 C08CA13 lercanidipine 23 469 28 958 33 491 36 038 37 459 51 0 1 300 19 562 16 597 23 626 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 26 226 24 757 23 260 21 851 20 196 55 13 786 7 604 11 793 19 763 C08DA Phenylalkylamine derivatives 19 138 18 204 17 237 16 444 15 365 56 13 710 5 712 8 930 10 466 C08DA01 verapamil 19 138 18 204 17 237 16 444 15 365 56 13 710 5 712 8 930 10 466 C08DB Benzothiazepine deriva-tives 7 157 6 633 6 091 5 473 4 875 54 0 77 1 905 2 893 9 297 C08DB01 diltiazem 7 157 6 633 6 091 5 473 4 875 54 0 77 1 905 2 893 9 297 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 430 122 452 974 473 386 498 501 517 042 48 474 28 261 281 215 207 092 808 671 C09A ACE INHIBITORS, PLAIN 120 705 123 584 125 437 130 265 132 245 42 426 7 218 61 416 63 185 64 390 C09AA ACE inhibitors, plain 120 705 123 584 125 437 130 265 132 245 42 426 7 218 61 416 63 185 64 390 C09AA01 captopril 3 988 3 500 3 233 2 858 2 509 45 210 93 823 1 383 4 134 C09AA02 enalapril 41 791 42 623 43 094 45 453 45 869 47 217 3 004 21 867 20 781 18 717 C09AA03 lisinopril 28 417 27 936 27 083 26 749 26 058 47 <5 1 577 12 630 11 849 13 132 C09AA05 ramipril 47 159 50 153 52 684 55 804 58 431 35 7 2 586 26 345 29 493 28 220 C09AA10 trandolapril 117 119 111 92 85 27 0 <5 45 36 187 C09B ACE INHIBITORS, COMBINATIONS 35 749 35 757 35 260 35 985 35 727 49 0 1 268 18 344 16 115 26 755 C09BA ACE inhibitors and diuretics 35 749 35 757 35 023 35 193 34 459 49 0 1 179 17 608 15 672 25 292 C09BA02 enalapril and diuretics 19 816 20 161 20 154 20 520 20 244 49 0 761 10 443 9 040 15 510 C09BA03 lisinopril and diuretics 15 959 15 625 14 889 14 697 14 237 50 0 420 7 177 6 640 9 782 C09BB ACE inhibitors and calcium channel blockers 0 0 259 820 1 307 44 0 91 760 456 1 463ATC group C ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 0 0 259 820 1 307 44 0 91 760 456 1 463 C09C ANGIOTENSIN II ANTAGONISTS, PLAIN 153 235 162 375 168 742 180 140 187 460 51 73 13 801 105 854 67 732 296 764 C09CA Angiotensin II antagonists, plain 153 235 162 375 168 742 180 140 187 460 51 73 13 801 105 854 67 732 296 764 C09CA01 losartan 44 600 44 127 42 955 51 872 57 359 51 37 3 574 31 497 22 251 38 070 C09CA02 eprosartan 2 213 2 386 2 322 2 063 1 785 52 0 62 846 877 3 525 C09CA03 valsartan 19 497 20 016 20 380 20 748 22 461 48 <5 1 457 12 974 8 029 34 421 C09CA04 irbesartan 23 786 23 422 22 328 21 419 20 345 50 0 998 11 744 7 603 44 366 C09CA06 candesartan 60 248 67 536 74 704 78 234 79 739 53 34 7 341 45 232 27 132 160 469 C09CA07 telmisartan 3 810 5 222 5 866 5 988 5 977 44 0 382 3 590 2 005 12 573 C09CA08 olmesartan medoxomil 1 093 1 539 1 751 1 680 1 642 50 <5 160 1 011 469 3 339 C09D ANGIOTENSIN II ANTAGO - NISTS, COMBINATIONS 158 621 172 489 184 232 195 551 202 968 50 0 8 435 118 664 75 869 420 522 C09DA Angiotensin II antagonists and diuretics 157 769 168 660 174 848 179 893 180 855 51 0 6 908 104 494 69 453 350 635 C09DA01 losartan and diuretics 63 364 64 598 63 952 66 088 66 981 53 0 2 269 37 046 27 666 60 509 C09DA02 eprosartan and diuretics 1 428 1 840 2 042 1 924 1 774 49 0 75 964 735 3 839 C09DA03 valsartan and diuretics 23 363 24 767 25 424 25 643 25 522 49 0 997 15 018 9 507 68 009 C09DA04 irbesartan and diuretics 29 862 31 288 31 418 30 818 29 807 50 0 955 17 144 11 708 79 332 C09DA06 candesartan and diuretics 39 096 43 908 48 685 51 649 52 874 51 0 2 441 31 910 18 523 126 712 C09DA07 telmisartan and diuretics 2 415 3 320 3 724 3 991 3 940 41 0 175 2 432 1 333 9 854 C09DA08 olmesartan medoxomil and diuretics 349 813 1 144 1 124 1 146 50 0 58 721 367 2 381 C09DB Angiotensin II antagonists and calcium channel blockers 1 356 5 351 11 764 16 484 18 664 41 0 1 241 11 907 5 516 46 707 C09DB01 valsartan and amlodipine 1 356 5 351 11 764 16 483 18 493 41 0 1 223 11 793 5 477 46 443 C09DB02 olmesartan medoxomil and amlodipine 0 0 0 <5 185 44 0 18 125 42 264 C09DX Angiotensin II antagonists, other combinations 0 0 0 4 017 8 368 39 0 572 5 379 2 417 23 180 C09DX01 valsartan, amlodipine and hydrochlorothiazide 0 0 0 4 017 8 368 39 0 572 5 379 2 417 23 180 C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 0 47 93 93 84 33 0 6 55 23 240 C09XA Renin-inhibitors 0 47 93 93 84 33 0 6 55 23 240 C09XA02 aliskiren 0 47 93 92 84 33 0 6 55 23 240 C09XA52 aliskiren and hydrochlorothiazide 0 0 0 <5 0 - 0 0 0 0 0 C10 LIPID MODIFYING AGENTS 398 211 426 023 452 790 478 362 495 438 47 95 21 654 274 248 199 441 497 192ATC group C ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 15-44 45-69 70 78 Legemiddelstatistikk 2012:2 FolkehelseinstituttetC10A LIPID MODIFYING AGENTS, PLAIN 397 850 425 411 452 090 477 639 494 324 47 94 21 613 273 531 199 086 491 059 C10AA HMG CoA reductase inhibitors 395 295 421 813 447 810 472 860 488 693 47 84 20 886 270 299 197 424 398 319 C10AA01 simvastatin 321 003 348 045 356 768 349 782 336 472 47 24 12 288 177 016 147 144 223 246 C10AA02 lovastatin 1 884 1 715 1 424 1 260 1 134 57 0 17 460 657 1 827 C10AA03 pravastatin 24 230 23 056 22 329 21 340 20 826 49 7 475 10 088 10 256 24 789 C10AA04 fluvastatin 7 097 7 268 7 465 7 510 7 474 47 0 570 4 321 2 583 12 423 C10AA05 atorvastatin 85 847 59 209 79 686 112 783 140 846 45 52 8 106 89 715 42 973 122 816 C10AA07 rosuvastatin 234 355 571 2 115 4 420 47 <5 556 3 050 812 13 219 C10AB Fibrates 320 328 317 331 317 31 0 64 227 26 1 783 C10AB02 bezafibrate 76 70 64 58 49 39 0 <5 41 <5 184 C10AB04 gemfibrozil 102 105 101 104 103 27 0 22 68 13 1 009 C10AB05 fenofibrate 143 156 154 170 167 31 0 40 118 9 590 C10AC Bile acid sequestrants 2 087 2 134 2 090 2 238 2 412 55 9 497 1 322 584 7 433 C10AC01 colestyramine 1 486 1 563 1 566 1 686 1 816 59 8 437 936 435 2 396 C10AC02 colestipol 430 384 308 292 273 42 <5 16 151 105 759 C10AC04 colesevelam 184 204 237 280 351 45 0 48 259 44 4 278 C10AD Nicotinic acid and derivatives 231 234 285 396 391 22 0 51 305 35 1 240 C10AD02 nicotinic acid 212 216 218 153 107 24 0 15 83 9 376 C10AD06 acipimox 19 20 11 12 9 22 0 0 8 <5 56 C10AD52 nicotinic acid, combinations 0 0 69 249 301 22 0 40 232 29 807 C10AX Other lipid modifying agents 7 997 12 591 14 589 16 505 19 314 43 <5 1 604 13 101 4 606 82 284 C10AX06 omega-3-triglycerides incl. other esters and acids 2 194 2 2 754 3 038 3 591 30 <5 539 2 571 480 24 663 C10AX09 ezetimibe 5 967 10 425 12 126 13 819 16 165 46 <5 1 098 10 892 4 173 57 620 C10B LIPID MODIFYING AGENTS, COMBINATIONS <5 <5 0 81 1 370 43 <5 80 938 351 4 101 C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents <5 <5 0 81 1 370 43 <5 80 938 351 4 101 C10BA02 simvastatin and ezetimibe <5 <5 0 81 1 370 43 <5 80 938 351 4 101ATC group C ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 450 587 812 611 440 624 324 54 79 383 234 254 210 351 100 336 228 140 D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 109 784 113 854 111 682 116 703 120 475 48 11 745 44 614 43 760 20 356 30 032 D01A ANTIFUNGALS FOR TOPICAL USE 95 467 98 958 96 750 101 082 105 074 49 11 552 38 691 36 295 18 536 16 330 D01AA Antibiotics 3 201 3 467 219 54 52 73 <5 29 13 7 11 D01AA01 nystatin 3 201 3 467 219 54 52 73 <5 29 13 7 11 D01AC Imidazole and triazole derivatives 70 653 73 508 74 998 79 238 83 270 49 9 684 29 996 28 213 15 377 10 555 D01AC01 clotrimazole 1)8 182 8 369 8 811 9 516 8 743 52 1 182 3 016 2 360 2 185 1 349 D01AC02 miconazole1)2 082 1 927 1 880 2 121 2 193 45 329 779 724 361 373 D01AC03 econazole1)2 230 2 197 2 177 1 119 588 61 24 110 188 266 74 D01AC08 ketoconazole1)15 366 15 005 14 992 15 121 16 253 41 1 032 7 300 5 869 2 052 2 661 D01AC20 combinations1)46 252 49 639 50 909 55 208 59 462 50 7 496 20 201 20 368 11 397 6 099 D01AC60 bifonazole, combinations 0 <5 0 0 0 - 0 0 0 0 0 D01AE Other antifungals for topical use 24 522 24 966 24 330 24 671 24 742 47 2 125 9 777 9 116 3 724 5 764 D01AE02 methylrosaniline 1)663 716 696 694 751 81 D01AE14 14 D01AE15 201 17 148 16 909 17 514 17 801 43 1 693 7 588 5 928 2 592 3 091 D01AE16 amorolfine 6 973 7 481 7 081 6 829 6 518 56 260 2 144 3 100 1 014 2 590 D01B ANTIFUNGALS FOR SYSTEMIC USE 17 544 18 326 18 300 19 232 19 013 40 310 7 469 8 978 2 256 13 702 D01BA Antifungals for systemic use 17 544 18 326 18 300 19 232 19 013 40 310 7 469 8 978 2 256 13 702 D01BA01 griseofulvin 14 16 19 15 19 58 18 0 <5 0 9 D01BA02 terbinafine 17 535 18 314 18 285 19 222 19 002 40 300 7 469 8 977 2 256 13 693 D02 EMOLLIENTS AND PROTECTIVES 1 572 1 750 1 841 2 223 2 338 54 339 745 762 492 783 D02A EMOLLIENTS AND PROTECTIVES 1 572 1 750 1 841 2 223 2 338 54 339 745 762 492 783 D02AB Zinc products 1)8 10 6 10 15 60 <5 5 7 <5 2 D02AE Carbamide products 222 459 670 859 971 55 133 323 284 231 489 D02AE01 carbamide1)222 459 670 859 971 55 133 323 284 231 489 D02AF Salicylic acid preparations 1 274 1 197 1 048 1 229 1 206 52 135 381 446 244 188 D02AX Other emollients and protectives 76 93 125 148 168 58 77 42 29 20 104 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 120 143 91 60 68 40 <5 12 34 20 14 D03A CICATRIZANTS 120 143 91 60 68 40 <5 12 34 20 143. 7 ATC group D - Dermatologicals ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 80 Legemiddelstatistikk 2012:2 FolkehelseinstituttetD03AA Cod-liver oil ointments 38 54 7 0 0 - 0 0 0 0 0 D03AX Other cicatrizants 82 89 84 60 68 40 <5 12 34 20 14 D03AX03 dexpanthenol 82 89 84 60 68 40 <5 12 34 20 14 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 2 996 3 195 3 676 3 871 4 257 66 551 1 603 1 083 1 020 753 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 2 996 3 195 3 676 3 871 4 257 66 551 1 603 1 083 1 020 753 D04AA Antihistamines for topical mepyramine 0 <5 0 0 0 - 0 0 0 0 0 D04AA13 dimetindene 5 <5 <5 1 D04AB Anesthetics for topical use 1 936 2 094 2 637 2 798 3 095 69 301 1 346 848 600 627 D04AB01 lidocaine 1)1 935 2 094 2 637 2 798 3 095 69 301 1 346 848 600 627 D04AB06 tetracaine1)<5 0 0 0 0 - 0 0 0 0 0 D04AX Other antipruritics 1 080 1 119 1 052 1 093 1 169 58 250 256 239 424 124 D05 ANTIPSORIATICS 25 466 26 570 27 497 29 930 31 261 46 523 9 612 16 033 5 093 46 138 D05A ANTIPSORIATICS FOR TOPICAL USE 24 289 25 328 26 165 28 654 29 913 45 515 9 332 15 173 4 893 38 839 D05AA Tars 1)954 1 007 980 1 044 1 016 60 85 339 350 242 253 D05AC Antracen derivatives 109 15 11 9 7 71 <5 <5 <5 <5 3 D05AC01 <5 <5 <5 3 D05AD Psoralens for topical use 11 10 6 <5 0 - 0 0 0 0 0 D05AD01 trioxysalen 11 10 6 <5 0 - 0 0 0 0 0 D05AX Other antipsoriatics for topical use 23 431 24 515 25 359 27 804 29 069 45 431 9 051 14 909 4 678 38 583 D05AX02 calcipotriol 11 694 9 932 8 744 8 029 5 639 44 83 1 553 2 970 1 033 3 696 D05AX03 calcitriol 929 1 125 1 084 1 127 1 092 51 25 319 586 162 775 D05AX52 calcipotriol, combinations 15 373 17 660 19 312 22 343 25 230 45 356 8 045 12 894 3 935 34 112 D05B ANTIPSORIATICS FOR SYSTEMIC USE 1 669 1 765 1 886 1 880 1 943 43 9 436 1 218 280 7 299 D05BA Psoralens for systemic use 59 35 34 40 32 53 0 10 17 5 28 D05BA02 methoxsalen 55 29 33 35 29 52 0 10 15 <5 24 D05BA03 bergapten <5 7 for treatment of psoriasis 1 603 1 709 1 819 1 808 1 866 43 9 409 1 176 272 5 344 D05BB02 acitretin 1 603 1 709 1 819 1 808 1 866 43 9 409 1 176 272 5 344 D05BX Other antipsoriatics for systemic use 15 25 41 42 50 38 0 19 27 <5 1 928 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales derivatives, combinations 15 25 41 42 50 38 0 19 27 <5 1 928 D06 ANTIBIOTICS AND CHEMO - THERAPEUTICS FOR DERMATOLOGICAL USE 110 305 108 179 105 182 111 213 113 785 58 15 110 46 903 34 866 16 906 21 915 D06A ANTIBIOTICS FOR TOPICAL USE 55 472 57 269 54 026 58 829 60 985 55 12 871 19 150 18 351 10 613 5 428 D06AA Tetracycline and derivatives 3 004 2 844 2 682 2 729 2 876 56 411 834 1 052 579 359 D06AA02 chlortetracycline 26 16 23 19 28 36 0 8 13 7 8 D06AA03 oxytetracycline 2 978 2 828 2 659 2 710 2 848 56 411 826 1 039 572 352 D06AX Other antibiotics for topical use 52 622 54 594 51 499 56 239 58 278 55 12 488 18 372 17 350 10 068 5 069 D06AX01 fusidic acid 50 936 52 409 49 106 53 684 55 118 56 11 313 17 435 16 762 9 608 4 567 D06AX05 bacitracin 1 819 1 972 1 802 1 739 2 376 51 780 722 464 410 333 D06AX07 gentamicin <5 0 0 0 0 - 0 0 0 0 0 D06AX09 mupirocin 8 19 17 14 31 42 6 10 9 6 6 D06AX13 retapamulin 7 374 746 1 008 1 005 56 463 290 172 80 163 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE 56 907 52 801 53 024 54 414 54 921 61 2 394 28 622 17 206 6 699 16 486 D06BA Sulfonamides 3 472 3 491 3 202 3 373 3 408 54 597 1 175 1 036 600 598 D06BA01 silver sulfadiazine 3 472 3 491 3 202 3 373 3 408 54 597 1 175 1 036 600 598 D06BB Antivirals 46 096 41 381 41 307 41 885 40 796 60 1 656 23 615 11 070 4 455 14 124 D06BB03 aciclovir 1)24 069 20 673 20 098 19 696 18 262 71 1 158 8 782 6 640 1 682 2 801 D06BB04 podophyllotoxin 12 249 13 170 13 402 13 567 13 735 47 148 12 313 1 206 68 2 976 D06BB06 penciclovir1)8 457 5 031 4 000 3 349 2 737 70 112 1 179 1 132 314 586 D06BB10 imiquimod 2 226 3 407 4 705 6 196 7 039 54 244 2 146 2 217 2 432 7 760 D06BB11 docosanol 0 6 <5 0 0 - 0 0 0 0 0 D06BX Other chemotherapeutics 7 572 8 151 8 721 9 426 11 015 68 144 3 960 5 208 1 703 1 765 D06BX01 metronidazole 7 572 8 151 8 721 9 426 11 015 68 144 3 960 5 208 1 703 1 765 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPA - RATIONS 345 383 349 460 347 215 359 113 361 112 54 51 891 110 500 130 649 68 072 82 815 D07A CORTICOSTEROIDS, PLAIN 275 450 285 574 286 433 299 004 300 571 55 44 822 91 680 107 528 56 541 62 459 D07AA Corticosteroids, weak (group I) 27 000 27 439 26 763 28 352 28 846 56 13 023 7 421 5 096 3 306 3 435 D07AA02 hydrocortisone 1)27 000 27 439 26 763 28 352 28 846 56 13 023 7 421 5 096 3 306 3 435 D07AB Corticosteroids, moder-ately potent (group II) 91 249 95 779 96 512 102 087 102 519 55 23 267 30 417 30 986 17 849 14 061 D07AB02 hydrocortisone butyrate 62 168 64 610 64 889 67 907 70 549 55 16 851 21 022 20 521 12 155 9 806 D07AB08 desonide 30 353 32 620 33 079 35 702 33 948 55 7 003 9 921 10 961 6 063 4 255 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 82 Legemiddelstatistikk (group III) 151 115 154 910 153 609 158 099 157 062 54 16 105 50 634 58 779 31 544 33 440 D07AC01 betamethasone 50 713 52 701 50 086 52 441 54 059 54 3 314 17 540 21 755 11 450 7 514 D07AC03 desoximetasone 13 759 13 814 13 853 13 701 12 997 53 498 3 646 5 656 3 197 4 893 D07AC04 fluocinolone acetonide 7 294 7 162 6 572 6 500 6 007 54 193 1 209 2 814 1 791 1 083 D07AC08 fluocinonide 991 872 792 724 670 53 7 139 326 198 114 D07AC13 mometasone 69 044 71 674 74 342 78 920 78 512 54 10 647 26 234 27 064 14 567 16 496 D07AC17 fluticasone 16 868 16 949 15 468 13 078 11 890 55 2 036 4 107 3 686 2 061 3 340 D07AD Corticosteroids, very potent (group IV) 45 615 48 233 49 945 52 825 54 566 57 1 606 16 595 25 890 10 475 11 522 D07AD01 clobetasol 45 615 48 233 49 945 52 825 54 566 57 1 606 16 595 25 890 10 475 11 522 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS 48 610 41 193 37 064 36 056 37 817 49 5 364 11 187 13 728 7 538 4 917 D07BB Corticosteroids, moder-ately potent, combinations with antiseptics 28 430 29 399 17 785 15 445 15 216 50 3 241 4 081 5 014 2 880 2 481 D07BB02 desonide and antiseptics 14 113 13 954 17 619 15 445 15 215 50 3 240 4 081 5 014 2 880 2 481 D07BB03 triamcinolone and antiseptics 351 <5 0 0 0 0 D07BB04 hydrocortisone butyrate and antiseptics 14 438 15 968 193 0 0 - 0 0 0 0 0 D07BC Corticosteroids, potent, combinations with antiseptics 21 617 13 184 20 114 21 373 23 504 49 2 365 7 355 8 962 4 822 2 436 D07BC01 betamethasone and antiseptics 18 726 9 686 17 301 18 864 21 240 49 2 197 6 723 7 959 4 361 2 214 D07BC02 fluocinolone acetonide and antiseptics 3 218 3 872 2 918 2 601 2 357 48 173 658 1 047 479 222 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS 23 925 26 606 26 357 26 769 26 142 54 5 433 7 782 8 421 4 506 3 220 D07CA Corticosteroids, weak, combinations with antibiotics 23 925 25 877 26 351 26 768 26 142 54 5 433 7 782 8 421 4 506 3 220 D07CA01 hydrocortisone and antibiotics 23 925 25 877 26 351 26 768 26 142 54 5 433 7 782 8 421 4 506 3 220 D07CC Corticosteroids, potent, combinations with antibiotics 0 768 6 <5 0 - 0 0 0 0 0 D07CC01 betamethasone and antibiotics 0 768 6 <5 0 - 0 0 0 0 0 D07X CORTICOSTEROIDS, OTHER COMBINATIONS 30 467 27 135 26 626 26 439 25 907 49 823 8 623 11 516 4 945 12 219 D07XA Corticosteroids, weak, other combinations <5 0 0 0 0 - 0 0 0 0 0ATC group D ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 0 - 0 0 0 0 0 D07XB Corticosteroids, moderately potent, other combinations 3 998 556 0 0 0 - 0 0 0 0 0 D07XB02 triamcinolone 3 998 556 0 0 0 - 0 0 0 0 0 D07XC Corticosteroids, potent, other combinations 26 629 26 672 26 626 26 439 25 907 49 823 8 623 11 516 4 945 12 219 D07XC01 betamethasone 26 629 26 672 26 626 26 439 25 907 49 823 8 623 11 516 4 945 12 219 D08 ANTISEPTICS AND DISINFECTANTS 17 778 18 291 18 621 19 280 19 080 60 2 730 7 887 6 348 2 115 2 565 D08A ANTISEPTICS AND DISINFECTANTS1) 17 778 18 291 18 621 19 280 19 080 60 2 730 7 887 6 348 2 115 2 565 D08AB Aluminium agents 266 265 285 278 338 49 129 82 79 48 58 D08AC Biguanides and amidines 13 937 14 689 15 171 15 910 15 682 62 1 762 6 925 5 480 1 515 1 993 D08AC01 dibrompropamidine 1)5 256 5 342 5 115 5 282 3 801 52 1 182 1 192 770 657 431 D08AC02 chlorhexidine1)8 934 9 595 10 315 10 883 12 089 65 659 5 810 4 738 882 1 562 D08AG Iodine products 56 53 54 74 62 52 7 13 22 20 12 D08AG01 iodine/octylphenoxypolyg-lycolethe 1)12 15 5 <5 0 - 0 0 0 0 0 D08AG02 povidone-iodine <5 0 20 31 26 62 0 <5 12 10 7 D08AG03 iodine1)44 38 29 42 36 44 7 9 10 10 5 D08AJ Quaternary ammonium compounds 136 147 135 151 173 54 24 35 52 62 88 D08AJ03 cetylpyridinium 1)136 147 135 151 173 54 24 35 52 62 88 D08AL Silver compounds 0 0 0 <5 <5 0 0 <5 0 0 0 D08AL01 silver nitrate 0 0 0 <5 <5 0 0 <5 0 0 0 D08AX Other antiseptics and disinfectants 3 564 3 292 3 131 3 022 2 969 52 855 866 747 501 414 D08AX01 hydrogen peroxide 1)2 462 2 223 2 059 1 829 1 739 54 529 522 408 280 196 D08AX06 potassium permanganate1)1 123 1 090 1 095 1 207 1 240 50 328 345 346 221 218 D09 MEDICATED DRESSINGS 2 203 2 077 1 937 1 913 1 848 55 149 401 568 730 250 D09A MEDICATED DRESSINGS 2 203 2 077 1 937 1 913 1 848 55 149 401 568 730 250 D09AA Medicated dressings with antiinfectives 2 203 2 077 1 937 1 913 1 848 55 149 401 568 730 250 D09AA02 fusidic acid 2 203 2 077 1 937 1 913 1 848 55 149 401 568 730 250 D10 ANTI-ACNE PREPARATIONS 47 760 48 261 51 472 54 317 60 873 64 3 867 44 767 9 818 2 421 29 436 D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE 45 425 45 378 47 904 50 390 56 360 65 3 789 40 542 9 616 2 413 15 962 D10AD Retinoids for topical use in acne 21 386 21 578 24 388 27 056 32 167 65 2 422 24 351 4 065 1 329 9 356 D10AD01 tretinoin 9 767 9 451 9 888 10 547 10 219 77 432 5 506 3 146 1 135 1 027ATC group D ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 84 Legemiddelstatistikk 2012:2 FolkehelseinstituttetD10AD02 retinol 44 97 117 170 176 64 14 43 105 14 55 D10AD03 adapalene 12 028 10 560 8 449 7 113 6 597 63 555 5 402 480 160 1 469 D10AD53 adapalene, combinations 0 2 247 7 081 10 280 16 388 59 1 538 14 440 383 27 6 804 D10AE Peroxides 2 359 2 001 2 245 2 267 2 351 53 278 1 976 85 12 419 D10AE01 benzoyl peroxide1)2 359 2 001 2 245 2 267 2 351 53 278 1 976 85 12 419 D10AF Antiinfectives for treatment of acne 17 353 16 763 16 046 16 076 16 709 64 1 261 12 597 2 477 374 3 381 D10AF01 clindamycin 17 305 16 729 16 009 16 054 16 672 64 1 257 12 566 2 475 374 3 364 D10AF02 erythromycin 54 39 41 24 38 63 5 31 <5 0 17 D10AX Other anti-acne prepara- tions for topical use 13 442 13 521 13 292 13 285 13 811 68 685 9 013 3 379 734 2 806 D10AX03 azelaic acid 13 428 13 516 13 286 13 276 13 806 68 685 9 010 3 378 733 2 806 D10AX30 various combinations 14 7 7 11 5 100 0 <5 <5 <5 1 D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE 3 424 4 227 5 153 5 748 6 609 44 173 6 172 253 11 13 474 D10BA Retinoids for treatment of acne 3 424 4 227 5 153 5 748 6 609 44 173 6 172 253 11 13 474 D10BA01 isotretinoin 3 424 4 227 5 153 5 748 6 609 44 173 6 172 253 11 13 474 D11 OTHER DERMATOLOGICAL PREPARATIONS 13 633 14 730 15 690 16 780 18 055 55 2 911 8 102 5 124 1 918 12 906 D11A OTHER DERMATOLOGICAL PREPARATIONS 13 633 14 730 15 690 16 780 18 055 55 2 911 8 102 5 124 1 918 12 906 D11AC Medicated shampoos 1 017 1 027 974 1 059 1 205 52 100 749 280 76 149 D11AC03 selenium compounds 1)1 017 1 027 974 1 059 1 205 52 100 749 280 76 149 D11AF Wart and anti-corn preparations 1)1 415 1 375 1 498 1 926 2 066 51 907 781 274 104 293 D11AH Agents for atopic dermatitis, excluding corticosteroids 8 117 9 500 10 323 10 818 12 172 57 1 902 5 499 3 789 982 7 900 D11AH01 tacrolimus 4 344 6 175 6 804 7 498 8 318 56 1 276 3 789 2 577 676 4 691 D11AH02 pimecrolimus 3 907 3 511 3 712 3 534 3 993 58 661 1 780 1 236 316 1 908 D11AH04 alitretinoin 0 0 0 0 80 51 0 28 48 <5 1 302 D11AX Other dermatologicals 3 116 2 868 2 940 3 036 2 677 51 11 1 108 794 764 4 564 D11AX01 minoxidil 172 192 175 202 161 60 <5 92 51 16 115 D11AX10 finasteride 766 815 797 742 673 0 0 544 <5 3 231 D11AX16 eflornithine 0 0 0 <5 126 98 <5 73 43 8 88 D11AX18 diclofenac 2 070 1 697 1 702 1 604 1 132 52 <5 17 405 709 925 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 715 703 423 721 846 745 296 82 3 276 415 107 230 716 96 197 842 612 G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 30 233 30 558 30 699 32 068 33 025 99 121 23 875 7 482 1 547 7 153 G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS 30 233 30 558 30 699 32 068 33 025 99 121 23 875 7 482 1 547 7 153 G01AA Antibiotics 14 367 14 416 15 244 20 707 20 470 100 48 14 849 4 885 688 4 878 G01AA10 clindamycin 14 367 14 416 15 244 20 707 20 470 100 48 14 849 4 885 688 4 878 G01AF Imidazole derivatives 17 083 17 328 16 777 12 788 13 891 99 74 10 057 2 861 899 2 270 G01AF01 metronidazole 9 944 10 346 9 685 5 467 6 545 100 10 4 860 1 483 192 843 G01AF02 clotrimazole 1)5 254 5 028 5 326 5 614 5 945 99 40 4 205 1 116 584 1 123 G01AF04 miconazole1)790 960 768 634 64 98 <5 44 14 5 10 G01AF05 econazole1)1 490 1 407 1 324 1 335 1 621 96 23 1 170 296 132 294 G01AX Other antiinfectives and antiseptics 12 18 0 <5 <5 6 G01AX03 <5 <5 <5 6 G02 OTHER GYNECOLOGICALS 41 330 42 936 44 047 45 250 46 734 99 6 41 227 5 342 159 47 654 G02A OXYTOCICS 31 26 12 15 11 100 0 10 <5 0 2 G02AB Ergot alkaloids 31 26 12 15 11 100 0 10 <5 0 2 G02AB01 methylergometrine 31 26 12 15 11 100 0 10 <5 0 2 G02B CONTRACEPTIVES FOR TOPICAL USE 39 043 40 634 41 674 42 960 44 408 100 6 39 771 4 627 <5 44 571 G02BA Intrauterine contraceptives 24 831 24 795 24 803 24 858 25 070 100 <5 20 858 4 209 <5 28 470 G02BA03 plastic IUD with progestogen 24 831 24 795 24 803 24 858 25 070 100 <5 20 858 4 209 <5 28 470 G02BB Intravaginal contraceptives 14 337 16 010 17 064 18 263 19 549 100 5 19 117 425 <5 16 100 G02BB01 vaginal ring with progestogen and estrogen 14 337 16 010 17 064 18 263 19 549 100 5 19 117 425 <5 16 100 G02C OTHER GYNECOLOGICALS 2 342 2 381 2 458 2 367 2 413 80 0 1 542 716 155 3 082 G02CB Prolactine inhibitors 2 342 2 381 2 458 2 367 2 413 80 0 1 542 716 155 3 082 G02CB01 bromocriptine 1 260 1 247 1 312 1 226 1 247 91 0 944 245 58 784 G02CB03 cabergoline 915 987 943 921 948 66 0 500 366 82 1 328 G02CB04 quinagolide 214 189 302 284 260 77 0 128 114 18 970 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 510 107 512 608 515 229 525 683 538 119 99 2 513 357 132 140 897 37 577 399 219 G03A HORMONAL CONTRACEP - TIVES FOR SYSTEMIC USE 301 407 304 423 307 262 315 379 321 829 100 1 180 308 874 11 752 23 172 687 G03AA Progestogens and estro - gens, fixed combinations 211 548 212 576 214 962 221 431 225 436 100 987 220 169 4 268 12 127 727 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.8 ATC group G - Genito urinary system and sex hormones ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 86 Legemiddelstatistikk 2012:2 FolkehelseinstituttetATC group ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 G03AA07 levonorgestrel and estrogen 83 628 88 668 87 148 90 257 97 285 100 491 95 015 1 772 7 46 005 G03AA09 desogestrel and estrogen 40 384 48 476 55 278 61 035 63 096 100 353 61 727 1 015 <5 22 030 G03AA12 drospirenone and estrogen 97 495 79 229 74 740 72 600 68 099 100 189 66 575 1 332 <5 53 232 G03AA13 norelgestromin and estrogen 9 019 9 016 8 924 8 982 9 054 100 17 8 830 206 <5 6 460 G03AB Progestogens and estrogens, sequential preparations 29 232 22 034 18 862 17 640 16 197 100 35 15 460 701 <5 5 956 G03AB03 levonorgestrel and estrogen 5 340 <5 0 0 G03AB04 norethisterone and estrogen 24 611 22 031 18 546 16 059 14 343 100 34 13 683 625 <5 4 363 G03AB08 dienogest and estrogen 0 0 326 1 624 1 895 100 <5 1 817 76 0 1 593 G03AC Progestogens 85 546 87 693 89 490 92 562 96 454 100 200 89 276 6 968 10 38 965 G03AC01 norethisterone 10 481 9 195 8 182 7 402 6 656 100 11 5 738 907 0 1 516 G03AC03 levonorgestrel 265 193 141 115 <5 100 0 <5 0 0 3 G03AC06 medroxyprogesterone 22 512 21 186 19 971 19 607 19 337 100 39 16 114 3 177 7 4 611 G03AC08 etonogestrel 2 600 2 683 2 807 3 298 4 146 100 14 4 018 114 0 5 171 G03AC09 desogestrel 51 995 56 589 60 277 64 136 68 328 100 142 65 356 2 827 <5 27 665 G03AD Emergency contraceptives 143 119 100 159 165 95 <5 155 6 0 38 G03AD01 levonorgestrel 1)143 119 99 79 87 93 <5 80 <5 0 17 G03AD02 ulipristal 0 0 <5 78 97 <5 75 <5 0 21 G03B ANDROGENS 4 291 4 801 5 234 5 552 6 300 7 56 1 846 3 598 800 21 243 G03BA 3-oxoandrosten (4) derivatives 4 291 4 801 5 231 5 550 6 282 7 56 1 828 3 598 800 21 194 G03BA03 testosterone 4 291 4 801 5 231 5 550 6 282 7 56 1 828 3 598 800 21 194 G03BB 5-androstanon (3) derivatives 0 0 <5 <5 22 0 0 20 <5 0 49 G03BB01 mesterolone 0 0 <5 <5 22 0 0 20 <5 0 49 G03C ESTROGENS 105 541 109 009 112 831 116 574 121 763 100 160 5 290 83 086 33 227 75 129 G03CA Natural and semisynthetic estrogens, plain 95 288 99 840 104 463 108 549 114 339 100 160 5 099 76 515 32 565 64 448 G03CA01 ethinylestradiol 159 146 140 127 112 88 55 44 12 <5 579 G03CA03 estradiol 76 472 83 236 89 792 95 212 102 302 100 20 4 791 73 297 24 194 57 894 G03CA04 estriol 1)20 430 18 208 16 213 14 807 13 567 100 85 303 3 968 9 211 5 974 G03CA53 estradiol, combinations 0 0 <5 0 0 - 0 0 0 0 0 G03CA57 conjugated estrogens 1 G03CX Other estrogens 11 193 10 007 9 183 8 841 8 224 100 0 224 7 270 730 10 681 G03CX01 tibolone 11 193 10 007 9 183 8 841 8 224 100 0 224 7 270 730 10 681 G03D PROGESTOGENS 39 348 40 529 37 790 38 788 39 081 100 1 138 28 677 9 126 140 17 154 G03DA Pregnen (4) derivatives 12 456 13 004 13 106 12 990 13 131 100 49 9 760 3 198 124 14 859 G03DA02 medroxyprogesterone 7 338 7 504 7 215 6 869 6 813 100 49 3 616 3 028 120 1 275 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 87ATC group G ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 G03DA04 progesterone 5 202 5 588 5 987 6 240 6 465 100 0 6 288 173 <5 13 584 G03DB Pregnadien derivatives 0 0 0 0 12 100 0 10 <5 0 12 G03DB08 dienogest 0 0 0 0 12 100 0 10 <5 0 12 G03DC Estren derivatives 27 603 28 284 25 413 26 536 26 699 100 1 092 19 513 6 077 17 2 283 G03DC02 norethisterone 27 603 28 284 25 413 26 536 26 699 100 1 092 19 513 6 077 17 2 283 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 50 987 47 395 45 758 44 082 43 370 100 <5 2 533 37 674 3 160 32 532 G03FA Progestogens and estro - gens, fixed combinations 40 064 37 409 36 195 35 051 34 457 100 0 812 30 643 3 002 26 458 G03FA01 norethisterone and estrogen 39 329 36 729 35 628 34 521 33 824 100 0 782 30 067 2 975 25 687 G03FA12 medroxyprogesterone and estrogen 500 474 527 estrogens, sequential preparations 12 441 11 369 10 851 10 322 10 082 100 <5 1 813 8 095 171 6 074 G03FB01 norgestrel and estrogen 5 0 0 0 0 - 0 0 0 0 0 G03FB05 norethisterone and estrogen 12 437 11 369 10 851 10 322 10 082 100 <5 1 813 8 095 171 6 074 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 10 113 10 938 11 093 10 343 10 634 95 <5 10 395 234 <5 70 288 G03GA Gonadotropins 5 552 5 884 6 013 6 137 6 273 98 <5 6 187 83 <5 68 559 G03GA01 chorionic gonadotrophin 1 391 1 667 1 277 1 476 1 660 92 <5 1 634 24 <5 701 G03GA02 human menopausal gonadotrophin 1 092 1 405 1 601 1 540 1 842 100 0 1 824 18 0 14 635 G03GA04 urofollitropin 0 0 0 85 154 100 0 151 <5 0 1 349 G03GA05 follitropin alfa 1 624 1 631 1 770 1 743 1 799 99 0 1 772 27 0 20 325 G03GA06 follitropin beta 2 878 3 052 2 916 3 016 2 824 100 0 2 795 28 <5 26 570 G03GA07 lutropin alfa 82 62 65 26 21 100 0 21 0 0 56 G03GA08 choriogonadotropin alfa 4 040 4 179 4 556 4 538 4 600 100 0 4 548 51 <5 2 475 G03GA09 corifollitropin alfa 0 0 0 132 316 100 0 315 <5 0 2 340 G03GA30 combinations 0 <5 8 <5 <5 100 0 <5 0 0 108 G03GB Ovulation stimulants, synthetic 5 846 6 453 6 483 5 387 5 645 92 0 5 468 175 <5 1 729 G03GB02 clomifene 5 846 6 453 6 483 5 387 5 645 92 0 5 468 175 <5 1 729 G03H ANTIANDROGENS 19 573 16 971 16 171 16 764 17 325 99 97 16 732 378 118 7 221 G03HA Antiandrogens, plain 232 189 181 205 199 4 0 26 57 116 524 G03HA01 cyproterone 232 189 181 205 199 4 0 26 57 116 524 G03HB Antiandrogens and estrogens 19 346 16 792 15 999 16 565 17 129 100 97 16 709 321 88 Legemiddelstatistikk 2012:2 FolkehelseinstituttetG03HB01 cyproterone estrogen 19 346 16 792 15 999 16 565 17 129 100 97 16 709 321 <5 6 697 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 1 720 1 507 1 298 1 142 979 96 0 17 361 601 2 965 G03XA Antigonadotropins and similar agents 52 51 50 49 50 34 0 14 27 9 187 G03XA01 danazol 52 51 50 49 50 34 0 14 27 9 187 G03XB Antiprogestogens <5 <5 0 1 G03XC Selective estrogen receptor modulators 1 666 1 452 1 248 1 092 927 100 0 <5 334 592 2 777 G03XC01 raloxifene 1 666 1 452 1 248 1 092 927 100 0 <5 334 592 2 777 G04 UROLOGICALS 131 461 141 633 148 765 156 067 166 507 21 653 16 015 87 396 62 443 388 586 G04B OTHER UROLOGICALS, INCL. ANTISPASMODICS 100 716 106 579 109 819 113 502 119 115 29 651 14 009 68 487 35 968 324 268 G04BA Acidifiers <5 <5 <5 0 0 - 0 G04BA01 ammonium chloride <5 <5 <5 0 0 - 0 0 0 0 0 G04BD Urinary antispasmodics 40 928 42 828 44 578 46 177 49 165 69 641 3 820 21 492 23 212 159 279 G04BD04 oxybutynin 2 054 1 690 1 480 1 504 1 516 69 162 280 593 481 9 101 G04BD07 tolterodine 23 747 21 577 18 355 15 679 14 237 71 426 834 5 467 7 510 47 135 G04BD08 solifenacin 13 975 15 757 17 349 19 877 21 933 68 70 1 821 10 086 9 956 64 279 G04BD10 darifenacin 4 336 5 430 5 630 5 126 4 566 72 <5 274 2 027 2 264 13 058 G04BD11 fesoterodine 0 1 818 5 380 7 639 10 610 67 13 911 4 977 4 709 25 705 G04BE Drugs used in erectile dysfunction 61 012 65 120 66 640 68 779 71 511 0 10 10 278 47 947 13 276 164 965 G04BE01 alprostadil 2 039 2 335 2 180 2 543 2 525 0 0 119 1 694 712 4 316 G04BE03 sildenafil 33 267 34 776 34 734 34 385 34 575 1 10 4 804 22 474 7 287 73 872 G04BE04 yohimbine 20 13 19 15 10 0 0 <5 7 <5 8 G04BE07 apomorphine 6 0 0 0 0 - 0 0 0 0 0 G04BE08 tadalafil 21 276 23 981 26 821 29 887 32 991 0 0 5 244 22 847 4 900 69 974 G04BE09 vardenafil 11 625 11 561 10 376 9 934 9 427 0 0 1 213 6 536 1 678 15 574 G04BE30 combinations 599 537 616 495 539 0 0 28 382 129 1 219 G04BX Other urologicals 10 10 10 11 11 45 0 7 <5 0 25 G04BX01 magnesium hydroxide 10 10 10 11 11 45 0 7 <5 0 25 G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 35 865 41 018 45 440 49 918 55 531 1 <5 2 201 22 900 30 428 64 317 G04CA Alpha-adrenoreceptor antagonists 27 133 31 502 34 945 38 363 43 210 1 <5 1 182 19 320 22 706 41 005 G04CA01 alfuzosin 937 777 536 498 451 2 0 16 195 240 686 G04CA02 tamsulosin 25 399 30 169 33 877 37 383 41 362 1 <5 1 104 18 493 21 764 37 810ATC group G ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 71 242 284 553 G04CA52 tamsulosin and dutasteride 0 0 0 <5 1 628 0 0 790 838 1 956 G04CB Testosterone-5-alpha reductase inhibitors 11 657 13 253 14 939 16 984 18 676 0 0 1 025 6 008 11 643 23 312 G04CB01 finasteride 5 804 10 194 12 852 15 194 17 122 0 0 991 5 578 10 553 18 574 G04CB02 dutasteride 5 943 4 054 2 331 1 939 1 661 0 0 39 464 1 158 4 738ATC group G ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 90 Legemiddelstatistikk 2012:2 FolkehelseinstituttetH SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 342 524 357 070 375 464 387 820 402 895 67 16 472 108 182 172 886 105 355 418 533 H01 PITUITARY AND HYPO - THALAMIC HORMONES AND ANALOGUES 23 659 24 310 24 490 24 831 24 913 66 9 433 12 736 1 703 1 041 285 161 H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 1 441 1 485 1 577 1 656 1 760 43 960 490 290 20 156 814 H01AA Somatropin and somatropin agonists 1 429 1 470 1 555 1 631 1 735 43 960 481 274 20 148 170 H01AC01 somatropin 1 429 1 470 1 555 1 631 1 735 43 960 481 274 20 148 170 H01AX Other anterior pituitary lobe hormones and analogues 10 13 21 24 24 46 0 9 15 0 8 645 H01AX01 pegvisomant 10 13 21 24 24 46 0 9 15 0 8 645 H01B POSTERIOR PITUITARY LOBE HORMONES 18 541 18 859 18 807 18 982 19 165 62 8 513 8 764 1 086 802 36 990 H01BA Vasopressin and analogues 11 706 11 623 11 288 11 248 11 386 36 8 455 1 072 1 057 802 35 535 H01BA02 desmopressin 11 706 11 623 11 288 11 248 11 385 36 8 455 1 072 1 056 802 35 469 H01BA04 terlipressin 0 0 0 0 <5 0 0 0 <5 0 66 H01BB Oxytocin and analogues 6 837 7 237 7 522 7 736 7 781 99 58 7 694 29 0 1 455 H01BB02 oxytocin 6 837 7 237 7 522 7 736 7 781 99 58 7 694 29 0 1 455 H01C HYPOTHALAMIC HORMONES 3 847 4 147 4 315 4 430 4 230 92 6 3 605 395 224 91 357 H01CA Gonadotropin-releasing hormones 3 021 3 101 2 829 2 314 2 088 99 0 2 054 25 9 5 220 H01CA02 nafarelin 3 021 3 101 2 829 2 314 2 076 100 0 2 054 22 0 5 082 H01CA03 histrelin 0 0 0 0 12 0 0 0 <5 9 138 H01CB Antigrowth hormones 460 494 498 593 630 49 6 59 350 215 80 835 H01CB02 octreotide 385 406 398 472 497 51 6 48 285 158 62 335 H01CB03 lanreotide 89 118 118 137 148 45 0 11 75 62 18 501 H01CC Anti-gonadotropin-releasing hormones 459 675 1 246 1 887 1 774 100 0 1 752 22 0 5 302 H01CC01 ganirelix 351 555 975 1 513 1 397 100 0 1 378 19 0 4 109 H01CC02 cetrorelix 120 149 298 481 413 100 0 406 7 0 1 193 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 169 704 177 573 190 387 197 258 208 059 56 4 887 62 025 85 773 55 374 50 295 H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN 169 577 177 454 190 243 197 074 207 823 56 4 886 61 976 85 630 55 331 50 215 H02AA Mineralocorticoids 1 145 1 160 1 178 1 223 1 267 56 87 392 565 223 3433.9 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 145 1 160 1 178 1 223 1 267 56 87 392 565 223 343 H02AB Glucocorticoids 169 433 177 308 190 109 196 939 207 680 56 4 879 61 945 85 581 55 275 49 872 H02AB01 betamethasone 1 907 1 736 1 700 1 637 1 528 45 746 272 386 124 476 H02AB02 dexamethasone 1 799 1 931 2 118 2 552 2 786 49 80 291 1 542 873 2 865 H02AB04 methylprednisolone 9 582 10 159 10 745 10 812 11 018 53 67 2 931 5 559 2 461 4 085 H02AB06 prednisolone 129 018 136 459 143 523 152 239 159 500 58 3 180 37 151 68 237 50 932 30 383 H02AB07 prednisone <5 <5 <5 82 246 76 <5 437 H02AB08 triamcinolone 29 129 29 048 34 538 32 179 35 707 49 684 22 005 11 253 1 765 4 657 H02AB09 hydrocortisone 429 422 437 481 548 68 45 210 255 38 1 099 H02AB10 cortisone 2 453 2 510 2 593 2 662 2 749 52 138 711 1 342 558 5 751 H02AB13 deflazacort 18 17 18 17 25 52 11 <5 9 <5 118 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS 359 340 332 372 415 63 <5 70 239 105 80 H02BX Corticosteroids for systemic use, combinations 359 340 332 372 415 63 <5 70 239 105 80 H02BX01 methylprednisolone, combinations 359 340 332 372 415 63 <5 70 239 105 80 H03 THYROID THERAPY 160 934 167 746 174 354 180 847 185 862 82 1 361 34 773 93 436 56 292 58 740 H03A THYROID PREPARATIONS 157 372 164 071 170 772 177 261 182 145 82 1 345 33 764 91 782 55 254 55 843 H03AA Thyroid hormones 157 372 164 071 170 772 177 261 182 145 82 1 345 33 764 91 782 55 254 55 843 H03AA01 levothyroxine sodium 157 115 163 750 170 484 176 910 181 635 82 1 340 33 567 91 514 55 214 51 595 H03AA02 liothyronine sodium 3 867 3 986 4 095 4 142 4 538 90 19 1 480 2 694 345 3 290 H03AA03 combinations of levothy - roxine and liothyronine 295 404 429 328 549 90 <5 213 314 20 614 H03AA05 thyroid gland preparations 0 0 0 182 187 91 0 78 104 5 344 H03B ANTITHYROID PREPARATIONS 4 985 5 131 5 019 5 125 5 432 81 33 1 673 2 522 1 204 2 897 H03BA Thiouracils 470 552 552 470 552 552 Sulfur-containing imidazole derivatives 4 624 4 741 4 590 4 727 5 042 80 32 1 457 2 397 1 156 2 417 H03BB01 carbimazole 4 624 4 741 4 590 4 727 5 042 80 32 1 457 2 397 1 156 2 417 H04 PANCREATIC HORMONES 4 775 5 265 5 336 5 490 5 588 47 1 118 2 783 1 382 305 2 460 H04A GLYCOGENOLYTIC HORMONES 4 775 5 265 5 336 5 490 5 588 47 1 118 2 783 1 382 305 2 460 H04AA Glycogenolytic hormones 4 775 5 265 5 336 5 490 5 588 47 1 118 2 783 1 382 305 2 460 H04AA01 glucagon 4 775 5 265 5 336 5 490 5 588 47 1 118 2 783 1 382 305 2 460 H05 CALCIUM HOMEOSTASIS 603 644 748 803 915 57 <5 119 434 361 21 877ATC group H ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 ANALOGUES 194 225 237 263 293 79 0 42 156 95 8 602 H05AA Parathyroid hormones and analogues 194 225 237 263 293 79 0 42 156 95 8 602 H05AA02 teriparatide 174 201 213 253 280 78 0 41 149 90 8 102 H05AA03 parathyroid hormone 22 25 25 12 13 92 0 <5 7 5 500 H05B ANTI-PARATHYROID AGENTS 411 421 511 541 623 48 <5 77 279 266 13 275 H05BA Calcitonin preparations 156 110 86 80 83 82 0 <5 23 57 352 H05BA01 calcitonin (salmon synthetic) 156 110 86 80 83 82 0 <5 23 57 352 H05BX Other anti-parathyroid agents 255 313 425 461 540 42 <5 74 256 209 12 923 H05BX01 cinacalcet 255 304 391 418 474 44 <5 62 223 188 11 593 H05BX02 paricalcitol 0 11 44 59 87 30 0 14 43 30 1 331ATC group H ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 1 236 736 1 247 164 1 394 472 1 252 356 1 326 119 59 176 429 536 866 423 376 189 448 699 249 J01 ANTIBACTERIALS FOR SYSTEMIC USE 1 168 650 1 181 344 1 138 203 1 180 372 1 250 193 59 171 674 499 130 397 477 181 912 295 364 J01A TETRACYCLINES 180 466 172 668 161 073 167 058 188 150 57 2 574 80 736 75 028 29 812 33 786 J01AA Tetracyclines 180 466 172 668 161 073 167 058 188 150 57 2 574 80 736 75 028 29 812 33 786 J01AA02 doxycycline 144 575 135 973 124 472 129 848 148 562 57 1 439 53 219 65 900 28 004 18 473 J01AA04 lymecycline 12 328 12 748 13 528 14 771 19 406 56 600 13 582 4 398 826 9 499 J01AA06 oxytetracycline 5 785 5 605 5 244 5 164 2 625 52 48 1 558 825 194 420 J01AA07 tetracycline 20 344 20 731 20 086 19 710 21 375 55 580 14 800 4 962 1 033 5 245 J01AA08 minocycline <5 8 16 58 85 71 0 75 J01AA12 tigecycline <5 6 J01B AMPHENICOLS 0 <5 0 <5 0 - 0 0 0 0 0 J01BA Amphenicols 0 <5 0 <5 0 - 0 0 0 0 0 J01BA01 chloramphenicol 0 <5 0 <5 0 - 0 J01C BETA-LACTAM ANTI-BACTERIALS, PENICILLINS 731 232 764 398 797 318 60 119 564 312 466 244 516 120 772 124 021 J01CA Penicillins with extended spectrum 262 484 281 587 283 578 301 349 309 152 74 37 457 100 855 98 852 71 988 48 538 J01CA01 ampicillin 32 35 19 39 24 25 <5 <5 8 11 25 J01CA02 pivampicillin 1 288 <5 0 0 <5 0 0 0 0 <5 0 J01CA04 amoxicillin 114 670 123 464 118 112 127 541 131 884 55 32 792 31 929 42 287 24 876 17 514 J01CA08 pivmecillinam 156 916 169 588 176 709 186 059 189 534 87 5 005 72 200 60 755 51 574 30 996 J01CA11 mecillinam 12 8 3 sensitive penicillins 460 871 475 189 444 689 458 149 466 090 54 85 938 196 841 135 618 47 693 44 447 J01CE01 benzylpenicillin 53 54 58 52 64 42 <5 6 22 35 52 J01CE02 phenoxymethylpenicillin 460 792 475 113 444 622 458 036 465 991 54 85 937 196 806 135 580 47 668 44 177 J01CE08 benzathine benzylpenicillin 50 46 40 99 83 29 <5 49 31 <5 218 J01CF Beta-lactamase resistant penicillins 73 745 79 411 85 870 92 702 100 282 48 5 784 43 340 34 463 16 695 30 749 J01CF01 dicloxacillin 71 515 77 178 84 083 91 099 98 888 48 5 707 42 815 33 968 16 398 29 654 J01CF02 cloxacillin 2 687 2 683 2 153 1 929 1 713 48 73 632 630 378 1 069 J01CF05 flucloxacillin 6 19 32 22 17 53 12 25 J01CR Combinations of penicillins, incl. beta- lactamase inhibitors 31 52 120 135 114 61 86 15 9 <5 287 J01CR02 amoxicillin and enzyme inhibitor 15 38 <5 153 J01CR05 piperacillin and enzyme inhibitor 16 19 17 20 40 0 12 5 <5 1333.10 ATC group J - Antiinfectives for systemic use ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK ANTIBACTERIALS 28 996 27 210 24 295 23 489 23 048 59 3 072 8 168 7 863 3 945 6 950 J01DB First-generation cephalosporins 28 757 26 924 23 974 23 116 22 700 60 3 014 8 070 7 757 3 859 3 254 J01DB01 cefalexin 28 733 26 914 23 952 23 099 22 691 60 3 014 8 069 7 753 3 855 3 247 J01DB03 cefalotin 24 10 23 17 9 56 0 <5 <5 <5 7 J01DC Second-generation cephalosporins 58 67 63 72 50 <5 9 24 38 68 J01DC02 cefuroxime 58 67 63 71 72 50 <5 9 24 38 68 J01DD Third-generation cephalosporins 198 232 263 310 275 43 58 82 85 50 1 824 J01DD01 cefotaxime 17 30 39 42 47 53 <5 5 21 17 80 J01DD02 ceftazidime 66 57 71 80 57 49 9 35 7 6 1 112 J01DD04 ceftriaxone 115 148 155 190 177 39 45 43 61 28 632 J01DF Monobactams 12 12 11 13 8 50 0 8 0 0 273 J01DF01 aztreonam 12 12 11 13 8 50 0 8 0 0 273 J01DH Carbapenems 29 31 56 43 53 42 8 25 11 9 1 531 J01DH02 meropenem 27 30 46 39 40 38 8 20 7 5 1 147 J01DH03 ertapenem <5 <5 8 SULFONAMIDES AND TRIMETHOPRIM 125 977 123 868 118 489 117 088 116 622 77 13 996 31 545 37 370 33 711 11 089 J01EA Trimethoprim and derivatives 96 543 93 084 88 503 86 108 84 322 85 8 324 23 729 26 384 25 885 6 879 J01EA01 trimethoprim 96 543 93 084 88 503 86 108 84 322 85 8 324 23 729 26 384 25 885 6 879 J01EE Combinations of sulfon-amides and trimethoprim, incl. derivatives 33 487 34 914 34 027 34 976 36 374 57 6 201 8 588 12 218 9 367 4 210 J01EE01 sulfamethoxazole and trimethoprim 33 487 34 914 34 027 34 976 36 374 57 6 201 8 588 12 218 9 367 4 210 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 326 229 310 374 283 337 301 083 349 564 57 58 325 157 672 105 052 28 515 58 244 J01FA Macrolides 292 195 272 328 244 678 257 943 304 681 58 54 231 139 212 88 862 22 376 46 504 J01FA01 erythromycin 158 396 142 942 123 140 129 188 170 300 57 44 653 66 911 46 220 12 516 21 922 J01FA02 spiramycin 4 368 3 575 3 033 2 794 2 742 60 85 1 075 1 227 355 468 J01FA09 clarithromycin 51 608 44 208 36 958 37 830 43 158 57 5 627 16 144 16 166 5 221 7 355 J01FA10 azithromycin 90 880 92 794 90 850 98 413 101 154 59 5 450 61 398 29 249 5 057 16 759 J01FF Lincosamides 41 699 46 064 45 847 51 154 53 671 54 5 075 22 666 18 933 6 997 11 740 J01FF01 clindamycin 41 699 46 064 45 847 51 154 53 671 54 5 075 22 666 18 933 6 997 11 740ATC group J ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 96 50 18 9 702 J01GA Streptomycins 0 <5 0 0 0 - 0 0 0 0 0 J01GA01 streptomycin 0 <5 0 0 0 - 0 0 0 0 0 J01GB Other aminoglycosides 282 277 289 273 252 46 88 96 50 18 9 702 J01GB01 tobramycin 253 245 258 250 219 46 82 84 41 12 8 425 J01GB03 gentamicin 25 28 26 16 19 42 <5 5 5 5 80 J01GB06 amikacin 5 6 5 10 14 1 196 J01M QUINOLONE ANTIBACTERIALS 55 879 59 957 60 651 64 703 67 255 49 616 17 019 28 641 20 979 15 757 J01MA Fluoroquinolones 55 879 59 957 60 651 64 703 67 255 49 616 17 019 28 641 20 979 15 757 J01MA01 ofloxacin 3 002 3 012 2 717 2 516 2 242 44 <5 669 924 647 799 J01MA02 ciprofloxacin 53 263 57 335 58 298 62 445 65 177 50 613 16 239 27 848 20 477 14 199 J01MA12 levofloxacin 5 5 15 21 31 61 0 8 18 5 160 J01MA14 moxifloxacin 36 65 71 142 205 47 <5 189 14 <5 599 J01X OTHER ANTIBACTERIALS 46 625 47 875 51 069 54 632 58 469 84 1 602 12 235 19 488 25 144 35 815 J01XA Glycopeptide antibacterials 23 29 27 23 27 41 11 <5 7 5 335 J01XA01 vancomycin 21 23 26 21 24 46 11 <5 <5 278 J01XA02 57 J01XB Polymyxins 66 60 64 55 63 56 13 32 12 6 2 246 J01XB01 colistin 66 60 64 55 63 56 13 32 12 6 2 246 J01XC Steroid antibacterials 866 865 711 757 663 54 30 231 225 177 468 J01XC01 fusidic acid 866 865 711 757 663 54 30 231 225 177 468 J01XD Imidazole derivatives 16 17 23 24 26 62 <5 <5 14 8 62 J01XD01 metronidazole 16 17 23 24 26 62 <5 <5 14 8 62 J01XE Nitrofuran derivatives 29 388 29 536 31 296 33 594 36 767 86 1 461 9 605 12 256 13 445 4 056 J01XE01 nitrofurantoin 29 388 29 536 31 296 33 594 36 767 86 1 461 9 605 12 256 13 445 4 056 J01XX Other antibacterials 19 854 21 193 23 185 24 887 25 917 83 116 3 019 8 601 14 181 28 647 J01XX05 methenamine 19 711 21 023 22 969 24 644 25 643 83 113 2 977 8 477 14 076 19 386 J01XX08 linezolid 146 177 223 252 279 42 <5 42 127 107 9 261 J02 ANTIMYCOTICS FOR SYSTEMIC USE 39 045 40 785 42 646 45 329 46 494 86 463 29 312 13 420 3 299 23 894 J02A ANTIMYCOTICS FOR SYSTEMIC USE 39 045 40 785 42 646 45 329 46 494 86 463 29 312 13 420 3 299 23 894 J02AA Antibiotics <5 <5 <5 0 29 J02AB Imidazole derivatives 2 325 2 294 2 262 2 163 2 227 44 27 1 502 621 77 644 J02AB02 ketoconazole 2 325 2 294 2 262 2 163 2 227 44 27 1 502 621 77 644ATC group J ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 36 794 38 599 40 488 43 282 44 372 88 438 27 877 12 828 3 229 22 326 J02AC01 fluconazole 36 547 38 354 40 227 42 966 43 929 88 431 27 693 12 622 3 183 12 961 J02AC02 itraconazole 316 307 526 471 635 77 <5 356 235 40 707 J02AC03 voriconazole 59 66 65 80 80 43 <5 22 41 14 5 926 J02AC04 posaconazole <5 7 9 22 40 30 <5 16 21 <5 2 733 J02AX Other antimycotics 0 0 <5 0 522 J02AX06 anidulafungin 0 0 <5 <5 0 0 0 <5 0 53 J04 ANTIMYCOBACTERIALS 913 917 1 336 1 573 1 645 48 101 737 496 311 4 497 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 479 486 931 1 126 1 194 51 90 629 300 175 4 123 J04AB Antibiotics 314 318 401 444 474 51 55 106 170 143 1 271 J04AB02 rifampicin 296 303 377 422 458 51 54 101 163 140 939 J04AB04 rifabutin 17 16 25 24 17 53 <5 5 7 <5 333 J04AB30 capreomycin <5 <5 0 0 0 - 0 0 0 0 0 J04AC Hydrazides 47 38 64 75 88 55 19 39 24 6 96 J04AC01 isoniazid 47 38 64 75 88 55 19 39 24 6 96 J04AD Thiocarbamide derivatives <5 <5 <5 0 0 0 0 J04AD01 protionamide <5 <5 <5 0 0 - 0 0 0 0 0 J04AK Other drugs for treatment of tuberculosis 127 99 126 203 207 51 5 104 75 23 761 J04AK01 pyrazinamide 25 13 20 28 37 46 <5 21 11 <5 68 J04AK02 ethambutol 123 97 115 198 200 51 <5 100 75 21 693 J04AM Combinations of drugs for treatment of tuberculosis 96 112 493 645 684 51 35 504 116 29 1 996 J04AM02 rifampicin and isoniazid 70 82 433 578 619 51 33 463 99 24 1 636 J04AM05 rifampicin, pyrazinamide and isoniazid 34 36 76 138 <5 77 22 8 249 J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid <5 13 58 47 47 51 0 32 13 <5 111 J04B DRUGS FOR TREATMENT OF LEPRA 437 433 405 449 454 41 11 110 197 136 373 J04BA Drugs for treatment of lepra 437 433 405 449 454 41 11 110 197 136 373 J04BA01 clofazimine 0 <5 0 0 0 - 0 0 0 0 0 J04BA02 dapsone 437 432 405 449 454 41 11 110 197 136 373 J05 ANTIVIRALS FOR SYSTEMIC USE 24 510 24 595 304 693 31 034 32 720 61 861 16 409 11 681 3 769 305 971ATC group J ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 510 24 595 304 693 31 034 32 720 61 861 16 409 11 681 3 769 305 971 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 19 845 21 809 23 038 24 889 27 461 64 574 13 688 9 669 3 530 48 018 J05AB01 aciclovir 8 787 9 892 10 264 11 316 12 171 67 412 6 137 3 970 1 652 4 735 J05AB04 ribavirin 728 803 770 705 760 36 6 449 16 230 J05AB06 ganciclovir 0 <5 0 <5 100 <5 0 0 0 16 J05AB11 valaciclovir 10 466 11 348 12 244 13 096 14 810 63 160 7 369 5 406 1 875 13 553 J05AB12 cidofovir 0 <5 0 0 0 - 0 0 0 0 0 J05AB14 valganciclovir 197 223 246 283 319 31 <5 83 185 49 13 484 J05AD Phosphonic acid deriva-tives <5 0 0 0 0 - 0 0 0 0 0 J05AD01 foscarnet <5 0 0 0 0 - 0 0 0 0 0 J05AE Protease inhibitors 961 1 108 1 238 1 347 1 562 39 10 872 659 21 69 150 J05AE01 saquinavir 19 17 11 9 7 14 0 <5 <5 326 J05AE02 indinavir 21 11 0 <5 0 0 41 J05AE03 ritonavir 310 379 499 604 720 36 <5 399 309 9 2 847 J05AE04 nelfinavir 51 0 0 0 0 - 0 0 0 0 0 J05AE06 lopinavir 525 582 583 551 510 52 7 335 160 8 15 872 J05AE07 fosamprenavir 5 <5 atazanavir 425 517 660 780 920 35 <5 504 399 14 36 632 J05AE09 tipranavir 7 <5 <5 0 0 - 0 0 0 0 0 J05AE10 darunavir 25 48 55 70 91 24 <5 25 65 0 6 018 J05AE11 telaprevir 0 0 0 0 16 44 0 5 11 0 2 163 J05AE12 boceprevir 0 0 0 0 76 39 0 36 40 0 5 173 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 400 394 388 399 420 35 17 190 199 14 16 040 J05AF01 zidovudine 61 55 41 34 35 40 <5 22 10 <5 559 J05AF02 didanosine 102 77 53 37 22 45 <5 8 11 <5 326 J05AF04 stavudine 47 28 13 13 <5 0 0 0 <5 0 4 J05AF05 lamivudine 174 145 117 100 93 47 14 32 45 <5 924 J05AF06 abacavir 52 46 48 51 54 50 11 21 21 <5 1 252 J05AF07 tenofovir disoproxil 155 148 158 163 88 <5 6 673 J05AF08 adefovir dipivoxil 36 38 33 22 15 33 0 6 9 0 797 J05AF09 emtricitabine 20 13 11 11 9 22 0 <5 <5 <5 174 J05AF10 entecavir 23 56 87 106 126 29 0 62 57 7 5 252 J05AF11 telbivudine <5 6 8 5 <5 0 0 0 <5 0 79ATC group J ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 210 232 12 11 269 J05AG01 nevirapine 179 183 186 191 184 40 6 85 88 5 4 064 J05AG03 efavirenz 398 455 382 321 258 40 6 120 125 7 5 950 J05AG04 etravirine 0 0 12 23 28 21 <5 5 22 0 1 255 J05AH Neuraminidase inhibitors 3 266 1 088 282 095 3 860 2 646 54 267 1 319 862 198 702 J05AH01 zanamivir <5 109 2 542 35 36 81 <5 18 15 0 10 J05AH02 oseltamivir 3 264 981 279 946 3 829 2 612 53 264 1 302 848 198 692 J05AR Antivirals for treatment of HIV infections, combinations 1 299 1 563 1 886 2 149 2 415 36 5 1 294 1 080 36 144 003 J05AR01 zidovudine and lamivudine 684 648 606 11 715 J05AR02 lamivudine and abacavir 161 230 258 279 290 33 <5 136 144 8 12 187 J05AR03 tenofovir disoproxil and emtricitabine 518 738 890 1 065 <5 549 15 63 854 J05AR04 zidovudine, lamivudine and abacavir 39 37 36 35 31 48 0 11 20 0 1 738 J05AR06 emtricitabine, tenofovir disoproxil and efavirenz 0 130 362 514 650 26 0 344 299 7 54 509 J05AX Other antivirals 8 50 97 179 271 49 0 125 144 <5 16 789 J05AX05 inosine pranobex <5 <5 <5 301 J05AX07 enfuvirtide 7 6 <5 0 0 - 0 0 0 0 0 J05AX08 raltegravir 0 48 96 148 190 36 0 72 117 <5 15 749 J05AX09 maraviroc 0 5 5 7 7 0 0 0 7 0 738ATC group J ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales AGENTS 65 309 70 154 72 795 76 656 81 605 54 1 180 17 972 38 192 24 261 2 168 965 L02 ENDOCRINE THERAPY 23 657 24 557 24 457 24 886 25 995 51 169 3 136 8 857 13 833 231 496 L02A HORMONES AND RELATED AGENTS 10 633 10 787 10 788 11 009 11 752 25 165 2 451 2 045 7 091 101 367 L02AA Estrogens 75 48 25 17 7 14 0 0 <5 5 8 L02AA02 polyestradiol phosphate 75 48 25 17 7 14 0 0 <5 5 8 L02AB Progestogens 294 223 188 178 202 84 0 13 95 94 421 L02AB01 megestrol 216 186 178 178 202 84 0 13 95 94 421 L02AB02 medroxyprogesterone 79 44 12 0 0 - 0 0 0 0 0 L02AE Gonadotropin releasing hormone analogues 10 299 10 547 10 590 10 827 11 549 24 165 2 438 1 949 6 997 100 938 L02AE01 buserelin 1 364 1 337 1 282 1 474 1 898 99 0 1 871 16 11 3 092 L02AE02 leuprorelin 3 546 3 804 3 887 3 891 4 012 14 164 348 560 2 940 40 335 L02AE03 goserelin 5 511 5 557 5 601 5 619 5 783 7 <5 246 1 420 4 116 57 475 L02AE04 triptorelin <5 <5 8 <5 12 100 0 12 0 0 36 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 16 023 16 898 16 800 17 127 17 876 58 <5 737 7 871 9 264 130 128 L02BA Anti-estrogens 5 565 5 502 4 959 4 109 3 861 97 <5 583 2 282 993 15 158 L02BA01 tamoxifen 5 314 5 251 4 716 3 893 3 597 97 <5 574 2 136 884 3 179 L02BA03 fulvestrant 272 270 267 242 296 98 0 9 161 126 11 979 L02BB Anti-androgens 6 006 6 370 6 380 6 641 7 006 0 0 <5 1 645 5 357 43 600 L02BB01 flutamide 431 389 352 305 253 1 0 <5 37 214 1 200 L02BB03 bicalutamide 5 597 6 003 6 058 6 362 6 773 0 0 <5 1 614 5 157 42 400 L02BG Enzyme inhibitors 5 521 5 968 6 601 7 219 7 378 99 <5 171 4 230 2 976 62 912 L02BG03 anastrozole 3 254 3 444 3 276 2 901 2 331 98 0 25 1 329 977 13 780 L02BG04 letrozole 1 180 1 396 2 360 3 478 4 365 100 <5 132 2 521 1 711 40 951 L02BG06 exemestane 1 272 1 363 1 200 1 108 929 100 0 22 534 373 8 181 L02BX Other hormone antago - nists and related agents 0 0 0 89 377 0 0 <5 136 240 8 459 L02BX02 degarelix 0 0 0 89 271 0 0 <5 104 166 2 597 L02BX03 abiraterone 0 0 0 0 107 0 0 0 33 74 5 862 L03 IMMUNOSTIMULANTS 4 890 5 353 5 663 5 883 6 294 61 54 2 495 3 234 511 344 502 L03A IMMUNOSTIMULANTS 4 890 5 353 5 663 5 883 6 294 61 54 2 495 3 234 511 344 502 L03AA Colony stimulating factors 1 714 1 928 2 085 2 222 2 426 59 37 457 1 472 460 81 902 L03AA02 filgrastim 378 364 362 415 587 48 34 117 343 93 10 464 L03AA13 pegfilgrastim 1 431 1 649 1 815 1 919 1 958 62 <5 363 1 210 382 71 438 L03AB Interferons 2 602 2 667 2 666 2 649 2 756 58 17 1 458 1 244 37 175 082 L03AB01 interferon alfa natural 0 <5 5 11 20 45 <5 9 9 <5 2 5283.11 ATC group L - Antineoplastic and immunomodulating agents ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 100 Legemiddelstatistikk 2012:2 FolkehelseinstituttetL03AB03 interferon gamma 11 11 9 9 9 44 5 <5 0 0 1 355 L03AB04 interferon alfa-2a 20 5 14 19 19 26 0 <5 14 <5 879 L03AB05 interferon alfa-2b 113 80 62 74 63 37 0 8 44 11 2 196 L03AB07 interferon beta-1a 1 311 1 335 1 348 1 217 1 183 70 <5 597 578 <5 103 324 L03AB08 interferon beta-1b 336 363 372 533 276 <5 34 391 L03AB10 peginterferon alfa-2b 504 465 416 310 273 43 6 138 117 12 9 442 L03AB11 peginterferon alfa-2a 324 424 468 <5 <5 0 0 aldesleukin <5 <5 0 0 100 0 <5 0 0 15 L03AX Other immunostimulants 670 862 1 023 1 148 1 266 73 0 681 571 14 87 502 L03AX03 BCG vaccine 5 <5 7 13 12 33 0 0 <5 9 62 L03AX13 glatiramer acetate 665 858 1 016 1 135 1 254 74 0 681 568 5 87 441 L04 IMMUNOSUPPRESSANTS 32 317 35 076 37 221 39 932 42 910 55 840 11 786 22 682 7 602 1 278 640 L04A IMMUNOSUPPRESSANTS 32 317 35 076 37 221 39 932 42 910 55 840 11 786 22 682 7 602 1 278 640 L04AA Selective immunosuppressants 3 796 4 317 4 619 4 910 5 466 48 71 1 239 3 225 931 101 674 L04AA06 mycophenolic acid 2 296 2 647 2 965 3 266 3 591 37 68 916 2 104 503 44 894 L04AA10 sirolimus 68 68 70 101 130 33 <5 21 90 17 5 411 L04AA13 leflunomide 1 264 1 318 1 362 1 458 1 539 71 0 180 951 408 9 004 L04AA18 everolimus 228 253 263 294 336 29 <5 51 231 53 21 340 L04AA21 efalizumab 127 196 118 0 0 - 0 0 0 0 0 L04AA23 natalizumab 0 42 58 49 0 - 0 0 0 0 0 L04AA24 abatacept 17 16 <5 <5 0 - 0 0 0 0 0 L04AA25 0 0 <5 9 677 L04AA27 fingolimod 0 0 0 0 186 72 0 118 68 0 11 348 L04AB Tumor necrosis factor alpha (TNF-) inhibitors 6 569 7 626 8 409 9 649 11 057 54 173 4 055 5 904 925 954 991 L04AB01 etanercept 4 565 5 280 5 162 5 078 6 122 56 116 1 979 3 425 602 449 967 L04AB02 infliximab 426 278 83 <5 0 - 0 0 0 0 0 L04AB04 adalimumab 1 791 2 329 3 519 3 993 4 121 50 60 1 796 2 010 255 381 326 L04AB05 certolizumab pegol 0 0 0 135 314 76 0 86 183 45 16 138 L04AB06 golimumab 0 0 0 1 038 1 208 51 <5 468 668 71 107 561 L04AC Interleukin inhibitors 61 58 69 127 180 46 11 73 92 <5 21 387 L04AC03 anakinra 61 58 68 75 85 48 9 33 41 <5 6 633 L04AC05 ustekinumab 0 0 <5 50 92 43 0 39 51 <5 9 747 L04AC08 canakinumab 0 0 0 <5 6 33 <5 <5 0 0 5 007 L04AD Calcineurin inhibitors 4 328 4 388 4 578 4 799 5 027 37 132 1 387 2 822 686 135 463ATC group L ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 307 3 332 37 50 738 1 951 593 76 705 L04AD02 tacrolimus 976 1 161 1 349 1 570 1 770 39 88 674 910 98 58 757 L04AX Other immunosuppressants 24 138 25 770 26 861 28 383 29 764 59 583 7 391 15 685 6 105 65 124 L04AX01 azathioprine 5 954 6 028 6 197 6 390 6 714 51 185 3 080 2 795 654 5 993 L04AX02 thalidomide 357 340 330 348 320 45 6 11 107 196 11 692 L04AX03 methotrexate 17 921 19 466 20 348 21 623 22 689 61 396 4 341 12 747 5 205 10 125 L04AX04 lenalidomide <5 60 106 157 171 44 0 <5 96 72 37 315ATC group L ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 415 907 360 891 127 901 910 927 190 57 14 195 334 035 421 567 157 393 286 442 M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 822 755 829 545 815 420 824 208 833 697 57 12 492 326 028 387 978 107 199 189 675 M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS 822 620 829 405 815 299 824 121 833 625 57 12 492 326 018 387 944 107 171 188 468 M01AA Butylpyrazolidines 0 <5 0 0 0 - 0 0 0 0 0 M01AA01 phenylbutazone 0 <5 0 0 0 - 0 0 0 0 0 M01AB Acetic acid derivatives and related substances 436 431 498 631 491 574 505 424 508 709 55 7 289 210 994 235 610 54 816 66 610 M01AB01 indometacin 12 784 12 154 11 675 2 710 1 116 59 15 381 593 127 790 M01AB02 sulindac 752 600 386 16 0 - 0 0 0 0 M01AB05 diclofenac 408 801 471 691 464 462 481 108 483 075 55 7 245 205 875 221 895 48 060 50 740 M01AB15 ketorolac 7 7 11 27 23 61 0 <5 15 <5 6 M01AB55 diclofenac, combinations 21 650 22 250 23 266 29 244 31 567 63 35 6 693 17 011 7 828 15 074 M01AC Oxicams 167 590 88 227 81 319 76 309 69 287 55 250 21 922 36 881 10 234 17 791 M01AC01 piroxicam 140 318 60 698 55 461 51 627 47 986 52 204 17 397 25 390 4 995 12 469 M01AC06 meloxicam 29 448 28 570 26 731 25 438 21 951 62 46 4 722 11 845 5 338 5 322 M01AE Propionic acid derivatives 262 707 278 524 273 810 276 001 294 326 61 5 194 116 515 134 732 37 885 64 572 M01AE01 ibuprofen 1)193 933 208 791 211 641 215 745 226 784 62 4 341 95 114 101 882 25 447 37 599 M01AE02 naproxen1)64 457 66 541 59 487 58 354 62 526 57 864 21 054 29 675 10 933 21 989 M01AE03 ketoprofen 8 799 8 541 7 912 7 478 7 396 60 21 1 666 4 168 1 541 3 143 M01AE14 dexibuprofen 2 180 2 124 1 417 1 025 881 62 5 359 425 92 194 M01AE52 naproxen and esomeprazole 0 0 0 0 5 217 64 5 1 403 2 901 908 1 646 M01AG Fenamates 849 827 669 106 304 84 <5 197 99 7 251 M01AG02 tolfenamic acid 849 827 669 106 304 84 <5 197 99 7 251 M01AH Coxibs 37 251 36 485 35 851 35 999 36 511 55 46 12 084 18 623 5 758 17 266 M01AH01 celecoxib 9 398 8 315 8 030 7 851 7 718 63 13 2 228 4 097 1 380 6 013 M01AH02 rofecoxib <5 0 0 0 0 - 0 0 0 0 0 M01AH03 valdecoxib <5 0 0 0 0 - 0 0 0 0 0 M01AH04 parecoxib 0 <5 <5 0 0 - 0 0 0 0 0 M01AH05 etoricoxib 28 099 28 365 28 047 28 365 29 011 53 33 9 912 14 653 4 413 11 254 M01AX Other antiinflammatory and antirheumatic agents, non-steroids 64 418 55 088 51 313 48 137 41 743 66 9 3 415 23 785 14 534 21 979 M01AX01 nabumetone 12 759 11 261 9 107 7 343 6 375 66 6 1 340 3 503 1 526 4 072 M01AX05 glucosamine1)51 520 43 576 41 918 40 410 34 881 67 <5 2 016 20 013 12 850 16 4593.12 ATC group M - Musculo-skeletal system ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 103M01C SPECIFIC ANTIRHEUMATIC AGENTS 360 325 285 242 207 76 0 35 122 50 1 207 M01CB Gold preparations 308 267 241 199 170 81 0 28 97 45 474 M01CB01 sodium aurothiomalate 109 97 74 36 29 76 0 <5 13 15 91 M01CB03 auranofin 200 171 167 163 141 82 0 27 84 30 384 M01CC Penicillamine and similar agents 15 15 12 14 13 46 0 <5 9 <5 62 M01CC01 penicillamine 15 15 12 14 13 46 0 <5 9 <5 62 M01CX Other specific antirheumatic agents 37 43 32 30 24 58 0 <5 16 <5 670 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 37 832 31 768 27 101 24 394 53 452 60 2 045 15 408 21 349 14 650 5 184 M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 37 832 31 768 27 101 24 394 53 452 60 2 045 15 408 21 349 14 650 5 184 M02AA Antiinflammatory preparations, non-steroids for topical use 37 721 31 675 27 032 24 200 53 244 60 2 035 15 345 21 271 14 593 5 161 M02AA10 ketoprofen 1)33 758 27 552 23 095 20 122 47 390 61 1 774 13 591 19 177 12 848 4 094 M02AA13 ibuprofen1)3 958 4 040 3 853 3 998 4 917 60 225 1 403 1 688 1 601 847 M02AA15 diclofenac 127 173 160 167 1 322 57 39 407 520 356 219 M02AB Capsaicin and similar agents 13 8 5 6 6 67 0 0 5 <5 2 M02AB01 capsaicin 13 8 5 6 6 67 0 0 5 <5 2 M02AC Preparations with salicylic acid derivatives 106 89 69 189 207 64 10 67 75 55 18 M02AX Other topical products for joint and muscular pain 21 7 11 13 9 89 0 <5 <5 5 3 M02AX10 various 21 7 11 13 9 89 0 <5 <5 5 3 M03 MUSCLE RELAXANTS 51 832 12 875 5 592 5 918 6 009 56 112 1 658 3 500 739 14 146 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 51 658 12 660 5 388 5 657 5 654 55 112 1 446 3 365 731 10 490 M03BA Carbamic acid esters 48 187 8 594 1 087 1 097 1 030 68 0 267 667 96 3 177 M03BA02 carisoprodol 48 173 8 583 1 087 1 097 1 030 68 0 267 667 96 3 177 M03BA52 carisoprodol, combinations excl. psycholeptics 25 30 <5 0 0 - 0 0 0 0 0 M03BB Oxazol, thiazine, and triazine derivatives <5 <5 M03BB03 chlorzoxazone <5 <5 0 0 to antihistamines <5 <5 <5 0 - 0 0 0 0 0ATC group M ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2012:2 FolkehelseinstituttetM03BC51 orphenadrine, combinations <5 <5 0 0 0 0 0 M03BX Other centrally acting agents 3 836 4 236 4 318 4 583 4 652 52 112 1 188 2 713 639 7 313 M03BX01 baclofen 3 804 4 195 4 277 4 544 4 608 52 112 1 177 2 684 635 6 924 M03BX02 tizanidine 60 72 59 59 71 42 0 23 42 6 389 M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS <5 <5 0 0 <5 0 0 0 <5 0 M03CA Dantrolene and derivatives <5 <5 0 M03CA01 dantrolene <5 <5 0 0 1 M04 ANTIGOUT PREPARATIONS 36 456 37 888 39 433 40 882 43 051 29 11 2 605 18 627 21 808 17 575 M04A ANTIGOUT PREPARATIONS 36 456 37 888 39 433 40 882 43 051 29 11 2 605 18 627 21 808 17 575 M04AA Preparations inhibiting uric acid production 33 756 34 952 36 397 37 670 39 465 29 <5 2 262 17 017 20 185 14 010 M04AA01 allopurinol 33 756 34 952 36 397 37 661 39 436 29 <5 2 256 17 005 20 174 13 374 M04AA03 febuxostat 0 0 0 9 33 24 0 6 15 12 636 M04AB Preparations increasing uric acid excretion 2 062 2 100 2 123 2 062 2 072 30 0 153 934 985 2 197 M04AB01 probenecid 2 062 2 100 2 123 2 062 2 072 30 0 153 934 985 2 197 M04AC Preparations with no effect on uric acid metabolism 2 069 2 373 2 597 3 070 3 686 22 10 386 1 698 1 592 1 368 M04AC01 colchicine 2 069 2 373 2 597 3 070 3 686 22 10 386 1 698 1 592 1 368 M05 DRUGS FOR TREATMENT OF BONE DISEASES 56 743 56 634 56 744 57 597 58 369 89 6 649 20 355 37 359 59 862 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 56 743 56 634 56 744 57 597 58 369 89 6 649 20 355 37 359 59 862 M05BA Bisphosphonates 53 895 54 146 54 669 55 785 56 548 89 6 629 19 921 35 992 54 671 M05BA01 etidronic acid 442 372 297 240 205 94 0 <5 34 170 204 M05BA02 clodronic acid 44 48 44 48 48 44 0 0 30 18 872 M05BA03 pamidronic acid <5 10 13 21 19 37 0 0 9 10 92 M05BA04 alendronic acid 51 589 51 829 52 053 52 702 52 891 89 6 568 18 347 33 970 39 118 M05BA06 ibandronic acid 719 704 704 696 668 94 0 7 270 391 2 642 M05BA07 risedronic acid 1 971 1 405 1 214 1 097 948 93 0 8 340 600 2 904 M05BA08 zoledronic acid 47 221 835 1 584 2 329 88 0 54 1 159 1 116 8 839 M05BB Bisphosphonates, combinations 3 235 2 745 2 267 1 950 1 659 94 0 7 333 1 319 3 729 M05BB01 etidronic acid and calcium, sequential 3 234 2 745 2 267 1 950 1 659 94 0 7 333 1 319 3 729 M05BB03 alendronic acid and colecalciferol <5 0 0 0 0 - 0 0 0 0 0ATC group M ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk bone structure and mineralization 0 0 0 27 398 83 0 17 186 195 1 462 M05BX04 denosumab 0 0 0 27 398 83 0 17 186 195 1 462 M09 OTHER DRUGS FOR DISOR-DERS OF THE MUSCULO-SKELETAL SYSTEM <5 <5 <5 0 0 - 0 0 0 0 0 M09A OTHER DRUGS FOR DISOR-DERS OF THE MUSCULO-SKELETAL SYSTEM <5 <5 <5 0 0 - 0 0 0 0 0 M09AX Other drugs for disorders of the musculo-skeletal system <5 <5 <5 0 0 - 0 0 0 M09AX01 hyaluronic acid <5 <5 <5 0 0 - 0 0 0 0 0ATC group M ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 106 Legemiddelstatistikk 2012:2 FolkehelseinstituttetN NERVOUS SYSTEM 1 181 693 1 208 796 1 230 916 1 248 502 1 279 567 59 30 739 407 577 554 377 286 874 2 554 961 N02 ANALGESICS 647 981 676 887 693 686 710 534 739 065 61 9 158 241 162 325 567 163 178 666 125 N02A OPIOIDS 470 928 484 768 487 517 491 940 500 580 56 4 884 165 283 220 979 109 434 382 432 N02AA Natural opium alkaloids 406 407 409 141 405 617 401 941 403 455 56 4 711 138 640 178 407 81 697 249 129 N02AA01 morphine 6 768 6 995 7 048 7 000 6 787 48 28 931 3 268 2 560 14 398 N02AA03 hydromorphone 65 53 41 40 48 56 0 7 33 8 3 086 N02AA05 oxycodone 12 637 14 983 16 910 19 067 20 442 53 11 3 131 9 410 7 890 76 518 N02AA08 dihydrocodeine 38 40 49 47 52 77 0 10 37 5 260 N02AA55 oxycodone, combinations 0 5 228 1 001 1 830 55 <5 170 790 867 6 075 N02AA59 codeine, combinations excl. 396 326 397 626 392 734 387 507 387 870 56 4 683 136 613 171 353 75 221 148 792 N02AB Phenylpiperidine derivatives 10 091 10 253 10 453 11 167 11 304 59 <5 1 974 4 899 4 427 43 078 N02AB01 ketobemidone 3 743 3 738 3 731 3 994 3 972 55 0 1 125 1 979 868 4 922 N02AB02 pethidine 1 403 1 377 1 340 1 343 1 243 63 0 403 666 174 1 973 N02AB03 fentanyl 5 500 5 657 5 857 6 331 6 581 61 <5 548 2 513 3 516 36 183 N02AC Diphenylpropylamine derivatives 9 262 8 523 7 442 4 700 30 63 0 <5 18 9 34 N02AC04 dextropropoxyphene 0 0 0 0 9 56 0 0 7 <5 7 N02AC54 dextropropoxyphene, comb. excl. psycholeptics 9 262 8 523 7 442 4 700 22 64 0 <5 12 7 27 N02AD Benzomorphan derivatives 52 49 45 41 35 60 0 <5 22 10 444 N02AD01 pentazocine 52 49 45 41 35 60 0 <5 22 10 444 N02AE Oripavine derivatives 7 911 10 244 12 080 13 189 14 006 71 <5 1 285 3 730 8 987 41 842 N02AE01 buprenorphine 7 911 10 244 12 080 13 189 14 006 71 <5 1 285 3 730 8 987 41 842 N02AG Opioids in combination with antispasmodics 1 857 1 819 1 729 1 840 1 774 57 <5 464 875 434 1 567 N02AG01 morphine and antispas-modics 179 218 218 263 309 46 <5 10 96 202 62 N02AG02 ketobemidone and antispas-modics 1 686 1 608 1 515 1 584 1 469 59 0 454 780 235 1 504 N02AX Other opioids 91 978 106 796 114 947 127 985 138 475 59 195 39 355 62 529 36 396 46 337 N02AX02 tramadol 91 978 106 796 114 947 127 985 138 458 59 195 39 353 62 520 36 390 46 313 N02AX06 tapentadol 0 0 0 0 31 61 0 6 16 9 24 N02B OTHER ANALGESICS AND ANTIPYRETICS 226 320 255 894 281 468 305 896 337 904 64 3 022 81 864 148 472 104 546 66 006 N02BA Salicylic acid and derivatives 792 769 806 840 883 62 221 256 233 acetylsalicylic acid 1)780 768 <5 <5 <5 100 0 0 <5 0 113.13 ATC group N - Nervous system ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription N02BB Pyrazolones 988 909 885 887 891 67 6 374 341 170 331 N02BB02 metamizole sodium 6 15 22 12 5 60 <5 4 N02BB51 phenazone, combinations 886 67 6 373 338 169 327 N02BE Anilides 225 013 254 655 280 253 304 672 336 593 64 2 798 81 366 148 066 104 363 65 386 N02BE01 paracetamol1)225 013 254 655 280 253 304 672 336 593 64 2 798 81 366 148 066 104 363 65 386 N02BE51 paracetamol, combinations excl. psycholeptics <5 0 0 0 0 - 0 0 0 0 0 N02BG Other analgesics and <5 <5 <5 - 0 0 0 0 0 N02BG08 ziconotide 0 0 0 0 <5 0 0 0 <5 0 25 N02BG10 nabiximols 0 0 0 0 <5 0 0 <5 <5 0 11 N02C ANTIMIGRAINE PREPARATIONS 86 670 88 060 87 608 88 920 91 681 79 1 789 43 338 42 976 3 578 217 687 N02CA Ergot alkaloids 4 265 3 827 3 477 3 072 2 916 82 10 485 1 770 651 1 290 N02CA04 methysergide 5 8 6 6 9 11 0 <5 5 <5 40 N02CA52 ergotamine, combinations excl. psycholeptics 14 14 13 15 15 73 0 <5 7 6 18 N02CA72 ergotamine, combinations with psycholeptics 4 247 3 808 3 458 3 053 2 893 82 10 481 1 759 643 1 232 N02CC Selective serotonin (5HT 1) agonists 80 455 82 235 81 971 83 475 85 960 79 1 725 42 130 39 369 2 736 214 410 N02CC01 sumatriptan 32 326 35 885 40 472 41 842 43 346 77 1 511 23 051 17 491 1 293 81 721 N02CC02 naratriptan 1 529 1 515 1 497 1 501 1 581 86 5 693 815 68 4 563 N02CC03 zolmitriptan 13 948 14 983 14 223 14 230 14 479 82 106 6 596 7 296 481 40 119 N02CC04 rizatriptan 24 819 24 519 22 306 22 398 23 367 81 184 12 036 10 459 688 46 150 N02CC05 almotriptan 4 687 3 915 3 286 3 053 2 936 83 8 1 496 1 365 67 6 167 N02CC06 eletriptan 12 534 11 871 11 192 11 289 11 401 82 48 5 244 5 836 273 35 671 N02CC07 frovatriptan 0 12 19 6 5 80 0 <5 <5 0 19 N02CX Other antimigraine preparations 3 154 3 129 3 163 3 418 3 920 77 62 1 115 2 495 248 1 987 N02CX01 pizotifen 75 63 53 61 60 82 0 19 36 5 146 N02CX02 clonidine 3 081 3 067 3 111 3 357 3 861 77 62 1 096 2 460 243 1 841 N03 ANTIEPILEPTICS 90 882 97 238 100 381 103 954 108 550 55 3 483 34 809 50 223 20 035 395 734 N03A ANTIEPILEPTICS 90 882 97 238 100 381 103 954 108 550 55 3 483 34 809 50 223 20 035 395 734 N03AA Barbiturates and deriva-tives 3 110 2 959 2 844 2 700 2 544 52 17 263 1 373 891 1 919 N03AA02 phenobarbital 2 884 2 718 2 574 2 426 2 270 52 16 232 1 237 785 1 404ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 108 Legemiddelstatistikk 2012:2 FolkehelseinstituttetN03AA03 primidone 243 255 284 288 287 51 <5 31 141 114 515 N03AB Hydantoin derivatives 2 486 2 332 2 218 2 051 1 938 43 25 231 1 084 598 930 N03AB02 phenytoin 2 485 2 332 2 217 2 051 1 937 43 25 231 1 084 597 926 N03AB05 fosphenytoin <5 0 <5 0 0 0 <5 5 N03AD Succinimide derivatives 110 116 139 149 173 65 79 69 21 <5 1 305 N03AD01 ethosuximide 110 116 139 149 173 65 79 69 21 <5 1 305 N03AE Benzodiazepine derivatives 13 991 13 927 13 712 13 528 13 005 54 169 3 696 6 714 2 426 6 648 N03AE01 clonazepam 13 991 13 927 13 712 13 528 13 005 54 169 3 696 6 714 2 426 6 648 N03AF Carboxamide derivatives 21 523 20 748 20 004 19 238 18 449 46 732 5 153 9 080 3 484 31 731 N03AF01 carbamazepine 19 480 18 586 17 750 16 830 15 931 47 417 4 149 8 180 3 185 15 086 N03AF02 oxcarbazepine 2 104 2 173 2 236 2 298 2 375 43 319 887 867 302 9 718 N03AF03 rufinamide 41 80 96 96 97 36 24 64 8 <5 2 554 N03AF04 eslicarbazepine 0 0 <5 205 213 53 <5 113 86 13 4 373 N03AG Fatty acid derivatives 12 756 13 320 13 867 14 184 14 347 45 1 587 5 895 5 680 1 185 31 675 N03AG01 valproic acid 12 656 13 227 13 786 14 111 14 279 45 1 566 5 873 5 655 1 185 30 833 N03AG04 vigabatrin 120 127 114 100 88 56 35 27 26 0 590 N03AG06 tiagabine 19 15 12 11 13 38 <5 6 6 0 252 N03AX Other antiepileptics 50 441 57 604 61 469 66 054 71 876 59 1 867 24 498 32 533 12 978 321 527 N03AX03 sultiame 51 54 64 98 130 43 94 33 <5 0 825 N03AX09 lamotrigine 18 798 20 820 22 368 23 711 24 878 59 1 061 12 446 9 272 2 099 91 209 N03AX10 felbamate 23 24 25 23 21 29 <5 14 <5 0 432 N03AX11 topiramate 2 975 3 051 3 039 3 060 3 047 69 265 1 664 1 012 106 15 091 N03AX12 gabapentin 7 483 14 682 20 412 24 447 26 607 60 50 5 837 13 925 6 795 41 977 N03AX14 levetiracetam 3 496 4 320 4 977 5 539 6 101 49 595 2 431 2 193 882 60 493 N03AX15 zonisamide 298 349 444 457 473 56 60 267 130 16 6 604 N03AX16 pregabalin 21 046 20 274 17 120 15 264 16 891 59 10 4 101 8 768 4 012 98 399 N03AX17 stiripentol 0 0 19 33 30 37 21 9 0 0 1 637 N03AX18 lacosamide 0 0 122 262 341 52 17 194 117 13 4 799 N03AX21 retigabine 0 0 0 0 18 56 <5 14 <5 0 60 N04 ANTI-PARKINSON DRUGS 17 101 17 191 17 238 17 787 18 177 51 16 1 569 7 891 8 701 131 133 N04A ANTICHOLINERGIC AGENTS 3 271 3 162 3 034 2 915 2 807 50 6 655 1 704 442 1 619 N04AA Tertiary amines 3 205 3 104 2 991 2 880 2 772 50 6 653 1 678 435 1 534 N04AA01 trihexyphenidyl 19 15 15 22 23 52 5 7 9 <5 154 N04AA02 biperiden 3 182 3 085 2 971 2 854 2 746 50 <5 646 1 668 N04AB Ethers chemically close to antihistamines 81 65 48 40 38 66 0 <5 29 7 85ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 66 0 <5 29 7 85 N04B DOPAMINERGIC AGENTS 13 906 14 096 14 267 14 940 15 436 51 10 918 6 218 8 290 129 514 N04BA Dopa and dopa derivatives 7 602 7 606 7 716 7 906 8 015 44 10 110 2 361 5 534 64 288 N04BA02 levodopa and decarboxylase inhibitor 7 067 6 995 7 051 7 180 7 277 45 10 102 2 058 5 107 47 136 N04BA03 levodopa, decarboxylase inhibitor and inhibitor 1 133 1 255 1 358 1 448 1 395 36 0 13 600 782 17 152 N04BB Adamantane derivatives 116 111 114 114 123 59 0 38 78 7 483 N04BB01 amantadine 116 111 114 114 123 59 0 38 78 7 483 N04BC Dopamine agonists 8 302 8 542 8 784 9 442 9 976 53 0 800 5 056 4 120 45 184 N04BC01 bromocriptine <5 <5 N04BC02 pergolide <5 0 0 0 0 - 0 0 0 0 0 N04BC04 ropinirole 1 820 1 842 2 316 2 665 2 667 45 0 171 1 482 1 014 17 366 N04BC05 pramipexole 5 919 6 236 6 258 6 501 6 946 56 0 636 3 429 2 881 18 084 N04BC06 cabergoline 796 514 322 209 177 51 0 8 54 115 702 N04BC07 apomorphine 13 18 19 18 21 33 0 <5 9 11 2 736 N04BC09 rotigotine 232 393 427 517 541 44 0 15 291 235 6 281 N04BD Monoamine oxidase B inhibitors 2 414 2 571 2 862 3 184 3 339 38 0 39 1 700 1 600 18 272 N04BD01 selegiline 2 099 2 081 2 116 2 126 2 087 38 0 21 1 075 991 3 022 N04BD02 rasagiline 405 575 864 1 183 1 329 38 0 20 666 643 15 250 N04BX Other dopaminergic agents 341 287 230 192 152 46 0 <5 56 95 1 287 N04BX01 tolcapone 15 13 13 11 11 27 0 0 <5 8 97 N04BX02 entacapone 327 274 218 181 141 48 0 <5 53 87 1 190 N05 PSYCHOLEPTICS 603 189 611 554 616 962 614 374 618 238 63 9 012 139 605 279 654 189 967 564 483 N05A ANTIPSYCHOTICS 105 763 104 087 104 081 104 075 104 345 56 848 35 261 46 564 21 672 281 276 N05AA Phenothiazines with aliphatic side-chain 29 896 26 862 25 877 24 617 23 179 57 12 6 362 12 005 4 800 9 011 N05AA01 chlorpromazine 3 952 702 492 439 389 57 <5 170 163 55 779 N05AA02 levomepromazine 26 807 26 247 25 435 24 212 22 825 57 11 6 203 11 863 4 748 8 232 N05AB Phenothiazines with piperazine structure 23 022 20 902 19 829 18 276 17 123 68 13 3 702 7 206 6 202 8 763 N05AB01 dixyrazine 620 76 54 32 <5 50 0 <5 <5 0 1 N05AB02 fluphenazine 89 59 27 22 20 55 0 0 11 9 50 N05AB03 perphenazine 6 182 5 993 5 736 5 423 5 083 58 <5 1 188 2 916 978 6 349 N05AB04 prochlorperazine 16 340 14 841 14 075 12 860 12 074 72 12 2 521 4 307 5 N05AC Phenothiazines with piperidine structure 85 79 70 62 61 56 0 5 34 22 218ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 2 N05AC02 thioridazine 77 73 66 58 57 54 0 5 31 21 171 N05AC04 pipotiazine 6 5 <5 <5 45 N05AD Butyrophenone derivatives 4 830 4 735 4 473 4 275 4 085 54 9 424 1 456 2 196 1 467 N05AD01 haloperidol 4 819 4 725 4 466 4 269 4 079 54 9 422 1 454 2 194 1 459 N05AD03 melperone 11 10 7 6 6 50 0 <5 <5 <5 9 N05AE Indole derivatives 1 463 1 383 1 302 1 164 1 033 59 <5 517 470 42 14 532 N05AE03 sertindole 119 165 186 161 138 55 0 96 42 0 1 494 N05AE04 ziprasidone 1 355 1 231 1 118 1 006 897 60 <5 422 429 42 13 038 N05AF Thioxanthene derivatives 24 177 24 515 24 245 23 752 22 931 55 27 7 939 11 295 3 670 11 077 N05AF01 flupentixol 5 519 5 381 5 006 4 918 4 621 67 <5 1 150 2 397 1 073 2 499 N05AF03 chlorprothixene 16 186 16 666 17 012 16 658 16 266 53 25 6 381 7 748 2 112 6 184 N05AF05 zuclopenthixol 3 198 3 156 2 908 2 822 2 660 51 <5 639 1 478 542 2 394 N05AG Diphenylbutylpiperidine derivatives 172 165 142 135 139 32 6 71 46 16 313 N05AG02 pimozide 138 133 116 118 117 33 6 60 38 13 264 N05AG03 penfluridol 34 33 27 17 22 27 0 11 8 <5 49 N05AH Diazepines, oxazepines, thiazepines and oxepines 24 918 26 510 28 510 31 688 35 235 51 105 16 516 14 921 3 693 122 313 N05AH02 clozapine 2 099 2 185 2 299 2 362 2 398 38 0 1 204 1 120 74 9 209 N05AH03 olanzapine 15 644 15 960 16 068 15 799 15 753 48 28 6 466 7 172 2 087 58 897 N05AH04 quetiapine 8 314 9 547 11 509 15 094 18 863 56 80 9 868 7 300 1 615 54 207 N05AL Benzamides 665 589 580 548 527 45 <5 277 224 23 3 635 N05AL01 sulpiride <5 0 0 0 0 - 0 0 0 0 0 N05AL03 tiapride 9 7 5 7 7 43 <5 <5 <5 <5 56 N05AL05 amisulpride 655 582 575 541 520 45 <5 274 223 22 3 578 N05AN Lithium 7 717 7 927 7 995 7 877 7 725 56 <5 2 234 4 338 1 151 9 671 N05AN01 lithium 7 717 7 927 7 995 7 877 7 725 56 <5 2 234 4 338 1 151 9 671 N05AX Other antipsychotics 10 222 10 930 11 445 12 299 12 801 48 717 5 818 4 191 2 075 100 275 N05AX07 prothipendyl 0 0 0 0 <5 100 0 <5 <5 0 2 N05AX08 risperidone 7 896 8 158 8 150 8 255 8 364 47 604 3 054 2 779 1 927 45 651 N05AX12 aripiprazole 2 611 3 055 3 624 4 379 4 743 51 147 2 946 1 491 159 54 280 N05AX13 paliperidone 0 0 0 0 37 27 0 31 5 <5 343 N05B ANXIOLYTICS 285 149 285 503 282 069 277 880 273 938 65 3 609 62 584 127 720 80 025 107 031 N05BA Benzodiazepine derivatives 264 682 265 344 261 073 255 446 250 009 65 3 166 53 433 118 551 74 859 93 615 N05BA01 diazepam 145 984 143 631 138 282 132 588 128 251 63 3 029 26 671 61 321 37 230 47 618 N05BA02 chlordiazepoxide 6 <5 <5 oxazepam 130 709 134 012 134 702 133 963 131 920 67 45 29 380 61 764 40 731 38 613ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 18 20 21 30 60 0 12 7 11 80 N05BA08 bromazepam 8 5 7 5 6 67 0 0 <5 <5 30 N05BA09 clobazam 532 547 558 615 645 52 203 315 120 7 1 809 N05BA12 alprazolam 4 680 4 631 4 521 4 340 4 023 48 <5 1 647 1 945 429 5 461 N05BB Diphenylmethane derivatives 27 098 27 294 28 280 30 163 31 956 62 445 11 441 13 004 7 066 8 834 N05BB01 hydroxyzine 27 098 27 294 28 280 30 163 31 956 62 445 11 441 13 004 7 066 8 834 N05BC Carbamates 10 9 10 6 7 71 0 0 0 7 17 N05BC01 meprobamate 10 9 10 6 7 71 0 0 0 7 17 N05BE Azaspirodecanedione derivatives 3 025 2 808 2 394 2 345 2 371 59 <5 819 1 203 347 4 565 N05BE01 buspirone 3 025 2 808 2 394 2 345 2 371 59 <5 819 1 203 347 4 565 N05C HYPNOTICS AND SEDATIVES 385 861 397 070 405 810 406 159 411 013 65 5 450 79 079 185 227 141 257 2 N05CD Benzodiazepine derivatives 49 522 46 685 44 520 41 807 39 247 60 781 7 240 15 442 15 784 19 823 N05CD01 flurazepam 24 22 20 17 16 50 0 0 10 6 48 N05CD02 nitrazepam 39 705 37 541 35 856 33 406 31 309 61 339 5 641 12 425 12 904 9 886 N05CD03 flunitrazepam 10 179 9 223 8 479 7 690 6 970 55 <5 1 161 3 002 2 804 4 851 N05CD04 estazolam <5 <5 <5 0 0 0 0 0 N05CD05 triazolam 99 103 105 115 98 60 0 23 39 36 102 N05CD08 midazolam 639 831 1 071 1 493 1 758 47 539 671 335 213 4 936 N05CF Benzodiazepine related drugs 341 196 346 261 351 044 349 539 352 252 66 76 60 465 165 502 126 209 125 726 N05CF01 zopiclone 303 779 306 246 308 363 305 045 306 079 66 57 48 423 143 160 114 439 108 887 N05CF02 zolpidem 48 400 51 245 53 835 55 244 56 944 66 21 14 899 27 215 14 809 16 839 N05CF03 zaleplon 5 5 7 <5 0 - 0 0 0 0 0 N05CH Melatonin receptor agonists 12 427 29 906 38 868 42 795 48 421 60 4 798 19 460 18 024 6 139 28 334 N05CH01 melatonin 12 427 29 906 38 868 42 795 48 421 60 4 798 19 460 18 024 6 139 28 334 N05CM Other hypnotics and sedatives 1 762 1 899 1 944 2 109 2 131 46 0 176 581 1 374 2 290 N05CM02 clomethiazole 1 736 1 843 1 870 2 048 2 057 46 0 171 552 1 334 2 163 N05CM05 scopolamine 24 57 77 65 75 52 0 <5 29 42 123 N05CM11 bromides <5 0 0 0 100 0 <5 0 0 4 N05CM18 dexmedetomidine <5 0 0 0 0 - 0 0 0 0 0 N06 PSYCHOANALEPTICS 315 835 319 757 325 941 333 132 340 991 63 10 930 113 867 142 190 74 004 548 373 N06A ANTIDEPRESSANTS 286 775 288 418 292 396 297 122 303 722 66 625 98 601 139 656 64 840 283 544ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 357 59 391 60 237 61 907 63 092 71 84 15 432 33 546 14 030 25 348 N06AA02 imipramine 40 47 34 26 22 50 <5 <5 9 7 86 N06AA04 clomipramine 3 594 3 455 3 276 3 080 2 907 70 7 549 1 662 689 2 305 N06AA05 opipramol <5 5 5 6 6 50 0 0 <5 5 14 N06AA06 trimipramine 13 344 12 628 11 930 11 431 10 943 69 7 2 139 5 594 3 203 6 967 N06AA07 lofepramine 18 18 15 13 12 67 0 <5 8 <5 93 N06AA09 amitriptyline 36 529 38 809 40 585 43 085 45 312 72 64 12 282 24 636 8 330 13 189 N06AA10 nortriptyline 1 548 1 651 1 837 2 104 1 983 69 <5 500 954 528 728 N06AA12 doxepin 4 065 3 580 3 348 3 017 2 749 70 <5 208 1 125 1 964 N06AA21 <5 N06AB Selective serotonin reuptake inhibitors 174 898 176 994 178 930 180 611 183 995 66 499 64 919 80 597 37 980 151 653 N06AB03 fluoxetine 8 632 8 827 9 010 9 289 9 632 76 175 5 357 3 444 656 14 432 N06AB04 citalopram 38 146 35 572 32 885 30 679 29 139 68 5 7 089 13 970 8 075 20 163 N06AB05 paroxetine 19 820 18 698 17 508 16 895 16 172 69 <5 3 408 8 802 3 959 15 846 N06AB06 sertraline 26 545 26 040 26 427 26 384 27 178 66 310 10 339 11 452 5 077 27 355 N06AB08 fluvoxamine 663 653 620 603 586 56 <5 230 287 68 1 155 N06AB10 escitalopram 87 524 93 703 98 493 102 626 107 161 65 24 41 015 44 921 21 201 72 702 N06AF Monoamine oxidase inhibitors, non-selective 117 110 111 111 102 61 0 26 58 18 993 N06AF03 phenelzine 108 100 102 102 94 59 0 23 54 17 623 N06AF04 tranylcypromine 9 10 9 9 9 78 0 <5 <5 <5 370 N06AG Monoamine oxidase A inhibitors 1 1 081 965 880 853 64 <5 189 481 182 1 901 N06AG02 moclobemide 1 204 1 081 965 880 853 64 <5 189 481 182 1 901 N06AX Other antidepressants 90 985 88 987 90 568 92 850 95 454 60 50 30 258 43 524 21 622 103 650 N06AX01 oxitriptan 217 187 244 261 308 78 15 175 111 7 330 N06AX02 tryptophan <5 11 5 4 N06AX03 mianserin 33 187 32 133 31 289 30 307 29 475 62 19 7 116 13 844 8 496 11 366 N06AX05 trazodone 0 <5 <5 0 4 N06AX06 nefazodone 55 48 43 42 36 44 0 <5 31 <5 260 N06AX11 mirtazapine 27 888 28 798 30 394 31 458 33 329 57 15 9 605 14 078 9 631 33 584 N06AX12 bupropion 4 434 3 892 5 978 7 641 8 808 58 <5 4 232 3 venlafaxine 28 833 28 349 28 734 28 791 29 238 62 <5 11 017 14 046 4 174 33 146 N06AX18 reboxetine 591 569 530 512 424 65 0 208 177 39 976 N06AX21 duloxetine 4 988 3 945 2 419 2 804 3 021 68 0 959 1 607 455 9 926 N06AX22 agomelatine 0 0 0 28 22 73 0 8 12 <5 255ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales ADHD AND NOOTROPICS 22 516 25 207 27 837 30 080 31 221 36 10 428 18 154 2 496 143 194 948 N06BA Centrally acting sympathomimetics 22 152 24 862 27 490 29 711 30 821 36 10 416 17 919 2 379 107 194 337 N06BA01 amfetamine 178 221 269 303 336 46 20 222 80 14 3 120 N06BA02 dexamfetamine 722 857 1 024 1 167 1 285 43 81 883 297 24 13 536 N06BA04 methylphenidate 19 200 21 769 24 240 26 471 27 302 36 9 764 15 628 1 853 57 140 982 N06BA07 modafinil 272 288 291 329 349 62 7 198 128 16 4 158 N06BA09 atomoxetine 3 184 3 246 3 213 3 055 3 108 33 1 127 1 830 151 0 32 542 N06BC Xanthine derivatives 327 294 281 285 326 45 5 203 90 28 132 N06BC01 caffeine 327 294 281 285 326 45 5 203 90 28 132 N06BX Other psychostimulants and nootropics 43 57 75 102 86 48 7 40 31 8 479 N06BX03 piracetam 43 49 65 77 70 46 <5 31 28 8 267 N06BX13 idebenone 0 8 10 8 10 80 <5 6 0 0 206 N06BX17 adrafinil 0 0 0 18 6 17 0 <5 <5 0 5 N06D ANTI-DEMENTIA DRUGS 13 484 13 367 13 343 14 174 14 758 63 <5 116 1 382 13 256 69 881 N06DA Anticholinesterases 12 430 12 377 12 371 12 920 12 850 63 0 5 1 179 11 666 53 121 N06DA02 donepezil 10 033 9 837 9 243 8 920 8 530 65 0 <5 721 7 805 26 170 N06DA03 rivastigmine 1 773 2 161 2 974 3 935 4 303 60 0 <5 459 3 843 23 608 N06DA04 galantamine 890 694 558 502 395 58 0 0 54 341 3 343 N06DX Other anti-dementia drugs 1 616 1 501 1 538 1 969 3 028 61 <5 111 372 2 541 16 760 N06DX01 memantine 1 616 1 501 1 538 1 816 2 835 60 0 <5 294 2 537 16 656 N06DX02 ginkgo biloba 0 0 0 153 193 81 <5 107 78 <5 104 N07 OTHER NERVOUS SYSTEM DRUGS 34 308 42 737 46 047 47 188 48 463 48 10 18 088 27 656 2 709 242 246 N07A PARASYMPATHOMIMETICS 750 743 721 660 684 68 <5 110 343 229 2 230 N07AA Anticholinesterases 484 476 493 509 523 62 <5 100 223 198 1 070 N07AA02 pyridostigmine 482 476 492 505 519 62 <5 99 1 065 <5 1 N07AB Choline esters 153 149 112 22 33 70 0 <5 22 10 70 N07AB01 carbachol 153 149 112 22 33 70 0 <5 22 10 70 N07AX Other parasympathomi-metics 122 129 123 130 131 93 0 9 101 21 1 090 N07AX01 pilocarpine 122 129 123 130 131 93 0 9 101 21 1 090 N07B DRUGS USED IN ADDICTIVE DISORDERS 32 861 41 283 44 559 45 751 46 709 48 <5 17 795 26 669 2 241 223 730 N07BA Drugs used in nicotine dependence 23 368 31 433 34 174 34 822 35 023 54 <5 12 110 20 966 1 945 48 995ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 999 50 0 130 620 249 642 N07BA03 varenicline 22 656 30 731 33 475 34 002 34 115 54 <5 11 996 20 411 1 706 48 352 N07BB Drugs used in alcohol dependence 4 867 4 990 4 984 4 866 4 953 29 <5 1 601 3 088 262 3 627 N07BB01 disulfiram 4 066 4 464 4 533 4 450 4 541 29 0 1 487 2 806 248 2 786 N07BB03 acamprosate 629 584 550 526 543 32 0 152 374 17 774 N07BB04 naltrexone 362 119 26 19 17 59 <5 7 6 <5 68 N07BC Drugs used in opioid dependence 4 853 5 164 5 709 6 375 7 065 30 0 4 211 2 809 45 171 109 N07BC01 buprenorphine 1 907 1 719 1 981 2 133 2 272 31 0 1 478 792 <5 54 100 N07BC02 methadone 2)2 852 2 956 3 146 3 345 3 657 32 0 1 890 1 724 43 92 489 N07BC51 buprenorphine, combinations 970 1 156 1 194 1 562 1 759 26 0 1 303 456 0 24 520 N07C ANTIVERTIGO PREPARATIONS 408 413 421 424 454 64 <5 106 Antivertigo preparations 408 413 421 424 454 64 <5 85 259 106 1 186 N07CA01 betahistine 404 401 410 413 438 64 0 77 255 106 1 160 N07CA03 flunarizine <5 12 11 11 16 69 <5 8 <5 0 26 N07X OTHER NERVOUS SYSTEM DRUGS 310 311 361 366 644 46 0 103 406 135 15 099 N07XX Other nervous system drugs 310 311 361 366 644 46 0 103 406 135 15 099 N07XX02 riluzole 252 253 286 278 294 34 0 16 164 114 7 712 N07XX04 sodium oxybate 26 28 33 49 58 57 0 40 15 <5 4 096 N07XX06 tetrabenazine 32 30 42 37 35 46 0 <5 24 7 694 N07XX07 fampridine 0 0 0 <5 257 58 0 43 203 11 2 597ATC group N ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2) The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive methadone dispensed according to special arrangements in the health regions.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 115P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 88 000 89 343 86 714 88 743 92 281 63 3 186 42 467 36 347 10 281 33 169 P01 ANTIPROTOZOALS 84 808 86 259 83 638 85 626 88 913 64 2 009 40 983 35 789 10 132 31 629 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 51 756 53 345 54 583 55 588 57 277 66 604 25 312 23 277 8 084 6 308 P01AB Nitroimidazole derivatives 51 753 53 340 54 576 55 587 57 276 66 604 25 312 23 276 8 084 6 285 P01AB01 metronidazole 51 753 53 340 54 571 55 540 57 223 66 604 25 281 23 254 8 084 6 241 P01AB02 tinidazole 0 0 7 6 9 44 0 <5 6 0 15 P01AB03 ornidazole 0 0 0 46 73 71 0 45 28 0 28 P01AC Dichloroacetamide derivatives 10 6 13 <5 11 27 0 <5 7 <5 23 P01AC01 diloxanide 10 6 13 <5 11 27 0 <5 7 <5 23 P01AX Other protozoal diseases <5 <5 <5 <5 0 0 0 0 0 0 P01AX05 mepacrine 0 <5 0 0 0 - 0 0 0 P01AX11 nitazoxanide <5 <5 <5 <5 0 - 0 0 0 0 0 P01B ANTIMALARIALS 33 687 33 502 29 645 30 716 32 446 59 1 411 16 075 12 864 2 096 25 321 P01BA Aminoquinolines 8 698 7 804 5 421 5 684 5 912 82 37 1 591 3 350 934 3 402 P01BA01 chloroquine 4 219 2 630 40 21 17 65 0 7 8 <5 13 P01BA02 hydroxychloroquine 4 485 5 211 5 371 5 661 5 897 82 37 1 584 3 343 933 3 389 P01BA03 primaquine 8 17 12 <5 0 - 0 0 0 0 0 P01BB Biguanides 20 830 21 153 19 494 20 468 21 918 53 947 11 919 8 257 795 19 762 P01BB01 proguanil 340 62 22 11 7 71 0 <5 <5 <5 5 P01BB51 proguanil, combinations 20 512 21 096 19 476 20 459 21 913 53 947 11 917 8 255 794 19 756 P01BC Methanolquinolines 5 013 5 056 5 044 4 802 4 841 59 432 2 715 1 324 370 2 157 P01BC01 quinine 621 595 629 569 473 66 0 17 192 264 266 P01BC02 mefloquine 4 392 4 463 4 415 4 235 4 368 58 432 2 698 1 132 106 1 891 P01BD Diaminopyrimidines 5 <5 5 <5 0 - 0 0 0 0 0 P01BD01 pyrimethamine 5 <5 5 <5 0 - 0 0 0 0 0 P01BF Artemisinin and deriva-tives, combinations 0 0 0 <5 <5 0 <5 0 0 1 P01BF01 artemether lumefantrine 0 0 0 <5 <5 0 0 <5 0 AND TRYPANOSOMIASIS <5 <5 <5 <5 0 - 0 0 0 agents against leishmaniasis and trypanosomiasis <5 <5 <5 <5 0 - 0 0 0 0 03.14 ATC group P - Antiparasitic products, insecticides and repellents ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 0 0 0 P02 ANTHELMINTICS 2 025 2 008 2 047 2 107 2 222 56 1 041 778 314 89 1 037 P02B ANTITREMATODALS 11 16 19 26 41 54 <5 26 10 <5 139 P02BA Quinoline derivatives and related substances 11 16 19 26 41 54 <5 26 10 <5 139 P02BA01 praziquantel 11 16 19 26 41 54 <5 26 10 <5 139 P02C ANTINEMATODAL AGENTS 1 997 1 985 2 016 2 068 2 169 56 1 029 748 306 86 878 P02CA Benzimidazole derivatives 1 861 1 853 1 870 1 900 2 002 55 984 655 283 80 808 P02CA01 mebendazole 1 845 1 835 1 847 1 877 1 958 55 978 628 274 78 376 P02CA03 albendazole 17 18 24 23 45 56 6 27 9 <5 433 P02CF Avermectines 41 43 47 62 58 60 <5 37 17 <5 54 P02CF01 ivermectin 41 43 47 62 58 60 <5 37 17 <5 54 P02CX Other antinematodals 117 103 114 120 119 69 46 62 7 <5 16 P02CX01 pyrvinium 117 103 114 120 119 69 46 62 7 <5 16 P02D ANTICESTODALS 20 10 18 18 26 42 10 10 <5 <5 20 P02DA Salicylic acid derivatives 20 10 18 18 26 42 10 10 <5 <5 20 P02DA01 niclosamide 20 10 18 18 10 <5 20 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS 1 283 1 216 1 157 1 176 1 297 51 151 803 278 65 503 P03A ECTOPARASITICIDES, INCL. SCABICIDES 1 283 1 216 1 157 1 176 1 297 51 151 803 278 65 503 P03AC Pyrethrines, incl. synthetic compounds 1 139 1 126 1 085 1 093 1 222 50 143 762 254 63 476 P03AC04 permethrin 1)1 139 1 126 1 085 1 093 1 222 50 143 762 254 63 476 P03AX Other ectoparasiticides, incl. scabicides 152 97 77 86 82 10 44 25 <5 27 P03AX01 benzyl benzoate 1)38 36 18 <5 17 8 <5 13 P03AX03 malathion1)114 61 59 62 54 69 8 27 17 <5 15ATC group P ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 117R RESPIRATORY SYSTEM 1 153 020 1 151 929 1 183 767 1 183 735 1 223 304 56 182 251 448 141 430 104 162 808 1 478 331 R01 NASAL PREPARATIONS 330 852 333 006 348 415 353 908 364 573 57 33 138 172 274 129 858 29 303 115 950 R01A DECONGESTANTS AND OTHER NASAL PREPARA - TIONS FOR TOPICAL USE 274 863 278 007 294 861 297 143 307 047 55 31 687 140 353 108 438 26 569 110 095 R01AA Sympathomimetics, plain 4 595 4 204 3 803 4 017 3 672 54 1 052 1 364 860 396 269 R01AA05 oxymetazoline1)1 895 1 734 1 550 1 802 1 781 55 756 605 306 114 113 R01AA07 xylometazoline1)2 722 2 483 2 264 2 233 1 899 53 301 760 556 282 157 R01AB Sympathomimetics, combinations excl. corticosteroids 0 1 124 514 602 602 59 17 283 204 98 72 R01AB06 xylometazoline 1)0 1 124 514 602 602 59 17 283 204 98 72 R01AC Antiallergic agents, excl. corticosteroids 47 363 44 711 44 853 39 407 40 938 56 11 078 19 513 8 818 1 529 10 872 R01AC01 cromoglicic acid 1)11 764 10 718 10 197 8 772 8 704 60 1 981 4 155 2 225 343 2 268 R01AC02 levocabastine1)35 661 34 025 34 686 30 659 32 360 55 9 187 15 390 6 598 1 185 8 576 R01AC03 azelastine1)303 261 227 198 127 55 17 59 39 12 27 R01AD Corticosteroids 229 612 234 552 252 559 259 097 267 878 55 20 808 122 280 100 119 24 671 98 494 R01AD01 beclometasone 2 395 2 228 1 943 11 <5 0 0 0 0 <5 1 R01AD04 flunisolide 4 527 4 133 2 634 11 9 78 0 0 6 <5 16 R01AD05 budesonide 46 628 43 762 39 753 34 996 32 641 56 1 997 13 032 14 036 3 576 12 176 R01AD08 fluticasone 34 290 32 446 27 939 24 352 22 506 55 1 095 8 582 10 058 2 771 9 250 R01AD09 mometasone 133 991 142 288 143 465 141 114 144 388 55 10 256 65 680 54 642 13 810 54 748 R01AD11 triamcinolone 14 824 13 593 11 025 9 687 8 711 57 501 3 651 3 624 935 3 571 R01AD12 fluticasone furoate 0 3 945 38 322 60 417 70 202 55 7 546 36 060 22 039 4 557 18 732 R01AX Other nasal preparations 439 459 572 630 727 54 44 183 215 285 387 R01AX03 ipratropium bromide 266 264 302 355 422 52 <5 42 131 248 279 R01AX06 mupirocin 173 195 270 276 305 56 43 141 84 37 108 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 75 595 75 926 75 490 81 771 83 155 66 1 860 45 954 31 392 3 949 5 856 R01BA Sympathomimetics 75 595 75 926 75 490 81 771 83 155 66 1 860 45 954 31 392 3 949 5 856 R01BA01 phenylpropanolamine 75 595 75 926 75 490 81 771 83 155 66 1 860 45 954 31 392 3 949 5 856 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 395 713 397 839 419 367 423 205 418 073 53 96 201 109 030 142 463 70 379 1 122 844 R03A ADRENERGICS, INHALANTS 309 383 309 382 328 513 335 492 347 882 54 61 878 99 209 126 503 159 adrenoreceptor agonists 196 185 <5 261 R03AA01 epinephrine 196 185 181 209 246 <5 261 R03AC Selective beta-2- adrenoreceptor agonists 230 949 230 012 244 326 249 080 258 818 54 58 527 75 352 85 609 39 330 146 4753.15 ATC group R - Respiratory system ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 118 Legemiddelstatistikk 2012:2 FolkehelseinstituttetR03AC02 salbutamol 171 637 175 373 190 768 198 277 208 507 54 56 471 59 757 64 036 28 243 80 990 R03AC03 terbutaline 43 401 39 227 38 318 35 556 34 145 57 1 984 13 315 13 497 5 349 14 706 R03AC04 fenoterol 22 23 17 17 16 50 0 <5 11 <5 63 R03AC12 salmeterol 11 119 10 847 10 555 10 563 9 698 55 223 1 053 4 593 3 829 17 610 R03AC13 formoterol 18 706 17 310 16 879 16 627 15 454 55 348 3 475 7 377 4 254 24 355 R03AC18 indacaterol 0 0 0 713 4 814 46 2 566 2 097 8 751 R03AK Adrenergics and other drugs for obstructive airway diseases 154 830 155 451 164 536 168 450 175 100 55 11 158 48 561 76 829 38 552 579 423 R03AK04 salbutamol and drugs for obstructive airway diseases <5 <5 <5 <5 0 - 0 0 0 0 0 R03AK06 salmeterol and other drugs for obstructive airway diseases 87 858 86 941 90 149 90 997 94 179 55 8 874 23 160 39 884 22 261 330 449 R03AK07 formoterol and other drugs for obstructive airway diseases 69 903 71 382 77 502 80 699 84 161 56 2 399 26 285 38 476 17 001 248 974 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 132 674 134 223 140 443 146 450 149 785 51 44 328 20 654 49 138 35 665 256 689 R03BA Glucocorticoids 87 587 85 762 88 434 91 633 92 753 50 44 083 17 693 21 351 9 626 84 720 R03BA01 beclometasone 4 906 4 825 4 729 4 380 4 075 55 818 1 004 1 529 724 3 675 R03BA02 budesonide 31 522 26 377 25 860 25 066 23 192 56 3 537 6 019 8 947 4 689 31 460 R03BA05 fluticasone 53 850 56 192 59 302 62 013 64 089 47 40 845 9 853 9 585 3 806 45 470 R03BA07 mometasone <5 <5 <5 0 0 0 0 0 R03BA08 ciclesonide 0 0 0 1 874 3 476 58 249 1 059 1 623 545 4 115 R03BB Anticholinergics 50 704 53 722 57 032 60 133 62 620 52 689 3 456 30 229 28 246 171 685 R03BB01 ipratropium bromide 41 598 41 832 39 555 38 289 35 877 56 688 2 950 16 183 16 056 44 786 R03BB04 tiotropium bromide 12 510 16 714 22 767 27 429 32 809 48 <5 595 16 854 15 356 126 excl. corticosteroids 633 539 cromoglicic acid 633 539 521 454 430 65 23 178 188 41 284 R03C ADRENERGICS FOR SYSTEMIC USE 65 153 67 040 68 733 63 272 40 580 49 31 671 3 760 3 795 1 354 5 307 R03CA Alpha- and beta- adrenoreceptor agonists 50 378 53 610 55 608 49 364 23 991 49 18 217 2 606 2 452 716 3 352 R03CA02 ephedrine 50 378 53 610 55 608 49 364 23 991 49 18 217 2 606 2 452 716 3 352 R03CC Selective beta-2- adrenoreceptor agonists 17 449 16 509 16 104 16 917 17 886 48 14 708 1 172 1 366 640 1 955 R03CC02 salbutamol 5 885 5 091 4 877 4 731 4 844 47 4 074 336 299 135 357 R03CC03 terbutaline 11 467 11 420 11 149 12 109 12 968 48 10 763 813 955 437 1 367 R03CC12 bambuterol 222 227 238 245 210 60 0 28 114 68 232ATC group R ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 119R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 37 528 39 324 40 012 41 123 42 178 55 9 444 10 617 15 766 6 351 134 690 R03DA Xanthines 6 529 5 938 5 287 4 785 4 300 59 <5 239 2 122 1 937 3 278 R03DA02 choline theophyllinate 13 12 8 10 6 100 0 0 6 0 42 R03DA04 theophylline 6 499 5 916 5 272 4 768 4 288 59 <5 237 2 113 1 936 3 105 R03DA05 aminophylline 37 29 26 19 19 79 0 <5 14 <5 131 R03DC Leukotriene receptor antagonists 32 110 34 436 35 710 37 220 38 266 55 9 439 10 453 13 927 4 447 113 622 R03DC01 zafirlukast 32 28 25 22 22 59 0 <5 14 5 217 R03DC03 montelukast 32 079 34 409 35 686 37 199 38 244 55 9 439 10 450 13 913 4 442 113 405 R03DX Other systemic drugs for obstructive airway diseases 34 44 53 145 751 51 9 82 377 283 17 790 R03DX05 omalizumab 34 44 53 84 133 57 9 75 48 <5 16 304 R03DX07 roflumilast 0 0 0 61 620 49 0 8 330 282 1 486 R05 COUGH AND COLD PREPARATIONS 389 460 373 473 385 149 382 370 422 375 59 38 302 143 219 165 594 75 260 68 995 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 125 939 126 488 133 512 135 839 147 139 58 8 465 34 705 61 702 42 267 33 424 R05CA Expectorants 3 571 3 135 3 334 3 671 4 351 55 1 933 1 010 857 551 303 R05CA10 combinations 1)3 571 3 135 3 334 3 671 4 351 55 1 933 1 010 857 551 303 R05CB Mucolytics 122 993 123 898 130 752 132 820 143 540 59 6 630 33 868 61 113 41 929 33 121 R05CB01 acetylcysteine 118 352 119 891 126 968 128 952 139 313 59 4 976 33 064 60 133 41 140 26 169 R05CB02 bromhexine1)5 508 4 836 4 561 4 658 4 973 54 1 658 896 1 301 1 118 746 R05CB12 tiopronin <5 <5 5 R05CB13 dornase alfa ( desoxyribonuclease) 99 110 109 118 128 51 42 77 9 0 6 179 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 265 549 255 435 258 843 254 586 283 891 60 27 679 106 896 111 275 38 041 30 907 R05DA Opium alkaloids and derivatives 262 753 255 434 258 843 254 586 283 891 60 27 679 106 896 111 275 38 041 30 907 R05DA01 ethylmorphine 252 064 246 451 249 477 245 677 274 375 60 27 144 103 569 107 133 36 529 28 166 R05DA03 hydrocodone 650 570 581 592 592 61 <5 118 318 155 213 R05DA04 codeine 8 196 7 660 7 715 7 203 7 751 64 145 2 977 3 480 1 149 1 585 R05DA07 noscapine 1)1 848 1 561 1 763 1 880 1 952 58 455 640 559 298 169 R05DA08 pholcodine1)292 0 0 0 0 - 0 0 0 0 0 R05DA09 dextromethorphan 0 <5 <5 <5 0 - 0 0 0 0 0 R05DA20 combinations 3 981 2 881 3 036 2 836 2 918 62 31 900 1 467 520 775 R05DB Other cough suppressants 3 507 <5 0 0 0 - 0 0 0 0 0ATC group R ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 120 Legemiddelstatistikk 2012:2 FolkehelseinstituttetR05DB05 pentoxyverine 3 507 <5 0 0 0 - 0 0 0 0 0 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 47 005 37 584 41 525 41 844 48 182 61 4 035 18 771 18 697 6 679 4 663 R05FA Opium derivatives and expectorants 47 005 37 584 41 525 41 844 48 182 61 4 035 18 771 18 697 6 679 4 663 R05FA02 opium derivatives and expectorants 47 005 37 584 41 525 41 844 48 182 61 4 035 18 771 18 697 6 679 4 663 R06 ANTIHISTAMINES FOR SYSTEMIC USE 513 164 514 755 519 116 511 537 529 086 58 74 819 218 370 184 498 51 399 170 541 R06A ANTIHISTAMINES FOR SYSTEMIC USE 513 164 514 755 519 116 511 537 529 086 58 74 819 218 370 184 498 51 399 170 541 R06AA Aminoalkyl ethers 24 18 18 15 0 0 0 0 R06AA04 clemastine 20 14 14 14 14 64 <5 <5 7 <5 38 R06AB Substituted alkylamines 38 566 40 313 35 818 25 263 22 710 66 6 797 7 849 5 523 2 541 6 869 R06AB02 dexchlorpheniramine 38 566 40 313 35 818 25 263 22 710 66 6 797 7 849 5 523 2 541 6 869 R06AD Phenothiazine derivatives 61 384 62 532 62 798 64 453 65 866 62 4 481 23 466 28 230 9 689 35 533 R06AD01 alimemazine 54 771 55 908 56 465 57 913 59 721 61 4 439 21 052 25 553 8 677 32 629 R06AD02 promethazine 7 310 7 311 6 991 7 154 6 717 67 46 2 642 2 957 1 072 2 895 R06AD03 thiethylperazine 8 8 <5 5 <5 67 0 0 0 <5 9 R06AE Piperazine derivatives 260 076 272 062 294 720 285 404 293 872 58 44 421 119 027 101 277 29 147 59 053 R06AE03 cyclizine 1)607 276 655 737 758 70 19 216 340 183 278 R06AE05 meclozine1)1 893 2 094 1 956 2 031 2 165 86 82 1 529 338 216 202 R06AE07 cetirizine1)256 512 269 004 291 604 282 294 290 648 58 44 308 117 159 100 443 28 738 58 059 R06AE09 levocetirizine 1 518 1 040 844 703 661 62 26 306 277 52 514 R06AX Other antihistamines for systemic use 192 319 180 177 164 938 169 564 178 097 59 23 415 81 203 60 536 12 943 69 049 R06AX02 cyproheptadine 57 61 59 40 17 35 8 6 <5 <5 9 R06AX13 loratadine 1)72 006 74 765 92 307 83 864 82 798 59 6 021 40 229 29 464 7 084 19 469 R06AX17 ketotifen 5 5 <5 7 10 70 0 <5 5 <5 13 R06AX22 ebastine1)25 660 23 548 11 035 10 315 10 431 65 245 4 822 4 506 858 8 826 R06AX26 fexofenadine 10 213 11 575 24 496 27 017 30 405 62 1 001 16 303 10 801 2 300 9 368 R06AX27 desloratadine 93 888 81 363 48 971 55 048 60 485 56 16 569 23 093 17 748 3 075 31 363ATC group R ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 121S SENSORY ORGANS 585 905 596 101 596 290 609 467 617 591 57 118 923 181 573 188 647 128 448 308 635 S01 OPHTHALMOLOGICALS 519 135 525 644 526 629 538 818 549 678 57 106 214 160 144 163 588 119 732 294 543 S01A ANTIINFECTIVES 250 656 262 875 250 367 269 034 266 877 56 76 164 78 449 74 222 38 042 51 346 S01AA Antibiotics 247 682 260 246 247 638 266 185 263 972 56 75 957 77 416 73 170 37 429 49 987 S01AA01 chloramphenicol 184 832 192 708 182 292 197 212 200 684 55 49 832 61 363 59 415 30 074 40 624 S01AA02 chlortetracycline 0 <5 2 121 2 022 1 763 1 702 595 57 160 527 594 314 180 S01AA12 tobramycin 2 218 2 455 2 332 2 302 2 321 58 359 684 812 466 215 S01AA13 fusidic acid 72 970 79 306 75 838 82 810 75 315 57 32 234 18 598 15 976 8 507 8 265 S01AA30 combinations of different antibiotics 4 584 4 917 4 936 5 105 5 268 58 306 1 368 2 018 1 576 704 S01AD Antivirals 3 092 3 080 3 249 3 266 3 170 56 145 893 1 279 853 790 S01AD01 idoxuridine 0 0 <5 0 0 - 0 0 0 0 0 S01AD02 trifluridine <5 <5 0 0 0 - 0 0 0 0 0 S01AD03 aciclovir 3 091 3 079 3 248 3 266 3 170 56 145 893 1 279 853 790 S01AX Other antiinfectives 2 110 1 925 1 984 2 140 2 331 52 186 990 789 366 569 S01AX13 ciprofloxacin 2 108 1 923 1 982 2 138 2 327 52 185 988 788 366 530 S01AX15 propamidine 0 0 0 0 <5 0 0 0 <5 0 0 S01B ANTIINFLAMMATORY AGENTS 39 680 42 882 44 119 45 945 46 749 57 1 545 8 947 17 397 18 860 14 358 S01BA Corticosteroids, plain 29 718 30 231 30 111 30 638 31 476 57 1 485 7 816 12 786 9 389 10 298 S01BA01 dexamethasone 17 005 17 332 18 319 18 993 20 146 54 504 4 683 8 618 6 341 7 240 S01BA04 prednisolone 14 721 15 017 12 418 11 840 10 923 59 921 3 253 4 434 2 315 1 727 S01BA07 fluorometholone 19 15 17 16 12 58 0 <5 7 <5 15 S01BA09 clobetasone 18 22 18 16 13 62 0 <5 7 <5 47 S01BA13 rimexolone 2 098 2 151 4 177 4 351 4 414 56 172 1 306 1 624 1 312 1 270 S01BC Antiinflammatory agents, non-steroids 11 292 14 254 15 618 17 141 17 550 58 69 1 557 5 509 10 415 4 057 S01BC03 diclofenac 11 292 14 254 15 618 15 814 11 682 58 62 1 437 3 719 6 464 2 336 S01BC10 nepafenac 0 0 0 1 528 6 084 58 7 129 1 860 4 088 1 721 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFEC-TIVES IN COMBINATION 54 854 57 374 56 226 56 906 57 656 58 1 179 9 479 20 364 26 634 10 851 S01CA Corticosteroids and antiin - fectives in combination 54 854 57 374 56 226 56 906 57 656 58 1 179 9 479 20 364 26 634 10 8513.16 ATC group S - Sensory organs ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 fectives 54 854 57 374 56 226 56 906 57 656 58 1 179 9 479 20 364 26 634 10 851 S01E ANTIGLAUCOMA PREPARA - TIONS AND MIOTICS 67 453 68 239 68 940 70 039 70 783 57 195 2 034 21 022 47 532 142 010 S01EA Sympathomimetics in glaucoma therapy 3 655 3 953 3 992 4 077 4 222 54 <5 144 1 087 2 988 3 873 S01EA01 epinephrine 5 1 S01EA02 dipivefrine 234 217 122 9 <5 50 0 0 <5 <5 2 S01EA03 apraclonidine 69 91 97 115 122 55 0 15 44 63 61 S01EA05 brimonidine 3 400 3 706 3 838 3 983 4 122 54 <5 134 1 048 2 937 3 808 S01EB Parasympathomimetics 1 637 1 498 1 433 1 291 1 254 61 5 52 324 873 743 S01EB01 pilocarpine 1 634 1 496 1 431 1 289 1 253 61 5 S01EC Carbonic anhydrase inhibitors 9 558 9 488 9 634 10 040 10 322 57 108 665 2 662 6 887 12 455 S01EC01 acetazolamide 1 695 1 597 1 531 1 699 1 828 53 43 514 636 635 1 032 S01EC03 dorzolamide 2 975 2 783 2 660 2 503 2 393 58 15 50 540 1 788 3 207 S01EC04 brinzolamide 5 148 5 415 5 811 6 195 6 452 57 55 110 1 591 4 696 8 217 S01EC05 methazolamide 6 <5 0 0 0 - 0 0 0 0 0 S01ED Beta blocking agents 47 230 47 883 48 377 48 841 49 026 56 133 1 159 14 556 33 178 78 095 S01ED01 timolol 23 426 23 313 22 977 22 326 21 730 57 108 559 7 248 13 815 22 360 S01ED02 betaxolol 2 525 2 233 2 012 1 778 1 587 67 <5 9 356 1 218 1 097 S01ED51 timolol, combinations 23 685 24 676 25 922 27 060 27 983 55 28 674 7 688 19 593 54 638 S01EE 231 35 402 36 048 36 697 37 168 58 18 674 10 267 26 209 46 844 S01EE01 latanoprost 29 947 29 658 28 946 27 890 26 155 58 8 396 6 840 18 911 24 504 S01EE03 bimatoprost 1 789 1 814 1 807 1 867 1 871 58 0 55 530 1 286 3 140 S01EE04 travoprost 4 050 4 469 4 844 5 035 6 464 56 <5 126 1 887 4 447 9 490 S01EE05 tafluprost 0 0 1 654 3 068 4 027 64 7 134 1 440 2 446 9 711 S01F MYDRIATICS AND CYCLOPLEGICS 4 586 4 744 4 899 5 066 5 041 47 428 1 258 2 185 1 170 932 S01FA Anticholinergics 4 568 4 737 4 891 5 062 5 038 47 428 1 257 2 183 1 170 926 S01FA01 atropine 2 598 2 750 2 670 2 549 2 323 45 347 540 927 509 454 S01FA02 scopolamine <5 0 0 0 0 - 0 0 0 0 0 S01FA04 cyclopentolate 1 897 2 034 2 277 2 546 2 746 47 74 738 1 271 663 440 S01FA05 homatropine 127 0 0 0 0 - 0 0 0 0 0 S01FA06 tropicamide 185 164 157 189 164 52 12 59 77 16 33 S01FB Sympathomimetics excl. antiglaucoma preparations 62 48 39 29 35 54 <5 10 18 6 5 S01FB01 phenylephrine 62 48 39 29 35 54 <5 10 18 6 5ATC group S ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 153 164 724 172 049 158 625 167 470 58 30 991 75 283 48 963 12 233 50 538 S01GA Sympathomimetics used as decongestants 25 905 23 730 23 098 20 728 21 277 61 2 672 9 729 6 992 1 884 6 337 S01GA51 naphazoline, combinations 11 11 11 <5 <5 4 S01GA52 tetryzoline, combinations1)25 894 23 719 23 089 20 725 21 272 61 2 672 9 729 6 989 1 882 6 334 S01GX Other antiallergics 153 727 144 671 152 775 141 091 149 611 58 28 973 67 098 42 974 10 566 44 201 S01GX01 cromoglicic acid1)27 687 24 839 25 305 22 551 23 398 62 3 713 10 265 7 629 1 791 5 922 S01GX02 levocabastine1)78 401 73 171 77 301 70 567 75 480 58 15 564 34 108 20 846 4 962 21 589 S01GX04 nedocromil 2 327 1 982 2 018 1 777 1 701 57 225 858 519 99 352 S01GX05 lodoxamide1)444 339 35 0 0 - 0 0 0 0 0 S01GX06 emedastine 645 546 490 379 384 61 70 135 131 48 131 S01GX07 azelastine 901 755 691 580 553 60 86 224 176 67 160 S01GX08 ketotifen1)18 601 16 912 17 926 16 305 17 277 59 3 180 7 606 5 167 1 324 6 498 S01GX09 olopatadine 30 543 30 752 34 046 32 856 35 322 56 7 367 15 505 9 845 2 605 9 549 S01X OTHER OPHTHALMOLOGICALS 6 080 6 859 18 266 26 371 34 495 76 286 3 457 15 088 15 664 24 483 S01XA Other ophthalmologicals 6 080 6 859 18 266 26 371 34 495 76 286 3 457 15 088 15 664 24 483 S01XA03 sodium chloride, hypertonic 18 16 20 15 17 35 0 <5 7 9 27 S01XA18 ciclosporin 25 27 41 70 112 60 <5 40 56 13 1 298 S01XA20 artificial tears and other indifferent preparations 1)6 041 6 823 18 234 26 329 34 442 76 283 3 441 15 065 15 653 23 157 S02 OTOLOGICALS 11 998 13 048 14 496 14 933 20 221 54 4 073 5 405 7 663 3 080 3 862 S02A ANTIINFECTIVES 5 580 7 097 7 037 7 346 10 565 48 3 815 2 989 2 705 1 056 1 905 S02AA Antiinfectives 5 580 7 097 7 037 7 346 10 565 48 3 815 2 989 2 705 1 056 1 905 S02AA01 chloramphenicol 253 202 123 75 75 41 21 21 25 8 56 S02AA15 ciprofloxacin 5 349 6 923 6 937 7 290 10 501 48 3 798 2 971 2 684 1 048 1 849 S02B CORTICOSTEROIDS 6 630 6 139 7 724 7 847 10 180 59 314 2 625 5 158 2 083 1 942 S02BA Corticosteroids 6 630 6 139 7 724 7 847 10 180 59 314 2 625 5 158 2 083 1 942 S02BA07 betamethasone 6 630 6 139 7 724 7 847 10 180 59 314 2 625 5 158 2 083 1 942 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 75 58 70 66 104 63 6 24 50 24 15 S02CA Corticosteroids and anti-infectives in combination 75 58 70 66 104 63 6 24 50 24 15 S02CA02 flumetasone and antiinfectives 75 58 70 66 104 63 6 24 50 24 15 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 74 455 78 318 75 322 77 041 68 883 54 12 853 20 837 24 919 10 274 10 230ATC group S ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 124 Legemiddelstatistikk 2012:2 FolkehelseinstituttetS03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 74 455 78 318 75 322 77 041 68 883 54 12 853 20 837 24 919 10 274 10 230 S03CA Corticosteroids and anti-infectives in combination 74 455 78 318 75 322 77 041 68 883 54 12 853 20 837 24 919 10 274 10 230 S03CA01 dexamethasone and antiinfectives 16 091 18 919 15 356 14 416 24 934 54 3 425 7 461 9 870 4 178 2 921 S03CA04 hydrocortisone and antiinfectives 61 091 62 532 62 503 65 038 47 788 54 9 873 14 380 16 702 6 833 7 309ATC group S ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2012:2 Folkehelseinstituttet 125V VARIOUS 10 023 11 571 13 317 15 900 18 601 49 2 926 6 862 5 641 3 172 71 097 V01 ALLERGENS 4 173 4 962 6 170 7 289 8 266 46 1 569 5 209 1 452 36 38 724 V01A ALLERGENS 4 173 4 962 6 170 7 289 8 266 46 1 569 5 209 1 452 36 38 724 V01AA Allergen extracts 4 173 4 962 6 170 7 289 8 266 46 1 569 5 209 1 452 36 38 724 V01AA02 grass pollen 2 502 3 056 4 021 5 033 5 756 44 935 3 970 841 10 22 264 V01AA03 house dust mites 211 284 301 349 425 47 109 254 60 <5 2 217 V01AA05 tree pollen 2 693 3 104 3 705 4 150 4 664 49 911 2 866 868 19 10 786 V01AA07 insects 192 206 185 183 181 54 25 65 81 10 774 V01AA10 flowers 36 54 90 108 138 59 10 86 41 <5 576 V01AA11 animals 178 201 217 288 382 50 93 198 91 0 2 1063.17 ATC group V - Various ATC level2007 2008 2009 2010 2011 2011 2011 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 Kjemisk (klassifikasjonssystem for Chemical (classification medicines) DDD Definert d\u00f8gndose Defined Daily Doses samarbeid FHI Folkehelseinstituttet GP General Practitioner ICD -10 International Classification of Diseases version 10 ICPC International Classification of Primary Care MA Markedsf\u00f8ringstillatelse Marketing Authorisation NIPH Norwegian Institute of Public Health NMD Norsk Medisinaldepot Norwegian Medicinal Depot (wholesaler) NOK Norske kroner NorPD Reseptregisteret Anti-Inflammatory Drug OTC Reseptfritt Over The Counter, non prescription drugs SPC Summary of Product Characteristics SSB Statistisk sentralbyr\u00e5 Statistics definerte befolkningsutvalget. Definitions PrevalenceUsers (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample. Incidence (new users) Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample. Legemiddelstatistikk 2012:2 Folkehelseinstituttet 127Folkemengde i Norge 2007-2011 (per 1. juli)/ Population in Norway 2007-2011 (as of 1st July) Y ear 2007 2008 2009 2010 2011 Population 4 709 284 4 768 076 4 829 800 4 888 946 4 953 216 Folkemengde etter alder i 2011 (per 1. juli)/ Population by age in 2011 (as of 1st July) Age groups <15 15-44 45-69 70 Population 890 151 2 011 227 1 516 775 535 064 Kilde: Statistisk sentralbyr\u00e5 / basert p\u00e5 data fra Reseptregisteret per mars 2012 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2012 2012: Bramness JG, Furu K, Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse Antidepressants to cancer patients during the last year of life - a population-based study. Psychooncology. 2012 Mar 6. doi: Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21:297-304. Handal Kieler Artama M, Engeland A, Ericsson O, Furu K, Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hyper - tension of the newborn: population based cohort study from the five Nordic countries BMJ. 2012 Jan 12;344:d8012. doi: 10.1136/bmj.d8012. Kjosavik SR, S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012, 68: 311-9. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206. Nordb\u00f8 transdermal buprenorphine - long-term use Acta Anaesthesiol G, Straand J, Brekke prescribing for the elderly - a modern epidemic? Eur J Clin Pharmacol. 2012 Feb 15. [Epub ahead of print]. Selmer R, Blix HS, Landmark K, Reikvam A. Choice of initial antihypertensive drugs and persistence of drug use-a 4-year follow-up of 78,453 incident users. Eur J K, Nordstr\u00f6m Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents - a prospective register linkage study. J Adolescent Health 2012. Jan 12, Epub ahead of print. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012. March 9, Epub ahead of print. 2011: Berg C, Sakshaug S, Skurtveit S. 2011:119:20-3. In Norwegian. Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. BMC Public Health. 2011;11:144. Dalen DM, Furu K, Locatelli M, Str\u00f8m S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49-59. Engeland A, Bj\u00f8rge S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157-63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243-8.Legemiddelstatistikk in opioid main- tenance therapy: A pharmacoepidemiological study. Drug Alcohol Depend [Epub ahead of print]. Furu High validity of mother-reported use of antiasthmatics among children: a comparison with a population-based prescription database. J Clin Epidemiol 2011 Jan 12. of print]. Nor 2011;131:461-3. B, Sakshaug C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engi- neer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121-9. Handal M, Furu K, Engeland of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011. In press. Hartz I, Tverdal Norwegian.Hjellvik V, Tverdal A, Str\u00f8m H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011 Mar 12. [Epub ahead of print]. Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011 Mar 22. [Epub ahead of P , Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepidemiol Drug Saf 2011 Jan 24. [Epub ahead of print]. Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial of antipsychotics and antidepressants in general prac - tice and specialist care in Norway. Acta Psychiatr Scand 2011 Mar 14.[Epub ahead of I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population-based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90-8. Log T, Hartz I, Tverdal A, Furu K, Skurtveit S. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. Scand J Pain 2011. In press. Skurtveit S, Furu K, Handal M, Borchgrevink P , Fredheim O. To which extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain 2011 29.[Epub ahead of \u00d8. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198-204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiol Saf 2010;19:273-9. A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445-50. Berg A, Furu analgetika [Use of need for other pain-relieving drugs]. Tidsskr Nor Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzo - diazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol 2010 Apr 23 [Epub Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, S\u00f8gaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306. Fasmer OB, 23 [Epub ahead [Epub of Fredheim OM, Skurtveit S, Breivik H, Borchgrevink P . Increasing use of opoids from 2004 to 2007 - Pharmacoepidemio - logical data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-294.Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen \u00d8, Borchgrevink P . Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. Pediatric Anesthesia 2010;20:537-544. Furu K, Skurtveit Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as of Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. Soc Sci Med 2010;70:921-5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465-73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235-42. K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol M, CJ. Psychiatric comorbidity in patients Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. Diabetes Technol Ther 2010;12:701-5. Korn\u00f8r H, Pedersen W, 2010 In Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005-2009. Pharmacoepidemiol Drug Saf 2010 Des 30 [Epub ahead of print]. Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids- a follow-up study of 17 074 men and women. Pain Med 2010;11:805-14.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 131Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010;66:823-9. JE. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand 2010 [Epub ahead of print]. 2009: Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs- a based LC, Engeland A, M\u00f8rland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. Tidsskr Nor Engeland Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study. J Affect Disord 2009; Bramness JG, Skurtveit S, Neutel I, M\u00f8rland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharmacoepidemiol Drug Saf 2009;18:492-6. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224-8. Devold H, Molden of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234-41. Engeland Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Prescription of codeine for non-malignant pain in Norway- a pharmacoepidemiological study Gjerden P , Bramness and potential abuse of anticholinergic antiparkinson drugs in Norway: a , between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol print]. Gjerden The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal orphenadrine. J Clin Pharmacol 2009;68:238-42. Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320-6. Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nation- wide administrative register. Nor J Epidemiol 2009;19:169-172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209-218. Aavitsland P . Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Bramness Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572-8. Landmark CJ, Larsson P , Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population-based study of prescriptions. Epilepsy Res 2009; 87: 31-9. Selmer Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355-62. Skurtveit Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study Pharmacoepidemiol Drug Saf 2009;18:737-42. Winther Legemiddelshopping av vanedannende medikamenter addictive Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185-90. Berg A, Furu Norwegian. Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167-72. Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074-5.Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescrip - tions of T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care 2008;26:80-5. Engeland JG, AK, R\u00f8nning M, Skurtveit S, Furu K. Prescription druguse among fathers and mothers before and during pregnancy. A population-based cohort studyof 106,000 pregnancies in register - basert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] A, J, B. an arctic population: BMC Health Serv Res 2008;8:117.Legemiddelstatistikk 2012:2 Folkehelseinstituttet 133Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescrip - tions of the hypnotics of antipsychotic medication: linking population-based prescription database to the HUNT study. Pharmacoepidemiol Drug Saf 2008;17:372-7. Litleskare I, Blix H, in Tidsskr opioider til norske kreftpasienter cancer in Laegeforen Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf 2008;17:926-933. Skurtveit S, Furu K, P . Introduction of low dose transdermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 2009;13:949-53. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714-17. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor J Epidemiol 2008;18:191-94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161-6. Blix f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Laegeforen 2007;127:2653-5. In Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. pharmacoepidemiological Br Clin Pharmacol 2007;64: 210-8. H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203-9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007;39:1050-5. Engeland A, Skurtveit S, M\u00f8rland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. Ann Epidemiol A, Nafstad P . Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription N, Hausken T, P . A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. Torkildsen O, Grytten N, Myhr av flunitrazepam etter 1999. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. Tidsskr Nor Laegeforen J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. diabetes mellitus? [How and who receiving medication for diabetes mellitus?] Tidsskr Nor Laegeforen 2006;126:768-70. Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53-56. 2001: Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor 21 07 81 05 Published by Norwegian Institute Public Health P.O. Box "}